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Summary 
 
Buruli ulcer (BU) is a slow progressing disease of the skin and subcutaneous tissue caused 
by Mycobacterium ulcerans. It presents in different clinical forms ranging from small non-
ulcerative nodules to large ulcers and sometimes multiple ulcerations. The highest 
prevalence of the focally occurring disease is found in rural areas of West African countries. 
Both the mode of transmission as well as the potential environmental reservoir of M. ulcerans 
remain unidentified to date. In Cameroon, the remote Mapé dam region has recently been 
identified as a new BU endemic area. To assess the age-adjusted prevalence and local 
geographic distribution of BU, a house-by-house survey in the Bankim health district was 
conducted. Results showed that children between the age of five to 15 and elderly people 
were over proportionally affected by BU. To confirm the clinical diagnosis of BU during and 
after the health survey in Bankim, fine needle aspirates and swabs from undermined ulcer 
edges were transported to the Swiss Tropical and Public Health Institute for laboratory 
confirmation by quantitative real time PCR. In parallel we developed a protocol for primary 
culture initiation of M. ulcerans from patient lesions after a long time span between sampling 
and processing in a BSL3 culture laboratory. The established two sets of Cameroonian 
patient isolates from the Mapé and the Nyong river valleys were used for a comparative 
genome sequencing study revealing the presence of two distinct phylogenetic clonal 
complexes in Cameroon. Despite the fact that BU can be treated with antibiotics, the 
socioeconomic impact of the disease on affected populations remains devastating. As long 
as it is not clearly known how the disease is contracted, interruption of transmission is not an 
option. A vaccine against M. ulcerans on the other hand could be used both as preventive 
measure and therapeutically. While sero-epidemiological studies imply the presence of 
protective immunity in some individuals, no vaccine is available to date. Within the framework 
of the EU funded collaborative project BuruliVac we investigated the potential for developing 
a protein subunit vaccine against M. ulcerans by delivering vaccine candidate antigens with 
three different systems: i. as recombinant proteins with an adjuvant, ii. as vesicular stomatitis 
virus replicon and iii. incorporated into a genetically modified mouse malaria parasite 
(Plasmodium berghei) in an infection - treatment - approach. All three formulations were 
assessed for their immunogenicity and their protective potential in a mouse model of BU. 
Although all three vaccination approaches elicited strong humoral immune responses, no full 
protection was observed for any of the formulations. However a slight partial protection was 
seen for a replicon - prime / recombinant protein boost regimen with a vesicular stomatitis 
virus replicon incorporating an expression cassette for the M. ulcerans protein MUL2232. 
Additionally, a transient delay of foot pad swelling was observed in mice receiving infection - 
treatment - vaccination with P. berghei expressing MUL4987. Despite the mainly extracellular 
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nature of M. ulcerans in infected tissue, antibody production against the protein vaccine 
candidates thus does not seem to be sufficient for protection. Considering marked 
differences between the mouse footpad model of BU and the disease in humans, we aimed 
at developing an animal model that better reflects local pathogenesis and host-pathogen 
interactions in the human BU lesions. Hence, we developed the pig as novel animal model 
for BU and showed that the observed histopathological changes in the infected pig skin 
closely represent those of human BU. Therefore the pig model has great potential for the 
validation of new therapeutic and prophylactic interventions. 
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Zusammenfassung 
 
Das Buruli Ulkus (BU) ist eine langsam voranschreitende Erkrankung der Haut und des 
Unterhautgewebes, welche durch Mycobacterium ulcerans verursacht wird. Die Erkrankung 
zeigt sich in verschiedenen klinischen Formen, die von kleinen, geschlossenen Knoten bis zu 
grossen Ulzera und manchmal mehreren Läsionen reichen. Die grösste Prävalenz der lokal 
gehäuft auftretenden Erkrankung ist in ländlichen Gebieten westafrikanischer Länder zu 
finden. Sowohl die Art der Übertragung als auch mögliche Umweltreservoire von M. ulcerans 
konnten bisher nicht vollständig identifiziert werden. In Kamerun wurde kürzlich die 
abgelegene Region um den Mapé Staudamm als neues endemisches BU Gebiet 
beschrieben. Um die altersangepasste Prävalenz und die lokale geographische Verteilung 
des BU festzustellen, wurde eine Umfrage in sämtlichen Haushalten des 
Gesundheitsdistrikts Bankim durchgeführt. Die Resultate zeigten, dass Kinder im Alter von 5 
bis 15 Jahren und ältere Personen überproportional vom BU betroffen sind. Zur Bestätigung 
der klinischen BU Diagnose während und nach der Umfrage in Bankim wurden 
Feinnadelaspirationen und Abstriche aus den unterhöhlten Ulzerrändern vorgenommen und 
im Schweizerischen Tropen- und Public Health Institut im Labor mit quantitativer real time 
PCR untersucht. Parallel dazu wurde ein Protokoll für das Ansetzen von M. ulcerans 
Primärkulturen aus Patientenproben etabliert, welches die lange Zeitspanne zwischen der 
Probenentnahme und der Verarbeitung in einem BSL3 Kulturlabor berücksichtigt. 
Vergleichende Genomsequenzstudien von so etablierten Isolat-Gruppen von kamerunischen 
Patienten aus dem Mapé und dem Nyong Flusstal zeigten, dass in Kamerun zwei 
verschiedene phylogenetisch klonale M. ulcerans Komplexe vorhanden sind. Obwohl das BU 
mit Antibiotika behandelt werden kann, sind die sozioökonomischen Auswirkungen der 
Krankheit auf die betroffenen Bevölkerungsgruppen verheerend. Solange unklar ist wie die 
Übertragung erfolgt, ist Ansteckungsprophylaxe keine Option. Hingegen könnte eine Impfung 
gegen M. ulcerans sowohl als vorbeugende Massnahme als auch therapeutisch eingesetzt 
werden. Seroepidemiologische Studien implizieren zwar, dass sich bei Einzelnen eine 
natürliche Immunität entwickelt, eine Impfung ist allerdings bisher nicht verfügbar. Im 
Rahmen des EU-finanzierten Konsortiums BuruliVac haben wir das Potenzial für die 
Entwicklung einer Protein-Untereinheits-Impfung gegen M. ulcerans untersucht. Hierfür 
haben wir Impfstoff Kandidaten Antigene mit drei verschiedenen Formulierungen verabreicht. 
i.) rekombinante Proteine mit einem Adiuvans, ii.) mittels Vesikulärem Stomatitis Virus (VSV) 
Replikons und schliesslich iii.) mittels genetisch veränderter Maus Malaria Parasiten 
(Plasmodium berghei) in einem Infektions - Behandlungs - Ansatz. Für alle drei 
Formulierungen wurden die Immunogenität und das Schutzpotenzial in einem BU 
Mausmodell beurteilt. Obwohl alle drei Impfansätze starke Antikörperantworten hervorriefen, 
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konnte mit keiner der drei Strategien ein vollständiger Schutz erreicht werden. Eine leichte, 
teilweise Schutzwirkung wurde für die Replikon prime / rekombinantes Protein boost Impfung 
mit MUL2232 verzeichnet. Zudem beobachteten wir für MUL4987 eine vorübergehende 
Verzögerung der Schwellung des infizierten Fusses bei Mäusen, welche mit einem Infektions 
- Behandlungs - Ansatz mit P. berghei geimpft wurden. Obwohl sich M. ulcerans im 
infizierten Gewebe hauptsächlich extrazellulär entwickelt, scheint die Antikörperproduktion 
gegen die Proteinimpfstoffkandidaten nicht für eine Schutzwirkung auszureichen. Angesichts 
der deutlichen Unterschiede zwischen dem Mausmodell und der Erkrankung im Menschen 
wollten wir ein Tiermodell entwickeln, welches die Pathogenese und die Wechselwirkung 
zwischen Wirt und Krankheitserreger in menschlichen Ulzera besser reflektiert. Daher haben 
wir das Schwein als neues experimentelles Tiermodell für das BU entwickelt. Wir konnten 
zeigen, dass die beobachteten histopathologischen Veränderungen der infizierten 
Schweinehaut denen des BU im Menschen sehr ähnlich sehen. Das von uns etablierte 
Schweinemodell hat grosses Potenzial für die Validierung von neuen therapeutischen und 
vorbeugenden Massnahmen.  
7 
 
Introduction 
 
Buruli ulcer (BU), caused by infection with Mycobacterium ulcerans, is a slow progressing, 
ulcerative disease of the skin and subcutaneous tissue. After years of disregard, the World 
Health Organization (WHO) recognized BU in 1998 as an emerging health problem and 
launched the Global Buruli Ulcer Initiative (GBUI) with the goal of coordinating BU control 
and research efforts [1]. At the same time, a first BU conference was organized by the WHO, 
drawing attention to the disease and leading to the Yamoussoukro Declaration [2], which 
clearly stated the will of the research community to solve the problems caused by BU.  
Despite all the efforts and advances in understanding BU, many major research questions 
are still unsolved, such as the existence of an environmental reservoir and transmission of 
the disease. 
History and geographical distribution of Buruli ulcer 
The discovery of BU presumably took place in Africa as early as 1897, when Sir Albert Cook 
described large ulcerations occurring on limbs, most probably caused by M. ulcerans [3]. In 
the 1920s Kleinschmidt described similar ulcerations in patients living in the former Northeast 
Zaire [4]. Only a little later, in 1937, the first cases were discovered in Australia, more 
precisely in Bairnsdale (Victoria) [5]. Australia is also the place where the first description of 
the etiological agent of these unusual skin infections eventually originated; MacCallum and 
colleagues described a total of six patients with ulcerative skin infections and isolated a 
Mycobacterium from one of these wounds, that could only be cultured at temperatures lower 
than those required for M. tuberculosis [6]. Two years later, the new microorganism was 
named M. ulcerans by Fenner [7]. BU, the name used nowadays for the disease caused by 
M. ulcerans infection, originates from reports of the Uganda Buruli group. Clancey et al. 
named the disease after a geographic area in Uganda, the Buruli county, where in the 1960s 
a large epidemic of BU occurred [8,9]. In the 1980s, cases were also reported from other 
Central and West African countries like Congo (now Democratic Republic of the Congo and 
The Republic of Congo), Nigeria, Cameroon and Ghana [10–13]. Since then, case numbers 
in West African countries have increased to the extent that BU is now more prevalent than 
leprosy in some regions of high burden countries [14].  
Today the highest prevalence of BU is still found in West Africa, especially in Côte d’Ivoire, 
Cameroon, Ghana and Benin (Fig. 1). As seen in Figure 1, Australia and Japan are also 
reporting considerable numbers of BU patients [15,16], whereas in other countries of the 
over 30 that have reported BU cases until now, the disease occurs only sporadically [17]. 
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Only rarely, and always as a result of travel, has M. ulcerans infection occurred in North 
America and Europe [18–20].  
Most likely, the 2630 cases reported to the WHO in 2013 [21] are an underestimation of the 
true number of cases due to the remote location of most endemic areas and limited access 
of patients to the formal health system and the lack of a point-of-care diagnostic test. On the 
other hand, the proportion of BU cases among the patients reporting at the health facilities 
may be an overestimation [22]. 
 
 
Figure 1: Worldwide distribution of Buruli Ulcer 2013 [23]. 
 
 
In Cameroon, BU was first described already in 1969. The reported cases at that time 
originated from a region in the Center Province, the Nyong River valley between the villages 
of Ayos and Akonolinga [12,24]. A second BU endemic region more in the north of 
Cameroon was reported by Marion et al. in 2011 [20]. In the Bankim health district, close to 
the Mapé river and dam, the first clinically suspected cases had already been reported in 
2004 and numbers increased until 2009.  
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Evolution and genomic diversity of M. ulcerans 
M. ulcerans is a member of the genus Mycobacterium, which comprises over 120 species. 
Many of these are important pathogens for animals and humans. M. leprae (the causative 
agent of leprosy) and M. tuberculosis (the causative agent of tuberculosis) are two examples 
for human pathogens, whereas M. marinum (fish pathogen) and M. bovis (causative agent of 
bovine tuberculosis) represent two (primarily) animal pathogens [25]. Early work based on 
multilocus sequence typing had already revealed a very close genetic relationship between 
M. ulcerans and M. marinum with an average nucleotide sequence identity of over 98 % in 
eight housekeeping and structural genes. It also indicated that all M. ulcerans strains had 
diverged from a common M. marinum progenitor once in evolution [26,27]. This finding was 
later confirmed when the first genome sequence of M. ulcerans became available in 2007 
[28]. Furthermore, it became clear that a hallmark in the divergence of M. ulcerans and M. 
marinum was the acquisition of pMUM001, a virulence plasmid of 174 kb that is required for 
production of mycolactone, a toxin produced by M. ulcerans [29,30]. A second genetic 
difference clearly distinguishing M. ulcerans from its progenitor is the presence of two 
insertion sequence elements (IS2404 and IS2606). While they are completely absent in the 
genome of M. marinum, they expanded to high copy numbers in the genome of M. ulcerans, 
and represent the target of the current most sensitive diagnostic method for BU [31]. The 
expansion of IS2404 to over 200 copies and IS2606 to over 80 copies has mediated the loss 
of around 1 Mbp of DNA compared to M. marinum. Furthermore the M. ulcerans genome 
contains over 700 pseudogenes. Among the genes rendered non-functional or completely 
lost are genes important for pigment biosynthesis, anaerobiosis, intracellular growth [28] and 
potent T-cell antigens [32]. Some of the changes in the genome are reflected in the 
phenotype of M. ulcerans, for example the very slow growth rate compared to M. marinum, 
with estimated replication times of 72 hours compared to 4-6 hours, respectively [33]. 
All the data described above indicate that M. ulcerans has passed an evolutionary bottleneck 
and is adapting to a niche, most likely a more stable environment. Genomic information 
suggests that this new environment is dark, at least microaerophilic and extracellular. 
Additionally the slow growth rate, the thermosensitivity, the loss of important immunogens 
and the production of an immunosuppressive toxin would be of selective advantage for long 
term survival in a mammalian host [28,34,35].  
The classical and the ancestral lineages of M. ulcerans causing clinical disease in humans 
[36], and the few other mycolactone-producing mycobacteria (MPM) that have been 
discovered so far like fish and frog pathogens, are genetically very closely related. 
Considering proper criteria for species differentiation, it is suggested to name all MPM M. 
ulcerans [35,37]. Analysis of insertion-deletion polymorphisms by Käser et al. has 
demonstrated the existence of two major lineages of M. ulcerans among clinical isolates: the 
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ancestral lineage, which is more closely related to M. marinum and comprises strains from 
South America, China and Japan, and the so called classical lineage with strains from 
Australia and Africa [36]. While cases caused by strains of the ancestral lineage are 
sporadic, the focal prevalence of cases caused by the classical lineage is much higher. Other 
conventional methods for genetic fine-typing were so far only able to discriminate between 
continental lineages and revealed the high clonality of circulating strains in different West 
African countries [38–41].  
The highest resolution in deciphering the phylogenetic relationship between locally found M. 
ulcerans strains in West Africa can be achieved by single nucleotide polymorphism (SNP) 
typing, based on whole genome SNP analysis. With this method it was possible to 
demonstrate the highly clonal population structure of African M. ulcerans and the focal 
transmission of BU in the Densu river valley in Ghana [42,43]. It was hypothesized that only 
whole genome sequencing approaches in microepidemiological studies would provide 
sufficient resolution for tracing transmission pathways [33,42,43].  
Results Chapter 3 of this thesis describes the findings of such a microepidemiological study 
in two BU endemic regions of Cameroon, where we analysed whole genome sequences of 
91 M. ulcerans isolates. 
Reservoir and Transmission 
M. ulcerans is traditionally considered to be an environmental bacterium like its progenitor M. 
marinum. The Uganda Buruli group, which described a first big outbreak of BU in the 1960s, 
reported that there was no evidence of spread from person to person and that the disease 
“occurs characteristically but inexplicably near to large rivers” [44]. Until today this opinion is 
still preserved. Transmission from human to human is reported very rarely and the idea that 
introduction of M. ulcerans through minor wounds from an environmental reservoir is an 
important part of BU transmission remains [45,46]. However the definitive environmental 
reservoir and the exact mode of transmission are still not known [47].  
To get further insight into the risk of contracting BU and the association of the disease to 
riverine areas, swamps and marshlands, a number of studies investigated risk factors in 
endemic areas of different West African countries. Results repeatedly confirmed that 
exposure to riverine areas by swimming and wading in swamps increased the risk for 
developing BU [48–50]. As pointed out by Meritt et al., almost all epidemiological studies 
have associated occurrence of BU with human-disturbed aquatic habitats due to 
deforestation, damming of streams and rivers or increased agricultural activities. In 
accordance with these findings, the habit of wearing protective clothing while farming was 
shown to reduce the risk for BU [47].  
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Since the introduction of polymerase chain reaction (PCR)-based methods for the detection 
of M. ulcerans DNA in the environment, various studies investigating the occurrence of the 
bacteria in the environment have been conducted. Specimens that have tested positive 
include soil, water filtrates, detritus, feces, fish, snails, frogs and insects [51–55]. Although 
the PCR method applied is very specific for diagnostic purposes, cross reaction with other 
mycobacteria in the environment cannot be completely excluded. Hence, the results of 
studies on environmental samples should be interpreted with caution, especially in the light 
of the very few positive samples in highly BU endemic areas, as well as the detection of 
positive samples in non-endemic regions [47,51]. Furthermore, positive PCR samples do not 
necessarily prove the presence of intact and live M. ulcerans in the environment. Due to its 
very slow growth rate and the presence of many other faster growing environmental 
organisms, cultivation of M. ulcerans from the environment remains very difficult [56]. 
Therefore the ultimate proof that M. ulcerans persists freely and alive in the environment is 
still missing.  
With the detection of M. ulcerans DNA associated with aquatic insects, the idea of 
transmission by such vectors arose [57]. Especially water bugs were suspected to play a 
major role in transmission of the disease [58,59]. However, the significance of transmission 
by water bugs controversial, because these insects rarely bite humans. Furthermore, no 
significant difference was found in abundance of water bugs and/or positivity of water bugs 
for M. ulcerans DNA between BU endemic and non-endemic sites [60]. Mosquitoes have 
been proposed as vectors for the disease in Australia, where the disease is most prevalent in 
the temperate south-eastern state of Victoria [52]. Recently it was also reported that more 
than 20 % of ringtail and brushtail possums in endemic foci of Victoria had skin lesions 
caused by M. ulcerans [52,61]. While possums in Australia seem to represent a substantial 
animal reservoir, the search for a comparable reservoir in Africa has remained unsuccessful 
[62,63]. 
In conclusion, the exact mode of transmission of BU remains unknown. Possibly multiple 
modes of transmission occur, depending on the geographical and epidemiological setting 
[47]. As concluded by Meritt et al., studies on human behaviour patterns in highly endemic 
African villages would be of great benefit in order to better understand exposure to M. 
ulcerans, identify transmission patterns and ultimately develop preventive measures for the 
affected communities [47].  
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Pathogenesis and the role of mycolactone 
BU affects all age groups, but lesions in children between the age of 5 and 15 are 
overrepresented [44,64]. In most studies an equal gender distribution has been found [65]. 
Lesions are typically observed on limbs of the patients, although they also occur less 
frequently on other body parts [44].  
BU is primarily an infection of the skin with very restricted systemic dissemination [66]. After 
infection via an unknown mechanism, clinical signs typically start to emerge in the form of a 
movable, subcutaneous nodule after an incubation time that is estimated to be 2 - 3 months 
(Figure 2, A) [67]. Other non-ulcerative, early forms of BU are plaques and oedema (Figure 
2, B and C) which tend to expand, leading to large ulcerations later in disease progression 
[68]. Additionally to this classification, the WHO has introduced a classification system that is 
mainly based on lesion size: Category I (single, small lesions < 5 cm in diameter), Category II 
(5 – 15 cm in diameter) and Category III (osteomyelitis and lesions with > 15 cm in diameter, 
disseminated forms, lesions in the head and neck region and in the face) [69]. Early forms of 
BU, especially nodules, can either heal spontaneously or progressive necrosis of the 
subcutaneous tissue eventually leads to collapse of the overlying dermis and epidermis, 
resulting in ulcers (Figure 2, D) [69]. Typical BU ulcerated lesions have undermined edges, 
slowly expand over time and are often painless, unless secondary infections occur [70]. The 
painless nature of the disease may be a consequence of nerve damage at the lesion site 
[71]. If left untreated, BU lesions can span entire body parts and can lead to complex and 
sometimes multiple lesions and to osteomyelitis [67]. It appears that co-infection with HIV 
would lead to more severe forms of BU but up to now, systematic studies on this topic are 
rare [72]. 
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Figure 2: Typical clinical presentations of three non-ulcerative forms of BU, the nodule (A), 
plaque (B) and oedema (C). Representative of the typical open forms, a medium sized ulcer 
is shown (D) [69]. 
 
 
Skin tropism, slow progression of the wounds and necrosis of the skin are explained by the 
low optimal growth temperature of the pathogen, its slow growth rate and the production of 
the unique toxin, mycolactone, respectively [73]. 
The ability to produce this toxin depends entirely on the presence of the virulence plasmid 
pMUM01. This large plasmid encodes the polyketide synthases, which are needed to 
produce a family of macrolide exotoxins, generally referred to as mycolactones [73]. So far, 
six different variants of mycolactones have been described and named A to F. Different 
lineages of M. ulcerans are known to produce these different variants whereof mycolactone 
A/B produced by the African isolates is the most potent toxin of this unique family of 
molecules [74–76].  
Mycolactone affects a broad range of mammalian cell types in vitro as well as in vivo. Added 
in small amounts to cell culture, it induces cell cycle arrest followed by apoptosis in fibroblast 
cell lines or reduces the phagocytic activity of cultured macrophages [73,77,78]. When 
injected into the skin of guinea pigs, the toxin causes ulcerations similar to the ones 
observed in human lesions [73,79]. Mycolactone injection results also in other species in the 
development of typical signs of BU on a histopathological level [80,81]. It is assumed that 
mycolactone is the main cause of the tissue destruction seen in BU lesions in humans, 
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however it is not entirely clear how it exerts its effects [82]. Local and systemic 
immunosuppressive effects of the toxin are also not entirely understood [83]. The diffusible 
nature of the lipid-toxin and technical restrictions in the quantification of mycolactone are 
limiting our current knowledge on tissue concentration and in vivo half-life of the toxin in 
human lesions.  
Histopathologically, BU lesions are characterized by the presence of clusters of extracellular 
acid-fast bacilli (AFB), coagulative necrosis, the presence of fat cell ghosts, epidermal 
hyperplasia and very limited cellular infiltration [84,85]. Typically the distribution of AFB in 
ulcerative lesions is very inhomogeneous [86]. All histopathological hallmarks of the disease 
were basically described from tissue excised during surgical treatment of patients before the 
era of antibiotic treatment or from punch biopsies. Tissue samples from early BU lesions 
(nodules) are rarely available, resulting in very limited knowledge on the histopathology of 
early stages of the disease [83]. From studies in the mouse model it became clear that 
despite its late extracellular location, M. ulcerans may also have an initial, transient 
intracellular stage [87,88,80]. Lack of cellular infiltration is confined to the central, necrotic 
part of a lesion which is typically surrounded by different layers of inflammatory infiltrates 
[68].  
It is currently thought that initial infection results in small accumulations of AFB (globi), which 
are needed to build up a sufficient mycolactone concentration to prevent elimination of the 
mycobacteria by infiltrating cells. As the amount of AFB, and with it the mycolactone cloud, 
increases, the infiltrating cells undergo apoptosis and a central necrotic area is developing 
[68,80,83].  
Diagnosis and Treatment 
Diagnosis of BU at health posts or hospitals in BU endemic areas is often based only on 
clinical grounds. Well trained staff can achieve an accuracy of up to 95 % but accuracy of 
clinical diagnosis is usually much lower [89]. Particularly in regions of low endemicity, where 
health workers are less experienced in diagnosing BU, laboratory confirmation is important to 
appropriately manage the disease [22,31].  
Although urgently needed, no point of care diagnostic test for BU is currently available. Four 
methods for microbiological confirmation are recommended by the WHO: 
- Direct smear examination for AFB 
- In vitro culture 
- Polymerase chain reaction (PCR) targeting the genomic multi-copy IS2404 sequence 
- Histopathological examination of tissue 
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Of the four methods, only direct smear examination of wound exudates stained with Ziehl-
Neelsen/Methylene blue is easily applicable at a local level [31]. However this method has a 
low sensitivity and does not differentiate between BU and cutaneous tuberculosis. 
The main drawback of culturing M. ulcerans is the slow growth of the bacteria as well as the 
low sensitivity. On the other hand, cultures of M. ulcerans can be used for monitoring 
development of drug resistance and treatment success [31,90]. Additionally, culturing is 
required for establishing a strain collection for microepidemological studies. Histopathology 
requires a sophisticated laboratory and an invasive sampling technique but can be used for 
studying the local immune response, wound healing problems and treatment success 
[68,91,92]. Currently, the most sensitive and specific method for BU diagnosis is PCR for 
IS2404, especially by real-time (q) PCR methods and has therefore become the gold 
standard for BU diagnosis [31,93]. 
According to WHO recommendations, suspected BU cases should be laboratory confirmed 
by at least one of the above mentioned methods, preferably two. In 2013, it was proposed 
that national control programs should ensure that at least 70 % of all reported cases are 
laboratory confirmed by PCR. However there are many reasons for the discord between 
clinical and laboratory diagnosis, such as incorrect clinical diagnosis, inadequate sampling or 
laboratory errors [22,31].  
For sampling of BU lesions, different methods exist, depending on the nature of the lesion 
(open or closed), the method of choice for laboratory confirmation and the place where 
specimens are collected. Closed lesions are typically sampled by fine-needle aspiration 
[31,94], whereas ulcers can be swabbed with a cotton wool swab. Both types of samples can 
be used for all laboratory confirmation methods except for histopathology for which punch 
biopsies or surgical excisions are needed [31].  
 
Historically, surgical excision with wide margins into healthy tissue was the only treatment 
option for BU [69,72]. Based on data in mice and humans [67,95,96], in 2004 the WHO 
published provisional guidelines for treating BU with an antibiotic regimen consisting of oral 
rifampin (10 mg/kg) and intramuscular streptomycin (15 mg/kg) (R/S) for the duration of eight 
weeks [97]. A randomized trial by Nienhuis et al. and a number of observational studies 
confirmed the effectiveness of this treatment for different forms of BU and all lesion sizes 
[98–100]. It became clear that with this therapy, recurrence rates were reduced to 2 % as 
compared to 16 - 45 % for surgical treatment [67,69,100,101]. Therefore current WHO 
recommendations for treatment of BU are a combination of specific antibiotics for eight 
weeks, wound care, prevention of disability and surgery to remove necrotic tissue, covering 
of large skin defects and correcting of deformities [67]. Due to the need for daily injections 
with streptomycin, research efforts are directed towards replacing streptomycin with 
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clarithromycin, an oral drug with less toxicity. First studies testing this alternative drug 
regimen are promising [102–105].  
Histopathological descriptions from humans as well as mice indicate that R/S therapy 
reduces or abolishes mycolactone production early after initiation of therapy [106]. Chronic 
leukocyte infiltration is observed and defined granuloma structures develop, allowing for 
specific immune responses against M. ulcerans. The majority of AFB after eight weeks of 
chemotherapy have beaded appearance, reflecting their destruction [68,107,108]. The 
massive immunostimulation observed during R/S therapy is considered to be a potential 
reason for the development of new ulcerations during or after antibiotic therapy, a 
phenomenon called “paradoxical reaction” [68]. The name is also used for the often observed 
clinical worsening of a BU lesion, for example an advanced progression of early plaques to 
ulceration, shortly after start of R/S [109–111].  
An alternative therapy approach to antibiotic treatment is based on the sensitivity of M. 
ulcerans to temperatures above its optimal growth temperature of 32°C. Meyers and 
colleagues successfully treated eight patients in Zaire with heat already in the nineteen 
seventies [112], but complicated devices and electricity requirements led to the 
abandonment of this approach. In 2009 application of heat by phase change material filled 
bags proved an easy, cheap and promising alternative to antibiotic therapy [113]. A follow-up 
clinical trial of thermotherapy after proof of principle in 2009 confirmed these results in a 
larger and more diverse patient cohort (Manuscript submitted). 
Immune response to M. ulcerans and prospects for a vaccine 
As already described in the section on the pathogenesis of BU, the local immune response in 
the affected tissue is greatly influenced by the production of mycolactone. Over time a 
necrotic focus develops at the site of infection that contains abundant clumps of extracellular 
bacilli and cellular debris. At the border of the necrotic areas, neutrophils and macrophages 
with intracellular bacilli are found. This entire structure is typically surrounded by intact mixed 
infiltration as observed in human and mouse lesions [83,88].  
The broad cross-reactivity with M. tuberculosis and M. bovis antigens complicates the 
analysis of M. ulcerans-specific immune responses and only limited data on humoral immune 
responses against M. ulcerans are available [68]. Studies using M. ulcerans culture filtrates 
found Immunoglobulin (Ig) G and IgM antibody responses in sera of BU patients, but also in 
sera of tuberculosis patients and Bacille Camette-Guérin (BCG)-immunized individuals 
[114,115]. The 18 kDa small heat shock protein of M. ulcerans, which has only a homologue 
in M. leprae but not in M. tuberculosis and M. bovis, was successfully used in serological 
analysis to distinguish between patients and individuals living in BU non-endemic areas 
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[116]. However, healthy household contacts in BU endemic regions showed reactivity as 
well, indicating that exposure to the pathogen is more frequent than the development of 
disease and that specific humoral responses develop in exposed individuals [116–118]. 
It is not entirely clear to what extent systemic cellular immune responses develop in BU 
patients. Skin testing with burulin, a lysate of M. ulcerans, frequently elicited delayed-type 
hypersensitivity responses in patients with healing or healed lesions but was rare in 
individuals with early BU lesions [114,119]. Such a reaction would be indicative of 
development of cell-mediated immunity but again, cross reaction with responses to BCG 
vaccination complicates the interpretation of these results. Further studies on systemic 
cellular responses against M. ulcerans were mainly conducted by ex vivo stimulation of 
peripheral blood mononuclear cells (PBMCs) isolated from BU patients or whole blood assay 
approaches revealed large individual variations as well as variations between individual 
studies. However impairment of IFNγ secretion was a common denominator of the reports 
[120–125]. Most probably early TH1 cellular responses that appear important for control of M. 
ulcerans infections are down regulated and the TH1/TH2 balance is shifted towards a TH2 
response, which does not seem beneficial for healing [120–122,125,126]. This scenario was 
illustrated in a case report from Australia, where development of a BU lesion coincided with 
the shift of a TH1 cytokine response before disease onset to a TH2 cytokine profile [127]. 
It is being debated to what extent systemic immunosuppression occurs and to what extent 
and how mycolactone influences systemic immune responses [68,83]. Results from mouse 
studies indicate that there may not be no systemic immunosuppression at all [128], but on 
the other hand systemic suppression of IFNγ responses was reported to resolve after 
surgical excision of BU lesions [123]. 
 
To date no specific vaccine against M. ulcerans is available [129]. The development of such 
a vaccine is complicated by the fact that M. ulcerans is not clearly an intracellular or a clearly 
extracellular bacterium and it is impossible to study early host-pathogen interactions due to 
the unknown mode of transmission of the bacilli [83]. Additionally, we do not know much 
about correlates of protection, except that a TH1 type of cellular response might be protective 
[129,130]. Furthermore, the toxin mycolactone is not highly immunogenic and the relative 
importance of specific antibodies against the toxin as well as against cell surface structures 
of extracellular M. ulcerans remains unknown [68]. Nevertheless vaccine development 
against M. ulcerans seems possible. The fact that not all infected individuals develop disease 
and reports on self-healing of BU indicate, that protective immunity naturally develops in 
some people living in BU endemic areas and hence it might be possible to induce such 
immunity by vaccination [116,117,131,132].  
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Vaccination with BCG appears to have a transient and only partial protective effect against 
the development of BU [133,134]. Osteomyelitis, the most severe form of the disease, was 
reported to occur less frequently in BCG-vaccinated individuals [135]. It was speculated that 
the major component conferring protection in BCG vaccination, the antigen (Ag) 85 complex, 
could offer increased protection against M. ulcerans if the species-specific variants were 
used for vaccination. Accordingly, immunization with Ag85A in a DNA vaccination approach 
conferred partial protection against M. ulcerans in a mouse model of the disease [136,137]. 
The limited number of other protein subunit vaccination approaches tested so far as well as 
immunization with a mycolactone-negative strain of M. ulcerans could not confer full 
protection in mouse models neither [138–140].  
Results Chapters 4 to 6 of this thesis describe the results of our studies employing different 
delivery systems for a potential protein subunit vaccine against M. ulcerans.  
Animal models for Buruli ulcer 
A range of animals (cats, dogs, alpacas) was reported over the years to be naturally infected 
with M. ulcerans [62,141–146]. Most of them were rare cases and not suitable as animal 
models in BU research. Actively tested as models for BU were the armadillo and the monkey 
but both are not used today [147,148]. The guinea pig model that was established 40 years 
ago is only rarely used as it does not offer substantial advantages over the mouse model 
described below [149,150].  
The most widely used animal model for BU today has its origin in the nineteen fifties when it 
was developed by Frank Fenner, an Australian virologist. He discovered that sub-cutaneous 
(s.c.) inoculation of M. ulcerans into mouse foot pads led to the development of swelling and 
lesions 1-16 weeks after injection in a dose-dependent manner [151]. The model is basically 
used in the same way today, mainly for testing antimicrobial compounds but also in studies 
of vaccine efficacy [104,137,139,140,152,153]. Possible read-outs for the progression of 
infection in the infected mouse feet are measurements of foot pad swelling by caliper or a 
grading system for the severity of infection, the so called lesion index (Figure 3) [72,88]. At 
any given time point, bacterial load in the foot pads can be determined by lysis of the foot 
and subsequent enumeration of M. ulcerans by counting methods according to Shepard and 
McRae or classical colony forming unit (cfu) plating [139,154,155]. For the enumeration of 
bacteria in our mouse model of M. ulcerans, we adapted a qPCR technique developed by 
Fyfe et al. [156,157]. This is illustrated in Results Chapters 4 - 6 of this thesis.  
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Figure 3: Mouse foot pad model of BU. S.c. injection of AFB into the healthy foot pad (0) 
leads to progressive swelling and inflammation. (1) Grade 1, slight swelling; (2 and 2+) 
Grade 2, swelling with inflammation; (3 and 3+) Grade 3, swelling with inflammation of the 
leg; (4) Grade 4, swelling with inflammation and possible ulceration, cage bedding sticking to 
the foot. 
 
 
Additionally to the determination of the bacterial load, the local immune response in mouse 
foot pads can be characterized by histopathology [88]. As opposed to typically affected 
human tissue, mouse feet contain only little subcutaneous fat. An alternative model for BU 
that is closer to the human in terms of physiology and skin structure is the pig. Results 
Chapter 7 of this thesis describes the successful evaluation of the pig as an M. ulcerans 
infection model for studying early pathogenesis of BU and for the development of new 
therapeutic and prophylactic interventions. 
20 Introduction  
 
References 
1.  WHO | The history of GBUI (n.d.). WHO. Available: http://www.who.int/buruli/gbui/en/. 
Accessed 30 September 2014. 
2.  WHO | The Yamoussoukro Declaration on Buruli ulcer (n.d.). WHO. Available: 
http://www.who.int/buruli/yamoussoukro_declaration/en/. Accessed 2 September 2014. 
3.  Cook A (1970) Mengo Hospital Notes, 1897. Makerere Medical School Library, Kampala, 
Uganda. BMJ 2: 378–379. doi:10.1136/bmj.2.5706.378-a. 
4.  Meyers WM, Connor DH, McCullough B, Bourland J, Moris R, et al. (1974) Distribution of 
Mycobacterium ulcerans infections in Zaire, including the report of new foci. Ann Société 
Belge Médecine Trop 54: 147–157. 
5.  Alsop DG (1972) The bairnsdale ulcer. Aust N Z J Surg 41: 317–319. 
6.  MacCALLUM P, Tolhurst JC (1948) A new mycobacterial infection in man. J Pathol 
Bacteriol 60: 93–122. 
7.  Fenner F (1950) The significance of the incubation period in infectious diseases. Med J 
Aust 2: 813–818. 
8.  Clancey J, Dodge R, Lunn HF (1962) Study of a mycobacterium causing skin ulceration 
in Uganda. Ann Société Belge Médecine Trop 42: 585–590. 
9.  Clancey JK (1964) MYCOBACTERIAL SKIN ULCERS IN UGANDA: DESCRIPTION OF 
A NEW MYCOBACTERIUM (MYCOBACTERIUM BURULI). J Pathol Bacteriol 88: 175–
187. 
10.  Smith JH (1970) Epidemiologic observations on cases of Buruli ulcer seen in a hospital in 
the Lower Congo. Am J Trop Med Hyg 19: 657–663. 
11.  Oluwasanmi JO, Solankee TF, Olurin EO, Itayemi SO, Alabi GO, et al. (1976) 
Mycobacterium ulcerans (Buruli) skin ulceration in Nigeria. Am J Trop Med Hyg 25: 122–
128. 
12.  Ravisse P (1977) [Skin ulcer caused by Mycobacterium ulcerans in Cameroon. I. Clinical, 
epidemiological and histological study]. Bull Société Pathol Exot Ses Fil 70: 109–124. 
13.  Bayley AC (1971) Buruli ulcer in Ghana. Br Med J 2: 401–402. 
14.  Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. (2004) Mycobacterium 
ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg 
Infect Dis 10: 1391–1398. doi:10.3201/eid1008.030886. 
15.  Boyd SC, Athan E, Friedman ND, Hughes A, Walton A, et al. (2012) Epidemiology, 
clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. 
Med J Aust 196. Available: https://www.mja.com.au/journal/2012/196/5/epidemiology-
clinical-features-and-diagnosis-mycobacterium-ulcerans-australian. Accessed 2 
September 2014. 
16.  Yotsu RR, Nakanaga K, Hoshino Y, Suzuki K, Ishii N (2012) Buruli ulcer and current 
situation in Japan: A new emerging cutaneous Mycobacterium infection. J Dermatol 39: 
587–593. doi:10.1111/j.1346-8138.2012.01543.x. 
17.  Johnson PDR, Stinear T, Small PLC, Pluschke G, Merritt RW, et al. (2005) Buruli ulcer 
(M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2: e108. 
doi:10.1371/journal.pmed.0020108. 
18.  McGann H, Stragier P, Portaels F, Gascoyne-Binzi D, Collyns T, et al. (2009) Buruli 
Ulcer in United Kingdom Tourist Returning from Latin America. Emerg Infect Dis 15: 
1827–1829. doi:10.3201/eid1511.090460. 
19.  Lindo SD, Daniels F, Jr. (1974) Buruli ulcer in new york city. JAMA 228: 1138–1139. 
doi:10.1001/jama.1974.03230340040028. 
 Introduction 21 
 
20.  Evans M r. w., Mawdsley J, Bull R, Lockwood D n. j., Thangaraj H, et al. (2003) Buruli 
ulcer in a visitor to London. Br J Dermatol 149: 907–909. doi:10.1046/j.1365-
2133.2003.05562.x. 
21.  World Health Organization (n.d.) Number of new cases of Buruli ulcer reported (per 
year). Available: http://apps.who.int/neglected_diseases/ntddata/buruli/buruli.html. 
22.  Portaels F, Silva MT, Meyers WM (2009) Buruli ulcer. Clin Dermatol 27: 291–305. 
doi:10.1016/j.clindermatol.2008.09.021. 
23.  WHO Annual meeting on Buruli ulcer, 2014 (2014) Distribution of buruli ulcer, 2013. 
24.  Boisvert H (1977) [Skin ulcer caused by Mycobacterium ulcerans in Cameroon. II. 
Bacteriological study]. Bull Société Pathol Exot Ses Fil 70: 125–131. 
25.  Tortoli E (2006) The new mycobacteria: an update. FEMS Immunol Med Microbiol 48: 
159–178. doi:10.1111/j.1574-695X.2006.00123.x. 
26.  Stinear TP, Jenkin GA, Johnson PD, Davies JK (2000) Comparative genetic analysis of 
Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent 
divergence. J Bacteriol 182: 6322–6330. 
27.  Yip MJ, Porter JL, Fyfe JAM, Lavender CJ, Portaels F, et al. (2007) Evolution of 
Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common 
Mycobacterium marinum progenitor. J Bacteriol 189: 2021–2029. doi:10.1128/JB.01442-
06. 
28.  Stinear TP, Seemann T, Pidot S, Frigui W, Reysset G, et al. (2007) Reductive evolution 
and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative 
agent of Buruli ulcer. Genome Res 17: 192–200. doi:10.1101/gr.5942807. 
29.  Stinear TP, Mve-Obiang A, Small PLC, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-
encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. 
Proc Natl Acad Sci U S A 101: 1345–1349. doi:10.1073/pnas.0305877101. 
30.  Stinear TP, Pryor MJ, Porter JL, Cole ST (2005) Functional analysis and annotation of 
the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiol Read Engl 151: 
683–692. doi:10.1099/mic.0.27674-0. 
31.  WHO | Laboratory diagnosis of buruli ulcer (n.d.). WHO. Available: 
http://www.who.int/buruli/laboratory_diagnosis/en/. Accessed 2 June 2014. 
32.  Huber CA, Ruf M-T, Pluschke G, Käser M (2008) Independent loss of immunogenic 
proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol 
CVI 15: 598–606. doi:10.1128/CVI.00472-07. 
33.  Röltgen K, Stinear TP, Pluschke G (2012) The genome, evolution and diversity of 
Mycobacterium ulcerans. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 12: 
522–529. doi:10.1016/j.meegid.2012.01.018. 
34.  Rondini S, Käser M, Stinear T, Tessier M, Mangold C, et al. (2007) Ongoing genome 
reduction in Mycobacterium ulcerans. Emerg Infect Dis 13: 1008–1015. 
doi:10.3201/eid1307.060205. 
35.  Doig KD, Holt KE, Fyfe JAM, Lavender CJ, Eddyani M, et al. (2012) On the origin of 
Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics 13: 258. 
doi:10.1186/1471-2164-13-258. 
36.  Käser M, Rondini S, Naegeli M, Stinear T, Portaels F, et al. (2007) Evolution of two 
distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. 
BMC Evol Biol 7: 177. doi:10.1186/1471-2148-7-177. 
37.  Pidot SJ, Asiedu K, Käser M, Fyfe JAM, Stinear TP (2010) Mycobacterium ulcerans and 
other mycolactone-producing mycobacteria should be considered a single species. PLoS 
Negl Trop Dis 4: e663. doi:10.1371/journal.pntd.0000663. 
22 Introduction  
 
38.  Portaels F, Fonteyene PA, de Beenhouwer H, de Rijk P, Guédénon A, et al. (1996) 
Variability in 3’ end of 16S rRNA sequence of Mycobacterium ulcerans is related to 
geographic origin of isolates. J Clin Microbiol 34: 962–965. 
39.  Ablordey A, Kotlowski R, Swings J, Portaels F (2005) PCR amplification with primers 
based on IS2404 and GC-rich repeated sequence reveals polymorphism in 
Mycobacterium ulcerans. J Clin Microbiol 43: 448–451. doi:10.1128/JCM.43.1.448-
451.2005. 
40.  Ablordey A, Swings J, Hubans C, Chemlal K, Locht C, et al. (2005) Multilocus variable-
number tandem repeat typing of Mycobacterium ulcerans. J Clin Microbiol 43: 1546–
1551. doi:10.1128/JCM.43.4.1546-1551.2005. 
41.  Chemlal K, De Ridder K, Fonteyne PA, Meyers WM, Swings J, et al. (2001) The use of 
IS2404 restriction fragment length polymorphisms suggests the diversity of 
Mycobacterium ulcerans from different geographical areas. Am J Trop Med Hyg 64: 270–
273. 
42.  Vandelannoote K, Jordaens K, Bomans P, Leirs H, Durnez L, et al. (2014) Insertion 
sequence element single nucleotide polymorphism typing provides insights into the 
population structure and evolution of Mycobacterium ulcerans across Africa. Appl 
Environ Microbiol 80: 1197–1209. doi:10.1128/AEM.02774-13. 
43.  Röltgen K, Qi W, Ruf M-T, Mensah-Quainoo E, Pidot SJ, et al. (2010) Single nucleotide 
polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer 
in a highly endemic region of Ghana. PLoS Negl Trop Dis 4: e751. 
doi:10.1371/journal.pntd.0000751. 
44.  Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda 
(1971). Trans R Soc Trop Med Hyg 65: 763–775. 
45.  Debacker M, Zinsou C, Aguiar J, Meyers WM, Portaels F (2003) First Case of 
Mycobacterium ulcerans Disease (Buruli Ulcer) Following a Human Bite. Clin Infect Dis 
36: e67–e68. doi:10.1086/367660. 
46.  Meyers WM, Shelly WM, Connor DH, Meyers EK (1974) Human Mycobacterium ulcerans 
infections developing at sites of trauma to skin. Am J Trop Med Hyg 23: 919–923. 
47.  Merritt RW, Walker ED, Small PLC, Wallace JR, Johnson PDR, et al. (2010) Ecology and 
transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 4: e911. 
doi:10.1371/journal.pntd.0000911. 
48.  Raghunathan PL, Whitney EAS, Asamoa K, Stienstra Y, Taylor TH, et al. (2005) Risk 
factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-
control study in Ghana. Clin Infect Dis Off Publ Infect Dis Soc Am 40: 1445–1453. 
doi:10.1086/429623. 
49.  Debacker M, Portaels F, Aguiar J, Steunou C, Zinsou C, et al. (2006) Risk factors for 
Buruli ulcer, Benin. Emerg Infect Dis 12: 1325–1331. doi:10.3201/eid1209.050598. 
50.  Pouillot R, Matias G, Wondje CM, Portaels F, Valin N, et al. (2007) Risk factors for buruli 
ulcer: a case control study in Cameroon. PLoS Negl Trop Dis 1: e101. 
doi:10.1371/journal.pntd.0000101. 
51.  Williamson HR, Benbow ME, Nguyen KD, Beachboard DC, Kimbirauskas RK, et al. 
(2008) Distribution of Mycobacterium ulcerans in buruli ulcer endemic and non-endemic 
aquatic sites in Ghana. PLoS Negl Trop Dis 2: e205. doi:10.1371/journal.pntd.0000205. 
52.  Johnson PDR, Azuolas J, Lavender CJ, Wishart E, Stinear TP, et al. (2007) 
Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, 
southeastern Australia. Emerg Infect Dis 13: 1653–1660. doi:10.3201/eid1311.061369. 
53.  Bratschi MW, Ruf M-T, Andreoli A, Minyem JC, Kerber S, et al. (2014) Mycobacterium 
ulcerans persistence at a village water source of Buruli ulcer patients. PLoS Negl Trop 
Dis 8: e2756. doi:10.1371/journal.pntd.0002756. 
 Introduction 23 
 
54.  Marsollier L, Sévérin T, Aubry J, Merritt RW, Saint André J-P, et al. (2004) Aquatic snails, 
passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol 70: 6296–6298. 
doi:10.1128/AEM.70.10.6296-6298.2004. 
55.  Willson SJ, Kaufman MG, Merritt RW, Williamson HR, Malakauskas DM, et al. (2013) 
Fish and amphibians as potential reservoirs of Mycobacterium ulcerans, the causative 
agent of Buruli ulcer disease. Infect Ecol Epidemiol 3. doi:10.3402/iee.v3i0.19946. 
56.  Portaels F, Meyers WM, Ablordey A, Castro AG, Chemlal K, et al. (2008) First cultivation 
and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop 
Dis 2: e178. doi:10.1371/journal.pntd.0000178. 
57.  Marsollier L, Robert R, Aubry J, Saint André J-P, Kouakou H, et al. (2002) Aquatic 
insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 68: 4623–4628. 
58.  Marion E, Eyangoh S, Yeramian E, Doannio J, Landier J, et al. (2010) Seasonal and 
regional dynamics of M. ulcerans transmission in environmental context: deciphering the 
role of water bugs as hosts and vectors. PLoS Negl Trop Dis 4: e731. 
doi:10.1371/journal.pntd.0000731. 
59.  Doannio JMC, Konan KL, Dosso FN, Koné AB, Konan YL, et al. (2011) [Micronecta sp 
(Corixidae) and Diplonychus sp (Belostomatidae), two aquatic Hemiptera hosts and/or 
potential vectors of Mycobacterium ulcerans (pathogenic agent of Buruli ulcer) in Cote 
d’Ivoire]. Médecine Trop Rev Corps Santé Colon 71: 53–57. 
60.  Benbow ME, Williamson H, Kimbirauskas R, McIntosh MD, Kolar R, et al. (2008) Aquatic 
invertebrates as unlikely vectors of Buruli ulcer disease. Emerg Infect Dis 14: 1247–
1254. doi:10.3201/eid1408.071503. 
61.  Fyfe JAM, Lavender CJ, Handasyde KA, Legione AR, O’Brien CR, et al. (2010) A major 
role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis 4: 
e791. doi:10.1371/journal.pntd.0000791. 
62.  O’Brien CR, Handasyde KA, Hibble J, Lavender CJ, Legione AR, et al. (2014) Clinical, 
microbiological and pathological findings of Mycobacterium ulcerans infection in three 
Australian Possum species. PLoS Negl Trop Dis 8: e2666. 
doi:10.1371/journal.pntd.0002666. 
63.  Durnez L, Suykerbuyk P, Nicolas V, Barrière P, Verheyen E, et al. (2010) Terrestrial 
small mammals as reservoirs of Mycobacterium ulcerans in benin. Appl Environ Microbiol 
76: 4574–4577. doi:10.1128/AEM.00199-10. 
64.  Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. (2004) Mycobacterium 
ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 
TM IH 9: 1297–1304. doi:10.1111/j.1365-3156.2004.01339.x. 
65.  Bratschi MW, Bolz M, Minyem JC, Grize L, Wantong FG, et al. (2013) Geographic 
distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the 
Mapé Basin of Cameroon. PLoS Negl Trop Dis 7: e2252. 
doi:10.1371/journal.pntd.0002252. 
66.  Junghanss T, Johnson RC, Pluschke G (2014) Mycobacterium ulcerans disease. 
Manson’s tropical diseases. Saunders. pp. 519–531. 
67.  Walsh DS, Portaels F, Meyers WM (2011) Buruli ulcer: Advances in understanding 
Mycobacterium ulcerans infection. Dermatol Clin 29: 1–8. doi:10.1016/j.det.2010.09.006. 
68.  Schütte D, Pluschke G (2009) Immunosuppression and treatment-associated 
inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). 
Expert Opin Biol Ther 9: 187–200. doi:10.1517/14712590802631854. 
69.  WHO | Treatment of Mycobacterium ulcerans disease (Buruli Ulcer) (n.d.). WHO. 
Available: http://www.who.int/buruli/treatment/en/. Accessed 11 September 2014. 
 
24 Introduction  
 
70.  Yeboah-Manu D, Kpeli GS, Ruf M-T, Asan-Ampah K, Quenin-Fosu K, et al. (2013) 
Secondary bacterial infections of Buruli ulcer lesions before and after chemotherapy with 
streptomycin and rifampicin. PLoS Negl Trop Dis 7: e2191. 
doi:10.1371/journal.pntd.0002191. 
71.  Goto M, Nakanaga K, Aung T, Hamada T, Yamada N, et al. (2006) Nerve damage in 
Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. 
Am J Pathol 168: 805–811. doi:10.2353/ajpath.2006.050375. 
72.  Converse PJ, Nuermberger EL, Almeida DV, Grosset JH (2011) Treating Mycobacterium 
ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the 
knife? Future Microbiol 6: 1185–1198. doi:10.2217/fmb.11.101. 
73.  George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) 
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. 
Science 283: 854–857. 
74.  Mve-Obiang A, Lee RE, Portaels F, Small PLC (2003) Heterogeneity of mycolactones 
produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect 
Immun 71: 774–783. 
75.  Scherr N, Gersbach P, Dangy J-P, Bomio C, Li J, et al. (2013) Structure-activity 
relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans. 
PLoS Negl Trop Dis 7: e2143. doi:10.1371/journal.pntd.0002143. 
76.  Ortiz RH, Leon DA, Estevez HO, Martin A, Herrera JL, et al. (2009) Differences in 
virulence and immune response induced in a murine model by isolates of Mycobacterium 
ulcerans from different geographic areas. Clin Exp Immunol 157: 271–281. 
doi:10.1111/j.1365-2249.2009.03941.x. 
77.  Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) 
Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune 
response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 1295–
1304. doi:10.1111/j.1462-5822.2005.00557.x. 
78.  Coutanceau E, Decalf J, Martino A, Babon A, Winter N, et al. (2007) Selective 
suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J 
Exp Med 204: 1395–1403. doi:10.1084/jem.20070234. 
79.  George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans toxin, 
mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect 
Immun 68: 877–883. 
80.  Bolz M, Ruggli N, Ruf M-T, Ricklin ME, Zimmer G, et al. (2014) Experimental infection of 
the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of 
Buruli ulcer disease. PLoS Negl Trop Dis 8: e2968. doi:10.1371/journal.pntd.0002968. 
81.  Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, et al. (2008) Mycolactone 
diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in 
peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2: e325. 
doi:10.1371/journal.pntd.0000325. 
82.  Hall B, Simmonds R (2014) Pleiotropic molecular effects of the Mycobacterium ulcerans 
virulence factor mycolactone underlying the cell death and immunosuppression seen in 
Buruli ulcer. Biochem Soc Trans 42: 177–183. doi:10.1042/BST20130133. 
83.  Silva MT, Portaels F, Pedrosa J (2009) Pathogenetic mechanisms of the intracellular 
parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 9: 699–710. 
doi:10.1016/S1473-3099(09)70234-8. 
84.  Hayman J (1993) Out of Africa: observations on the histopathology of Mycobacterium 
ulcerans infection. J Clin Pathol 46: 5–9. 
85.  Guarner J, Bartlett J, Whitney EAS, Raghunathan PL, Stienstra Y, et al. (2003) 
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis 9: 651–
656. 
 Introduction 25 
 
86.  Rondini S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas S, et al. (2006) 
Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by 
histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol 208: 
119–128. doi:10.1002/path.1864. 
87.  Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of 
the host immune response by a transient intracellular stage of Mycobacterium ulcerans: 
the contribution of endogenous mycolactone toxin. Cell Microbiol 7: 1187–1196. 
doi:10.1111/j.1462-5822.2005.00546.x. 
88.  Ruf M-T, Schütte D, Chauffour A, Jarlier V, Ji B, et al. (2012) Chemotherapy-associated 
changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer 
mouse model. Antimicrob Agents Chemother 56: 687–696. doi:10.1128/AAC.05543-11. 
89.  Mensah-Quainoo E, Yeboah-Manu D, Asebi C, Patafuor F, Ofori-Adjei D, et al. (2008) 
Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in 
Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop 
Med Int Health TM IH 13: 191–198. doi:10.1111/j.1365-3156.2007.01990.x. 
90.  Marsollier L, Honoré N, Legras P, Manceau AL, Kouakou H, et al. (2003) Isolation of 
three Mycobacterium ulcerans strains resistant to rifampin after experimental 
chemotherapy of mice. Antimicrob Agents Chemother 47: 1228–1232. 
91.  Andreoli A, Ruf M-T, Sopoh GE, Schmid P, Pluschke G (2014) Immunohistochemical 
monitoring of wound healing in antibiotic treated Buruli ulcer patients. PLoS Negl Trop 
Dis 8: e2809. doi:10.1371/journal.pntd.0002809. 
92.  Ruf M-T, Chauty A, Adeye A, Ardant M-F, Koussemou H, et al. (2011) Secondary Buruli 
ulcer skin lesions emerging several months after completion of chemotherapy: 
paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis 5: e1252. 
doi:10.1371/journal.pntd.0001252. 
93.  Beissner M, Herbinger K-H, Bretzel G (2010) Laboratory diagnosis of Buruli ulcer 
disease. Future Microbiol 5: 363–370. doi:10.2217/fmb.10.3. 
94.  Yeboah-Manu D, Danso E, Ampah K, Asante-Poku A, Nakobu Z, et al. (2011) Isolation of 
Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin 
Microbiol 49: 1997–1999. doi:10.1128/JCM.02279-10. 
95.  Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (2002) Bactericidal activity of 
rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents 
Chemother 46: 3193–3196. 
96.  Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new 
macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. 
Antimicrob Agents Chemother 45: 3109–3112. doi:10.1128/AAC.45.11.3109-3112.2001. 
97.  WHO | Provisional guidance on the role of specific antibiotics in the management of 
Mycobacterium ulcerans disease (Buruli ulcer) (n.d.). WHO. Available: 
zotero://attachment/245/. Accessed 19 June 2014. 
98.  Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) 
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised 
controlled trial. Lancet 375: 664–672. doi:10.1016/S0140-6736(09)61962-0. 
99.  Chauty A, Ardant M-F, Adeye A, Euverte H, Guédénon A, et al. (2007) Promising clinical 
efficacy of streptomycin-rifampin combination for treatment of buruli ulcer 
(Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029–4035. 
doi:10.1128/AAC.00175-07. 
100.  Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of 
combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans 
disease. Antimicrob Agents Chemother 54: 3678–3685. doi:10.1128/AAC.00299-10. 
 
26 Introduction  
 
101.  Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. (2010) Response 
to treatment in a prospective cohort of patients with large ulcerated lesions suspected to 
be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 4: e736. 
doi:10.1371/journal.pntd.0000736. 
102.  Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JAM, et al. (2010) All-oral 
antibiotic treatment for Buruli ulcer: a report of four patients. PLoS Negl Trop Dis 4: e770. 
doi:10.1371/journal.pntd.0000770. 
103.  Chauty A, Ardant M-F, Marsollier L, Pluschke G, Landier J, et al. (2011) Oral 
treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin 
Infect Dis Off Publ Infect Dis Soc Am 52: 94–96. doi:10.1093/cid/ciq072. 
104.  Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) 
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against 
mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis 5: e933. 
doi:10.1371/journal.pntd.0000933. 
105.  Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, et al. (2013) 
Mycobacterium ulcerans disease: experience with primary oral medical therapy in an 
Australian cohort. PLoS Negl Trop Dis 7: e2315. doi:10.1371/journal.pntd.0002315. 
106.  Schütte D, Umboock A, Pluschke G (2009) Phagocytosis of Mycobacterium ulcerans 
in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J 
Dermatol 160: 273–283. doi:10.1111/j.1365-2133.2008.08879.x. 
107.  Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007) 
Development of highly organized lymphoid structures in Buruli ulcer lesions after 
treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2. 
doi:10.1371/journal.pntd.0000002. 
108.  Ruf M-T, Sopoh GE, Brun LV, Dossou AD, Barogui YT, et al. (2011) Histopathological 
changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a 
role for surgical removal of necrotic tissue? PLoS Negl Trop Dis 5: e1334. 
doi:10.1371/journal.pntd.0001334. 
109.  O’Brien DP, Robson ME, Callan PP, McDonald AH (2009) “Paradoxical” immune-
mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of 
treatment success, not failure. Med J Aust 191: 564–566. 
110.  Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, et al. (2012) 
Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans 
infection. Clin Infect Dis Off Publ Infect Dis Soc Am 54: 519–526. doi:10.1093/cid/cir856. 
111.  O’Brien DP, Robson M, Friedman ND, Walton A, McDonald A, et al. (2013) 
Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical 
reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect 
Dis 13: 416. doi:10.1186/1471-2334-13-416. 
112.  Meyers WM, Shelly WM, Connor DH (1974) Heat treatment of Mycobacterium 
ulcerans infections without surgical excision. Am J Trop Med Hyg 23: 924–929. 
113.  Junghanss T, Um Boock A, Vogel M, Schuette D, Weinlaeder H, et al. (2009) Phase 
change material for thermotherapy of Buruli ulcer: a prospective observational single 
centre proof-of-principle trial. PLoS Negl Trop Dis 3: e380. 
doi:10.1371/journal.pntd.0000380. 
114.  Dobos KM, Spotts EA, Marston BJ, Horsburgh CR, King CH (2000) Serologic 
response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer 
disease. Emerg Infect Dis 6: 158–164. doi:10.3201/eid0602.000208. 
115.  Okenu DMN, Ofielu LO, Easley KA, Guarner J, Spotts Whitney EA, et al. (2004) 
Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination 
between cases of active Buruli ulcer disease and matched family controls in areas where 
the disease is endemic. Clin Diagn Lab Immunol 11: 387–391. 
 Introduction 27 
 
116.  Diaz D, Döbeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A, et al. (2006) Use 
of the immunodominant 18-kiloDalton small heat shock protein as a serological marker 
for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol CVI 13: 1314–1321. 
doi:10.1128/CVI.00254-06. 
117.  Röltgen K, Bratschi MW, Ross A, Aboagye SY, Ampah KA, et al. (2014) Late onset of 
the serological response against the 18 kDa small heat shock protein of Mycobacterium 
ulcerans in children. PLoS Negl Trop Dis 8: e2904. doi:10.1371/journal.pntd.0002904. 
118.  Schütte D, Pluschke G (2009) Immunosuppression and treatment-associated 
inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). 
Expert Opin Biol Ther 9: 187–200. doi:10.1517/14712590802631854. 
119.  Stanford JL, Revill WD, Gunthorpe WJ, Grange JM (1975) The production and 
preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans 
infection. J Hyg (Lond) 74: 7–16. 
120.  Gooding TM, Johnson PDR, Smith M, Kemp AS, Robins-Browne RM (2002) Cytokine 
profiles of patients infected with Mycobacterium ulcerans and unaffected household 
contacts. Infect Immun 70: 5562–5567. 
121.  Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, et al. (2004) Differential 
production of systemic and intralesional gamma interferon and interleukin-10 in nodular 
and ulcerative forms of Buruli disease. Infect Immun 72: 958–965. 
122.  Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, et al. (2005) 
Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease 
in Ghana. Clin Diagn Lab Immunol 12: 125–129. doi:10.1128/CDLI.12.1.125-129.2005. 
123.  Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D, et al. 
(2006) Systemic suppression of interferon-gamma responses in Buruli ulcer patients 
resolves after surgical excision of the lesions caused by the extracellular pathogen 
Mycobacterium ulcerans. J Leukoc Biol 79: 1150–1156. doi:10.1189/jlb.1005581. 
124.  Phillips R, Horsfield C, Kuijper S, Sarfo SF, Obeng-Baah J, et al. (2006) Cytokine 
response to antigen stimulation of whole blood from patients with Mycobacterium 
ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol 
CVI 13: 253–257. doi:10.1128/CVI.13.2.253-257.2006. 
125.  Schipper HS, Rutgers B, Huitema MG, Etuaful SN, Westenbrink BD, et al. (2007) 
Systemic and local interferon-gamma production following Mycobacterium ulcerans 
infection. Clin Exp Immunol 150: 451–459. doi:10.1111/j.1365-2249.2007.03506.x. 
126.  Gooding TM, Johnson PD, Campbell DE, Hayman JA, Hartland EL, et al. (2001) 
Immune response to infection with Mycobacterium ulcerans. Infect Immun 69: 1704–
1707. doi:10.1128/IAI.69.3.1704-1707.2001. 
127.  Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PDR (2003) Acquired 
T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin 
Infect Dis Off Publ Infect Dis Soc Am 36: 1076–1077. doi:10.1086/368315. 
128.  Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011) Mycobacterium 
ulcerans triggers T-cell immunity followed by local and regional but not systemic 
immunosuppression. Infect Immun 79: 421–430. doi:10.1128/IAI.00820-10. 
129.  Einarsdottir T, Huygen K (2011) Buruli ulcer. Hum Vaccin 7: 1198–1203. 
doi:10.4161/hv.7.11.17751. 
130.  Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, et al. (2009) Buruli ulcer 
disease: prospects for a vaccine. Med Microbiol Immunol (Berl) 198: 69–77. 
doi:10.1007/s00430-009-0109-6. 
131.  Revill WDL, Morrow RH, Pike MC, Ateng J (1973) A CONTROLLED TRIAL OF THE 
TREATMENT OF MYCOBACTERIUM ULCERANS INFECTION WITH CLOFAZIMINE. 
The Lancet 302: 873–877. doi:10.1016/S0140-6736(73)92005-9. 
28 Introduction  
 
132.  Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, et al. (2011) 
Spontaneous Clearance of Mycobacterium ulcerans in a Case of Buruli Ulcer. PLoS Negl 
Trop Dis 5. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201911/. Accessed 
20 August 2014. 
133.  BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results 
of a trial in Uganda (1969). Lancet 1: 111–115. 
134.  Smith PG, Revill WD, Lukwago E, Rykushin YP (1976) The protective effect of BCG 
against Mycobacterium ulcerans disease: a controlled trial in an endemic area of 
Uganda. Trans R Soc Trop Med Hyg 70: 449–457. 
135.  Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, et al. (2004) 
Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans 
osteomyelitis in Buruli ulcer disease. Infect Immun 72: 62–65. 
136.  Tanghe A, Content J, Van Vooren J-P, Portaels F, Huygen K (2001) Protective 
Efficacy of a DNA Vaccine Encoding Antigen 85A from Mycobacterium bovis BCG 
against Buruli Ulcer. Infect Immun 69: 5403–5411. doi:10.1128/IAI.69.9.5403-5411.2001. 
137.  Tanghe A, Dangy J-P, Pluschke G, Huygen K (2008) Improved protective efficacy of 
a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from 
Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis 2: e199. 
doi:10.1371/journal.pntd.0000199. 
138.  Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, et al. (2006) 
Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a 
Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect 
Inst Pasteur 8: 2075–2081. doi:10.1016/j.micinf.2006.03.009. 
139.  Roupie V, Pidot SJ, Einarsdottir T, Van Den Poel C, Jurion F, et al. (2014) Analysis of 
the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase 
domains in Mycobacterium ulcerans infected mice. PLoS Negl Trop Dis 8: e2604. 
doi:10.1371/journal.pntd.0002604. 
140.  Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, et al. (2012) Cellular 
immunity confers transient protection in experimental Buruli ulcer following BCG or 
mycolactone-negative Mycobacterium ulcerans vaccination. PloS One 7: e33406. 
doi:10.1371/journal.pone.0033406. 
141.  Fyfe JAM, Lavender CJ, Handasyde KA, Legione AR, O’Brien CR, et al. (2010) A 
major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis 
4: e791. doi:10.1371/journal.pntd.0000791. 
142.  Mitchell PJ, McOrist S, Bilney R (1987) Epidemiology of Mycobacterium ulcerans 
infection in koalas (Phascolarctos cinereus) on Raymond Island, southeastern Australia. 
J Wildl Dis 23: 386–390. 
143.  Sakaguchi K, Iima H, Hirayama K, Okamoto M, Matsuda K, et al. (2011) 
Mycobacterium ulcerans infection in an Indian flap-shelled turtle (Lissemys punctata 
punctata). J Vet Med Sci Jpn Soc Vet Sci 73: 1217–1220. 
144.  O’Brien C, Kuseff G, McMillan E, McCowan C, Lavender C, et al. (2013) 
Mycobacterium ulcerans infection in two alpacas. Aust Vet J 91: 296–300. 
doi:10.1111/avj.12071. 
145.  Van Zyl A, Daniel J, Wayne J, McCowan C, Malik R, et al. (2010) Mycobacterium 
ulcerans infections in two horses in south-eastern Australia. Aust Vet J 88: 101–106. 
doi:10.1111/j.1751-0813.2009.00544.x. 
146.  Elsner L, Wayne J, O’Brien CR, McCowan C, Malik R, et al. (2008) Localised 
Mycobacterium ulcerans infection in a cat in Australia. J Feline Med Surg 10: 407–412. 
doi:10.1016/j.jfms.2008.03.003. 
147.  Walsh DS, Meyers WM, Krieg RE, Walsh GP (1999) Transmission of Mycobacterium 
ulcerans to the nine-banded armadillo. Am J Trop Med Hyg 61: 694–697. 
 Introduction 29 
 
148.  Walsh DS, Dela Cruz EC, Abalos RM, Tan EV, Walsh GP, et al. (2007) Clinical and 
histologic features of skin lesions in a cynomolgus monkey experimentally infected with 
Mycobacterium ulcerans (Buruli ulcer) by intradermal inoculation. Am J Trop Med Hyg 
76: 132–134. 
149.  Krieg RE, Hockmeyer WT, Connor DH (1974) Toxin of Mycobacterium ulcerans. 
Production and effects in guinea pig skin. Arch Dermatol 110: 783–788. 
150.  Williamson HR, Mosi L, Donnell R, Aqqad M, Merritt RW, et al. (2014) Mycobacterium 
ulcerans Fails to Infect through Skin Abrasions in a Guinea Pig Infection Model: 
Implications for Transmission. PLoS Negl Trop Dis 8. Available: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983084/. Accessed 3 September 2014. 
151.  Fenner F (1956) The pathogenic behavior of Mycobacterium ulcerans and 
Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc 
73: 650–673. 
152.  Converse PJ, Xing Y, Kim KH, Tyagi S, Li S-Y, et al. (2014) Accelerated detection of 
mycolactone production and response to antibiotic treatment in a mouse model of 
Mycobacterium ulcerans disease. PLoS Negl Trop Dis 8: e2618. 
doi:10.1371/journal.pntd.0002618. 
153.  Converse PJ, Almeida DV, Nuermberger EL, Grosset JH (2011) BCG-mediated 
protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis 
5: e985. doi:10.1371/journal.pntd.0000985. 
154.  Shepard CC, McRae DH (1968) A method for counting acid-fast bacteria. Int J Lepr 
Mycobact Dis Off Organ Int Lepr Assoc 36: 78–82. 
155.  Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, et al. (2012) 
Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy 
of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Negl Trop Dis 6: 
e1925. doi:10.1371/journal.pntd.0001925. 
156.  Fyfe JAM, Lavender CJ, Johnson PDR, Globan M, Sievers A, et al. (2007) 
Development and application of two multiplex real-time PCR assays for the detection of 
Mycobacterium ulcerans in clinical and environmental samples. Appl Environ Microbiol 
73: 4733–4740. doi:10.1128/AEM.02971-06. 
157.  Lavender CJ, Fyfe JAM (2013) Direct detection of Mycobacterium ulcerans in clinical 
specimens and environmental samples. Methods Mol Biol Clifton NJ 943: 201–216. 
doi:10.1007/978-1-60327-353-4_13. 
  
 
31 
 
Objectives 
 
Within the framework of the establishment of a new field site in the remote Mapé dam region 
of Cameroon, specific objectives of this thesis were to: 
1. describe the epidemiology of Buruli ulcer in the Mapé Basin of Cameroon with a 
special focus on the laboratory confirmation of the clinically diagnosed patients by 
quantitative real time PCR and M. ulcerans cultivation 
2. initiate the build-up of a M. ulcerans isolate collection from Cameroonian patients by 
devising an optimal procedure for transport and decontamination of clinical samples 
after a long time span between sampling and culture initiation 
3. study the phylogeny of the cultivated Cameroonian M. ulcerans strains by whole 
genome sequencing with the aim of gaining insight into transmission by combining 
genomic and geographical data 
 
A vaccine against M. ulcerans would be of great benefit if used for prophylaxis as well as 
therapeutically. As a partner in the EU funded collaborative project BuruliVac we aimed at 
evaluating the potential for developing a protein subunit-vaccine against M. ulcerans and at 
gaining insight into the nature of protective immune responses against M. ulcerans and 
correlates of protection.  
Within the framework of the BuruliVac project specific objectives of this thesis were to: 
4. identify and produce M. ulcerans protein vaccine candidates as recombinant proteins 
in E. coli and formulate the purified proteins with immunostimulatory molecules 
(adjuvants) 
5. generate vesicular stomatitis virus (VSV) replicons encoding for M. ulcerans protein 
vaccine candidates, study their expression in VSV-infected cells and define an 
optimal immunization protocol in mice 
6. deliver M. ulcerans protein vaccine candidates in genetically modified Plasmodium 
berghei parasites in an infection treatment vaccination approach 
7. investigate the immunogenicity and the protective potential of the three different 
delivery systems in a mouse model of Buruli ulcer 
8. develop the pig as animal model for Buruli ulcer for the profiling of advanced 
candidate vaccines and to study early forms of the disease 
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Abstract 
Buruli ulcer (BU), a neglected tropical disease of the skin, caused by Mycobacterium 
ulcerans, occurs most frequently in children in West Africa. Risk factors for BU include 
proximity to slow flowing water, poor wound care and not wearing protective clothing. Man-
made alterations of the environment have been suggested to lead to increased BU 
incidence. M. ulcerans DNA has been detected in the environment, water bugs and recently 
also in mosquitoes. Despite these findings, the mode of transmission of BU remains poorly 
understood and both transmission by insects or direct inoculation from contaminated 
environment have been suggested. Here we investigated the BU epidemiology in the Mapé 
basin of Cameroon where the damming of the Mapé River since 1988 is believed to have 
increased the incidence of BU. Through a house-by-house survey in spring 2010, which also 
examined the local population for leprosy and yaws, and continued surveillance thereafter, 
we identified, till June 2012, altogether 88 RT-PCR positive cases of BU. We found that, the 
age adjusted cumulative incidence of BU was highest in young teenagers and in individuals 
above the age of 50 and that very young children (<5) were underrepresented among cases. 
BU lesions clustered around the ankles and at the back of the elbows. This pattern neither 
matches any of the published mosquito biting site patterns, nor the published distribution of 
small skin injuries in children, where lesions on the knees are much more frequent. The 
option of multiple modes of transmission should thus be considered. Analyzing the 
geographic distribution of cases in the Mapé Dam area revealed a closer association with the 
Mbam River than with the artificial lake. 
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Author Summary 
Buruli ulcer (BU) is an infectious disease caused by Mycobacterium ulcerans that is affecting 
mostly children in endemic areas of West Africa. Proximity to slow flowing water is a risk 
factor, but the exact mode of transmission of BU remains unclear. Man-made environmental 
changes, such as sand mining, damming of rivers and irrigation have been implicated with 
increases in disease incidence. Here we report findings from a survey for BU and continued 
case detection thereafter in the Bankim Health District of Cameroon. In this area, the local 
population believed that the damming of the Mapé River has led to the emergence of BU. In 
28 months we identified 88 laboratory confirmed cases of BU. Studying these cases, we 
found that the age adjusted cumulative incidence of BU in the elderly is similar to that in 
children and that the distribution pattern of BU lesions neither matches mosquito biting 
patterns nor the distribution of small skin injuries. Multiple modes of transmission should 
therefore be considered. Our data further showed that the patients appear to have closer 
contact to the local Mbam River than to the artificial Mapé dam reservoir. 
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Introduction 
Buruli ulcer (BU), a neglected tropical disease (NTD) of the skin, is caused by 
Mycobacterium ulcerans [1] and if untreated, can lead to disability. Worldwide, local BU 
incidence rates are highest in West Africa and Australia, where the classical lineage of M. 
ulcerans is found [2–4] and the disease occurs at different foci in the endemic countries. Both 
sexes can be affected by the disease and although individuals of all ages can get BU, most 
of the patients are less than 15 years old [5]. In Cameroon, BU was first described in 1969 in 
the Nyong river valley where during a cross-sectional survey in 2001, a total of 436 clinically 
diagnosed cases of active or inactive BU were found [6]. Since then, the Bankim Health 
District (HD) has been identified as an additional BU endemic area in Cameroon [7]. In this 
area, where our research has been carried out, the local population suspects that the 
creation of an artificial lake, by damming of the Mapé River in 1988, has led to an increase in 
BU incidence. Risk factors for BU include proximity to slow flowing water, poor wound care 
and not wearing protective clothing [8]. However, the exact mode of transmission has not yet 
been elucidated [9,10]. Clinically, BU presents with symptoms ranging from nodules, plaques 
and oedemas to ulcers [11]. The cytotoxic and immunosuppressive toxin, mycolactone, 
uniquely produced by M. ulcerans, is believed to account for most of the pathology of BU 
[12]. The severity of cases is classified into three categories, with ‘1’ being patients with small 
(≤ 5cm dimeter) lesions, ‘2’ patients with medium size lesions (5–15 cm) and ‘3’ being 
patients with large (> 15cm) lesions, multiple lesions or lesions at critical sites [13]. Many BU 
cases identified in rural areas are still diagnosed based on clinical symptoms only, although 
the use of laboratory diagnosis is highly recommended by the World Health Organization 
(WHO). In 2004, the WHO introduced the use of the combination of streptomycin and 
rifampicin given daily for 8 weeks as treatment [14]. However, surgery and wound 
management remain critical aspects of BU care [15,16]. 
During our investigations of BU in the Bankim HD, we also examined the local population for 
two other NTDs of the skin, namely yaws and leprosy. Yaws is caused by Treponema 
pallidum (T. pallidum) subspecies pertunu, and is transmitted through skin and mucous 
membrane contact [17,18]. After an initial single lesion, the disease progresses to secondary 
multiple lesions and in about 10% of cases it causes permanent disability [18]. Leprosy is 
caused by Mycobacterium leprae, which is believed to be transmitted by the respiratory route 
and can cause major disabilities through nerve damage. Diagnosis of yaws and leprosy 
relies mainly on physical examinations [17,19] and treatment of both diseases is feasible with 
antibiotics [17,20]. 
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The objectives of the present study were i) to conduct an exhaustive survey for BU, yaws 
and leprosy in the Bankim HD; ii) to continuously monitor the occurrence of BU in the Mapé 
Dam area; and iii) to examine the age distribution, geographic origin and distribution of 
lesions of the real-time polymerase chain reaction (RT-PCR) confirmed cases of BU to 
underpin future environmental and social science studies. 
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Materials and Methods 
Ethical Statement 
Approval for the survey and the subsequent continuous enrolment of cases was obtained 
from the Cameroon National Ethics Committee (N°041/CNE/DNM/09 and 
N°172/CNE/SE/2011) and the Ethics Committee of Basel (EKBB, reference no. 53/11). 
Participation in all aspects of the study was voluntary and all patients, independent of their 
study participation, were treated according to national treatment standards. All clinically 
confirmed cases who participated in the study provided written informed consent. 
Study Area 
The study was conducted in the Mapé Dam region of Cameroon (Figure 1) at two different 
geographical scales. The initial phase of the study was conducted in the Bankim HD which 
consists of seven Health Areas (HA): Atta; Songkolong, Somié, Nyamboya, Bandam, Bankim 
Urban and Bankim Rural. The health care infrastructure of the Bankim HD consists of one 
public district hospital, six primary and four private health centres (HC). All of these facilities 
employ two medical doctors and approximately 30 nurses. For the later part of the study, 
bordering regions in the 4 HD surrounding the Bankim HD (Nwa HD, Malantouen HD, Mayo 
Darle HD, Yoke HD) were also included in the study area. The main environmental features 
of the area are the Mapé Dam and the Mbam River. 
Survey procedures 
In early 2010 (March 22 to April 19), we conducted an exhaustive cross-sectional house-by-
house survey for BU, leprosy and yaws in the 88 villages of the Bankim HD (Figure 1). 
Eleven teams of three trained field workers, namely one local nurse and two local community 
relays, were employed to interview all inhabitants. Field workers were trained for two days on 
the use of the questionnaire and the clinical signs of the three diseases investigated. At the 
household level, demographic information of all inhabitants was collected and posters with 
photographs of the clinical presentations of the diseases were shown. Households with 
suspected cases were re-visited by staff with extensive experience in the diagnosis of BU, 
leprosy and yaws. From clinically confirmed BU cases, samples were collected for laboratory 
confirmation as follows. Two or three dry swabs were collected from ulcerative lesions or a 
fine needle aspirate (FNA) was drawn from non-ulcerative lesions [21]. To facilitate handling 
of FNA samples, they were transferred onto a swab. 
Prospective BU surveillance 
Following the survey, we continued to monitor the occurrence of all new cases of BU in the 
Bankim HD by community and HC based case referral and regular supervision until the end 
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of June 2012. For this, a health worker, trained and experienced in the diagnosis of BU, 
regularly visited all HC in the Bankim HD and areas of the adjacent Malantouen HD. During 
these visits, suspected cases who independently came forward or who were referred to the 
HC by community or family members, were evaluated and if clinically confirmed, asked to 
come for treatment. Before treatment, swabs or an FNA were collected for laboratory 
confirmation as described above. In addition to demographic and clinical information, the 
houses where the patients lived for at least a year before disease onset were mapped using 
a GPS device. From the GPS device, coordinates were only recorded once the GPS receiver 
showed an accuracy of below 10m. Details of the location of the lesions on the patient’s 
bodies were also collected and documented by photographs. Both clinically confirmed BU 
cases identified in the survey and during the continuous case detection were included in the 
cohort of patients investigated here. 
Laboratory Confirmation of BU Cases 
Samples were locally stored at 4ºC before transport to the laboratory where definite BU 
diagnosis was obtained by insertion sequence (IS) 2404 RT-PCR. Analysis was done 
according to the protocol developed by Fyfe et al. [22,23]. In brief, swabs were transferred 
into glass bottles containing glass beads with 2-5mL of PBS, and the bottle vortexed for 1.5 
minutes. From 1mL of the solution, DNA was extracted and RT-PCR performed. DNA was 
amplified in a StepOnePlus Real-Time PCR System (Applied Biosystems) and data analyzed 
using the Applied Biosystems StepOne Software (2.2.2). 
Analysis of lesion distribution 
Using published age specific relative body surface areas (RBSA) [24] and the number of 
patients in each of the age groups, the weighted average RBSAs of a model person (all 
ages), a model child (<15), and a model adult (≥15) were computed. If required to perform a 
Fisher's exact test, RBSA were converted to counts which add up to the observed number of 
lesions. The shape file used to analyze lesion localizations is found in Dataset S1. 
Statistical analysis 
Continuous variables were summarized as means and standard deviation or medians and 
interquartile ranges and categorical ones as counts and percentages. The Fisher’s exact or 
Chi-squared tests were used to compare categorical characteristics between groups and 
Student t-tests or Mann-Whitney U-test in the case of continuous variables. Multiple 
comparisons were adjusted for using a Bonferroni correction. The software, SAS (SAS 
Institute, Cary, USA; release 9.3), RStudio (RStudio, Boston, USA, version 0.95.262) and R 
(The R Foundation for Statistical Computing; version 2.15.1) were used to perform the 
statistical analysis. Geographic data and the localisation of lesions were analyzed with 
ArcGIS ArcMap (Economic and Social Research Institute, Redlands, USA; version 10.0). 
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Results 
Survey for BU, leprosy and yaws in the Bankim HD 
In the course of the survey, a total of 48 962 individuals in 9 344 households (Figure 1) were 
interviewed. The population of one village (approximately 550 people) refused to participate 
in the study. Assessing demographics and living conditions in the Bankim HD (Table 1), we 
found that the local population is very young with an average age of 19.3±17.0 (median = 
14.0, interquartile range = 6.0 to 28.0), that 51.4% of the population are women and that 
overall, 61.2% of the population have attended school at some point in their lives. We further 
observed that Christianity is the most common (64.9%) religion and that, apart from the 
young members of society which are either students (32.2%) or children (23.5%), the most 
common professions in the district are farming (16.9%) and household work (17.4%). In 
terms of living conditions we found that there are on average 5.2 individuals living in each 
household and 26.8% of the households have a mosquito net. Further, our data showed that 
only 38.3% of the population have access to clean drinking water that comes at least from a 
fortified well and that the roofs and floors of the local houses are often very poorly 
constructed. Table 1 also shows that, the main local differences in the level of development 
in the HD exist between the six rural HA and the Bankim Urban HA (BA HA), which includes 
the town of Bankim (77.4% of the BA HA population) and nine small settlements around it. 
The higher level of development in the BA HA is reflected by the significantly higher 
percentage of people having gone to school at some point in their lives (p-value < 0.0001) or 
by the significantly better access to clean drinking water (p-value < 0.0001). Furthermore, in 
the BA HA the proportion of houses with better flooring (p-value < 0.0001) and walls (p-value 
= 0.0037) is also significantly higher compared to the other HA. 
In the survey, we identified 32 cases of leprosy, 29 cases of yaws and 25 cases of BU based 
on clinical symptoms. With 32 cases of leprosy, the population-adjusted prevalence was at 
6.5 cases per 10’000. The majority (70%) of the identified leprosy cases suffered from the 
multibacillary form of the disease and 22% of them were previously known but had 
abandoned their treatment and needed treatment re-initiation. Of the 29 yaws cases 
identified, 28% presented with the advanced symptom of hyperkeratosis and of the BU 
cases, 23% (6 cases) could be re-confirmed by RT-PCR. 
Laboratory confirmation of BU 
In the five months after the survey (April 2010 to August 2010), only two new RT-PCR 
reconfirmed BU cases were identified (Figure 2). Following this lag, between September 
2010 and June 2012 (22 months) there was a steady flow of about 2.5 new RT-PCR 
confirmed BU cases per month from the Bankim HD. During this period, RT-PCR confirmed 
BU patients from the surrounding HDs (about 1.2 per month) also reported to BU treatment 
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facilities in the Bankim HD. Overall, our study identified 157 clinically confirmed cases of BU 
of which 88 (56%) could be confirmed by RT-PCR. Of the non-confirmed patients, 48 (31%) 
tested negative in RT-PCR and of 21 patients (13%) no samples were collected. Gender 
ratio, age distribution, average disease duration prior to consultation, and proportion of 
category 3 cases were comparable between the RT-PCR positive and negative patients. 
Only age differed significantly (p-value = 0.034) between the RT-PCR confirmed and the 
non-confirmed cases with the average age of the confirmed cases being 21.2 and that of the 
non-confirmed ones being 29.3. To ensure the reliability of our conclusions we focused the 
remaining analysis only on the 88 RT-PCR confirmed BU cases. Age distribution (p-value = 
0.4754) and professions (p-value = 0.5161) did not differ significantly between the population 
of the Bankim HD and the confirmed BU patients. The gender distribution among patients 
was moderately different (p-value = 0.061) from that of the overall population with a larger 
proportion of males among the confirmed BU cases. 
Spatial distribution of BU cases in the Mapé basin 
To better describe BU epidemiology in the Mapé basin we set out to identify the exact 
geographic origin of all 88 laboratory confirmed cases in our cohort. Based on information 
from the patients or their close relatives we were able to determine the HD of origin for 86 
(98%) of the cases (Figure S1). For the remaining 2 cases we could only determine that they 
did not live in the Bankim HD for the year before the onset of symptoms, but we could not 
conclusively determine which HD they were from. Studying the distribution of cases by HD, 
we found that the proportion of category 1 cases among the patients originating from inside 
the Bankim HD (24/62) was significantly higher (p-value = 0.039) compared to the cases 
from the surrounding HDs (5/26; Figure S1). For the 62 cases that originated from within the 
Bankim HD we were also able to determine their HA of origin. Using the population data as 
collected by the survey, we were then able to calculate the cumulative incidence rate of BU 
per HA in the Bankim HD during our study. As shown in Figure 3A, the cumulative incidence 
rate of BU in the Bankim HD is highest in the BR HA (5.08/1’000). The cumulative incidence 
rate in this HA is significantly higher compared to all other HA in the HD (p-value < 0.001). 
Interestingly the cumulative incidence rate is also significantly higher in the southern HA (BR, 
BA, BD, NY) compared to the northern HA (AT, SO, SG) of the Bankim HD (p-value < 0.001) 
(Figure 3A). Finally, for more detailed spatial analysis, the exact domiciles of 79 (89.8%) of 
the confirmed BU cases were mapped (Figure 3B). For 7 of the remaining cases (Bankim 
HD: 3 from the Bandam HA, 1 from the Somié HA; surrounding HD: 1 from the Malantouen 
HD, and 2 of unknown origin) we could not conclusively identify the exact house where they 
lived before the onset of BU. An additional two cases (1 each from the Nwa HD and Mayo 
Darle HD) are not considered in the analysis because they originated from outside of the 
Mapé basin. Based on the known exact origin of the cases that came from within the Bankim 
 Results     Chapter 1 43 
 
HD (n=58) and who were therefore identified by the same case finding strategy, a Kernel 
function was used to compute the density of BU in the Bankim HD (Figure 3B). This BU 
density map shows that most of the cases occur in the southern part of the Bankim HD, 
particularly along the Mbam River and in the area between the Mapé Dam reservoir and that 
river. The exact origins of 80.8% (21/26) of the BU cases from outside of the Bankim HD, 
indicate that the local BU focus expands outside of the Bankim HD, in particular westwards 
into the Malantouen HD (Figure 3B). 
Age and gender distribution of cases 
The median age of the 88 RT-PCR confirmed cases was 12.5 (interquartile range= 8.0 to 
30.0). The age of patients ranged from 0.5 to 73, 52 out of 88 (59.1%) were children (age 
<15) and 11 (12.5%) were older than 50. The gender ratio of all cases was 1.44 male / 
female. In children this ratio was 1.89, in the 15 to 50 year olds it was 0.79 and in the above 
50 year olds, it was 1.75. The age dependent variation in the gender ratio was not 
statistically significant (p-value = 0.20). 
With the ages of the 62 (70.5%) cases of BU which originated from within the Bankim HD 
and the population age distribution as collected in the survey (Figure 4A and Table 1), we 
computed the age adjusted cumulative incidence rate of BU in the Bankim HD for the period 
of the study. As shown in Figure 4B, we observed a low age adjusted cumulative incidence 
rate of BU in individuals aged below four years. The rate then peaked in children aged 
between four and < 14 years of age, with the 12 to <14 year olds particularly affected (34.4 
cases per 10’000 inhabitants). Interestingly, the age adjusted cumulative incidence rate 
peaks again in the over 50 year olds (27.0 cases per 10’000 inhabitants; Figure 4B). 
Localisation of BU lesions  
In the laboratory confirmed BU patients studied here, 49/88 (55.7%) lesions occurred on the 
lower limbs, 27/88 (30.7%) on the upper limbs, 2/88 (2.3%) on the head and neck and 10/88 
(11.4%) on the trunk. One of the trunk lesions occurred on the genitals. Two patients had 
multiple lesions and only the initial lesion was considered for analysis. The distribution of 
lesions differed significantly (p-value <0.001) from the relative body surface area (RBSA; 
Table S1). Interestingly, most of the lesions (52.3%) occurred in close proximity to joints with 
clusters around the ankles (19.2 %) and elbows (15.9 %; Figure 5A, 5B and Table S2). When 
analyzing the occurrence of lesions on the different body parts, we did not observe any 
statistically significant difference between lesions occurring on the right or left or front or back 
of the patients. However, when analyzing the occurrence of lesions on the joints, we did 
observe a statistically significant difference between the lesions on the front or back of the 
joints (p-value = 0.012), in particular there was a significant difference between the 
occurrence of lesion on the front or back of the elbow (p-value = 0.005). No such difference 
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was observed when analyzing the joint lesions on the right of left of the patients’ bodies. 
Analyzing the distribution of the lesions by body part, we found a moderately significant 
difference between males and females (p-value = 0.076) with the percentage of lesions on 
the trunk being significantly higher (p-value = 0.033) in males (Table S1). 
The distribution of lesions by body parts in children (Figure 5C and Table S1) was 
significantly different (p-value = 0.009) from the RBSA of children. Interestingly, only children 
(n=2) had lesions on the head and neck. Overall, the lesions appear more dispersed in 
children (Figure 5C and 5D). While, the difference in the general lesion distribution by body 
parts between adults and children (Table S1) was not statistically significant (p-value = 
0.154), there was a significant difference (p-value = 0.011) between the distribution of lesions 
at joints in children and adults. In particular, most joint lesions in adults occurred at the ankle 
(36.1%), whereas most joint lesions in children occurred at the elbow (19.2%). Finally in 
adults, lesions occurred mainly on the front and back of the feet and the distribution also 
differed significantly (p-value = 0.004) from what is expected based on the RBSA of adults 
(Figure 5C). 
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Discussion 
The 2011 Cameroon Demographic Health Survey (DHS) examined approximately 22’000 
adults (>14 years old) and found that the population is very young with roughly 24% being 
15-19 years old [25]. In the Bankim HD, we also observed a population that is strongly 
skewed towards young individuals and we found that living conditions and access to clean 
drinking water are very poor. Given the basic health infrastructure, these factors pose big 
challenges when addressing any health care related issues [26,27]. 
Although Cameroon has achieved nationwide leprosy elimination as defined by the WHO (< 
1 case per 10’000 inhabitants) [28], our data showed that leprosy remains endemic in the 
Bankim HD. The substantial proportion of leprosy patients that had previously abandoned 
treatment further demonstrated that the oral treatment regimen requires better patient 
monitoring to achieve good compliance. In 2010 Cameroon reported 800 cases of yaws [29] 
and our survey confirmed that the Bankim HD is a yaws focus. Studies on the use of oral 
antibiotics have again raised hope for the eradication of yaws [30–32]. However, until 
eradication is possible, the focus of leprosy and yaws care should be early detection, 
complete cure and prevention of disabilities. To achieve this, front line medical staff needs to 
be trained on clinical diagnosis and efficient case management. 
Characteristics of BU and the remote areas where it occurs have been suggested to 
necessitate active case searches for early case detection [33,34]. Indeed, house-by-house 
surveys have helped to elucidate BU epidemiology in Ghana and Ivory Coast [35,36]. In 
Cameroon a study around the Nyong River, identified 135 PCR confirmed cases of BU [6]. In 
the survey described here, the number of RT-PCR confirmed BU cases identified was 
smaller than expected. However, the lag of new cases during the first months after the 
survey indicated that the survey identified the cases present at that time. It cannot be 
excluded however, that a proportion of BU patients seeks to avoid contact with the formal 
health system. By continuous case detection, also accounting for the trust needed for cases 
to come forward [37], we identified 157 clinically diagnosed cases of BU (from April 2010 to 
June 2012). To increase validity of the findings [38,39], our analysis focused on the 88 
(56.1%) RT-PCR confirmed cases among them. False negative RT-PCR results are unlikely 
since we analyzed multiple samples from each patient (data not shown). Although accurate 
BU clinical diagnosis is possible [40], misdiagnosis rates of up to 40% have been reported 
emphasizing the pressing need for a point-of-care rapid diagnostic test [5,38,39,41–43]. 
Based on the number of BU cases in each of the HA in the Bankim HD and their respective 
populations, the BR HA was determined to have the highest cumulative incidence rate of BU 
in the Bankim HD. Furthermore, by detailed mapping of cases and through the use of a 
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geographic information system (GIS), we identified hot-spots of BU transmission along the 
Mbam River. With only few cases living in the immediate proximity of only the Mapé Dam 
reservoir, our data does not support the suspected direct importance of this man-made lake. 
This does not exclude that environmental changes associated with the damming of the Mapé 
River may have had a more indirect effect on the spread of BU in the wider area. Whether 
the relatively large proportion of patients living in the town of Bankim (11/79 GPS mapped 
cases), contracted BU there, remains to be investigated. By also mapping cases from 
outside of the Bankim HD, we found that the local BU endemic area is larger then previously 
described [7]. Indeed it is possible that, because of the differences in case finding strategy 
inside and outside of the Bankim HD, our findings from outside the HD under represent the 
true degree of BU endemicity in the areas surrounding the Bankim HD. Further studies are 
therefore needed to investigate BU endemicity in the entire Mapé basin in more detail. 
Ongoing environmental and social science research at the identified hot-spots of disease is 
aiming to further elucidate the mode of transmission of BU. 
BU affects individuals of all ages [15,34] but in the African endemic regions most patients are 
children [9,44]. However, when adjusting for the population age distribution, studies in Benin 
[45] and in Australia [46] showed that 75 to 79 year olds or the ≥74 olds, respectively, have 
the highest risk of contracting BU. Our data similarly showed that the age adjusted risk of BU 
is as high in the > 50 year olds as in children, a trend possibly associated with 
immunosenescence, the gradual deterioration of the immune system associated with natural 
age advancement [46,47]. It is interesting to note that cases among very young (< 5) 
children, which make up an even larger part of society than the 5 – 10 year olds, are 
relatively rare. This may indicate that compared to older children the very young children are 
less exposed to risk factors due to a smaller movement radius away from the house [10]. In 
the exposed individuals, host factors are likely to contribute to the degree of susceptibility 
[48]; seroepidemiological studies indicate that only a small proportion of exposed individuals 
develop clinical disease [49,50]. 
Detection of M. ulcerans DNA-positive mosquitoes in an Australian BU focus [46] as well as 
identification of the failure to wear protective clothing as a risk factor and of the use of 
mosquito repellent as a protective factor for BU [8], support the hypothesis that insects are 
involved in M. ulcerans transmission [10]. Most biting arthropods selectively feed at specifics 
sites based on visual, physical or chemical cues such as distance of the ground, breath and 
skin temperature of the bait [51–55]. The resulting feeding patterns are often focused either 
on the feet and ankles or the head of the human subject [52]. Interestingly for vector 
transmitted parasitic diseases with local manifestations such as cutaneous leishmaniasis and 
filariasis, it has been found that the lesion distribution correlates with the biting sites of the 
responsible vectors [56,57]. BU lesions occur mostly on the lower limbs [15,45,58–60] and in 
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adults, a focus on joints, specifically the elbows and ankles, has been reported [15,58]. 
Studies on the distribution of lesions also show that they are usually equally distributed 
between the left and right side of the body and compared to adults, children tend to have 
more lesions on the trunk [45,60]. Using GIS methodology we observed in this study that 
lesions cluster at specific locations on the limbs. We found that, particularly in adults, lesions 
occur mostly at locations where the skin is not commonly protected with clothing. As 
previously described, in females, which are more likely to cover their upper body with 
clothing, we found that there are less lesions on the trunk. In rural African villages children 
may often have their upper body exposed explaining the more dispersed distribution of their 
lesions. 
Detection of M. ulcerans DNA in the environment [10] and identification of poor wound care 
and failure to wear protective clothing as risk factors for BU [8] have led investigators to 
speculate that transmission may alternatively occur by skin trauma and direct contact with M. 
ulcerans contaminated environment [10]. A study in Canadian children found that children 9 
months and older have on average >3.5 recent skin injuries [61]. In 5 to 17 year olds injuries 
most often occur where the bones are close to the skin, i.e. at shins, knees, elbows and 
forearms. Injuries on the head were most common in children less than 5 years of age and 
lesions on genitals were rare in all ages [61]. While this study may have, due to differences in 
dress code and activities, limited relevance for Cameroonian children, it is remarkable that 
both BU lesions on the head in our cohort occurred in patients under the age of 5 [61]. While 
BU lesion distribution does not seem to correlate closely with the published distribution of 
insect bites, inoculation of skin injuries by a contaminated environmental source should lead, 
for example, to more lesions on the knees. Based on these data, the option of multiple 
modes of transmission should be considered. 
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Figure 1: Environmental Features and Population of the Bankim HD. 
The Bankim HD is located in the South-Western corner of the Adamaoua Region of 
Cameroon and encompasses most of the Mapé basin. The main environmental features of 
the area are the Mapé Dam reservoir and the Mbam River. The Bankim HD consists of 7 HA 
(red crosses depict the location of the main HC in each of the HA; BR: Bankim Rural; BA: 
Bankim Urban; BD: Bandam; NY: Nyamboya; SO: Somié; SG: Songkolong; AT: Atta) and is 
surrounded by four other HD. In early 2010 we conducted an exhaustive house-by-house 
survey and examined a total of 48’962 individuals in all HA of the district; population sizes of 
villages based on this survey are indicated by green circles. The village of Koumtchoum 
(black star; estimated population of 550) as a whole refused to participate in the survey and 
the village of Djaouro Tchi Arouna (470 inhabitants, located in the Somié HA between the HC 
of Somié and the town at the Nigerian border to the North-West of it) could not be mapped. 
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Figure 2: Identification of BU Cases in the Mapé Basin following the Survey. 
In the 27 months following the exhaustive survey all clinically diagnosed BU cases in the 
Bankim area were included in a cohort study. Cases are separated into the RT-PCR 
confirmed cases which occurred inside (black) and outside (grey) of the Bankim HD. RT-
PCR negative and non-laboratory examined cases occurring anywhere in the Mapé basin 
during the same time period are also shown (white). 
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Figure 3: Geographic Distribution of BU in the Mapé Basin. 
Based on the HA of origin of the 62 BU cases who originated within the Bankim HD and the 
population data collected in the survey, we computed the per HA cumulative incidence rate 
of BU in the Bankim HD (A). For detailed analysis, the places of residence of 58 (black 
points) of the 62 cases from the Bankim HD were mapped using a GPS device (B). For the 
remaining 4 RT-PCR confirmed cases which occurred inside the Bankim HD (3 from the 
Bandam HA, 1 from the Somié HA) we could not identify their home. Using a Kernel function 
the density of BU in the Bankim HD was computed based on the mapped cases (red: highest 
BU density). Panel B further shows the places of residence of 21 of the 26 RT-PCR 
confirmed cases of BU who originated from outside of the Bankim HD (brown points). For 
three of the remaining cases (1 from the Malantouen HD, and 2 of unknown origin) we could 
not identify their exact origin and two additional cases (1 each from the Nwa HD and Mayo 
Darle HD) are not shown because they originated from outside of the region shown on the 
map.
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Figure 4: Population Age Distribution and Age Adjusted Cumulative BU 
Incidence Rate in the Bankim HD. 
In the course of the exhaustive survey, data on the population age structure of the Bankim 
HD were collected (A). Using this age distribution and the ages of the RT-PCR confirmed BU 
cases which occurred inside of the Bankim HD (n=62), the age adjusted cumulative BU 
incidence rate (cases per 1’000 inhabitants) for the duration of the study could be computed 
(B).
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Figure 5: Lesion Localization. 
The localization of the lesions of all the RT-PCR confirmed BU patients (88) were mapped in 
detail and Kernel function was used to create a heat map of the lesion distribution (A). The 
localization of the lesions on the front and back and left (L) and right (R) of the patient’s 
bodies are shown. Studying the distribution of lesions, it was noted that they often occur at 
joints (B, example of two lesions on the ankle and one on the shoulder). Distribution of 
lesions in children (C, n=52) and adults (D, n=36) were also analyzed separately. 
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Figure S1: Disease Category by Health District. 
Most of the RT-PCR confirmed cases that were identified in the Bankim area originated from 
within the Bankim HD (n=62). However, patients from all of the surrounding HD also came to 
Bankim for BU treatment (Malantouen: 17; Nwa: 3; Yoko: 3; Mayo Drale: 1). The number of 
cases that occurred in each of the HD are classified by disease severity (red: category 3, 
orange: category 2, yellow: category 1). Two RT-PCR confirmed cases (both category 3, 
both from outside of the Bankim HD) could not be displayed because the location where the 
patient first showed symptoms of BU could not be conclusively determined. 
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Abstract 
Background: While cultivation of pathogens represents a foundational diagnostic approach 
in the study of infectious diseases, its value for the confirmation of clinical diagnosis of Buruli 
ulcer is limited by the fact that colonies of Mycobacterium ulcerans appear only after about 
eight weeks of incubation at 30ºC. However, for molecular epidemiological and drug 
sensitivity studies, primary isolation of M. ulcerans remains an essential tool. Since for most 
of the remote Buruli ulcer endemic regions of Africa cultivation laboratories are not easily 
accessible, samples from ulcers often have to be stored for extended periods of time prior to 
processing. The objective of the current study therefore was to determine which transport 
medium, decontamination method or other factors decrease the contamination rate and 
increase the chance of primary isolation of M. ulcerans bacilli after long turnover time.  
Methods: Swab and FNA samples for the primary cultivation were collected from clinically 
confirmed Buruli ulcer patients in the Mapé Basin of Cameroon. The samples were either 
stored in the semi-solid transport media 7H9 or Amies or dry for extended period of time prior 
to processing. In the laboratory, four decontamination methods and two inoculation media 
were evaluated and statistical methods applied to identify factors that decrease culture 
contamination and factors that increase the probability of M. ulcerans recovery.  
Results: The analysis showed: i) that the use of moist transport media significantly 
increased the recovery rate of M. ulcerans compared to samples kept dry; ii) that the choice 
of the decontamination method had no significant effect on the chance of M. ulcerans 
isolation; and iii) that Löwenstein-Jensen supplemented with antibiotics as inoculation 
medium yielded the best results. We further found that, ten extra days between sampling and 
inoculation lead to a relative decrease in the isolation rate of M. ulcerans by nearly 20 %. 
Finally, collection and processing of multiple samples per patient was found to significantly 
increase the M. ulcerans isolation rate. 
Conclusions: Based on our analysis we suggest a procedure suitable for the primary 
isolation of M. ulcerans strains from patients following long delay between sample collection 
and processing to a M. ulcerans strain collection for research purposes. 
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Background 
Buruli ulcer (BU), a neglected tropical disease of the skin caused by Mycobacterium 
ulcerans, has been reported from over 30 countries worldwide with most cases occurring in 
West Africa. Clinically BU presents with both non-ulcerative lesions, such as nodules, 
plaques and edema, as well as ulcers. The major burden of the disease falls on children 
between 5 and 15 years of age [1, 2]. Despite intensive research efforts, both the reservoir 
and the mode of transmission of M. ulcerans have remained unclear [1]. Currently available 
methods for laboratory diagnosis of BU are microscopy, histopathology, PCR for the M. 
ulcerans specific insertion sequence 2404 (IS2404) or primary culturing. Based on the high 
sensitivity and specificity, the IS2404 PCR test is considered the gold standard in BU 
diagnosis [2]. Historically, BU was treated by wide excision of lesions and tissue samples 
could easily be obtained for laboratory diagnosis. Since the introduction of rifampicin and 
streptomycin combination therapy in 2004 [3], samples for laboratory testing are fine needle 
aspirates (FNA) taken from closed lesions and swab specimens taken from the undermined 
edges of ulcers [4]. 
Although primary culturing of M. ulcerans can provide a definitive BU diagnosis, the value of 
this method for primary diagnosis is strongly hampered by the fact that colonies take two to 
three months to appear and even under optimal conditions the sensitivity of the method is 
limited [5, 6]. For clinical diagnosis, culturing therefore only represents an auxiliary to other 
methods for the laboratory confirmation of BU. However, for studies on treatment efficacy, 
molecular epidemiology, and drug sensitivity, primary isolation of M. ulcerans remains crucial 
[7, 8]. 
To prevent overgrowth with other faster growing microorganisms, primary culturing requires 
decontamination of clinical samples prior to culture inoculation [6]. The commonly used 
decontamination methods use NaOH and HCl (Petroff and reverse Petroff method) or oxalic 
acid (OA). Although necessary to prevent overgrowth, all of these methods have been shown 
to have a detrimental effect on the viability of M. ulcerans [6, 9, 10]. As for the culturing 
media on which M. ulcerans is isolated, PANTA, a mixture of the antibiotics polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim and azlocillin, can be used to prevent the growth 
of a range of microorganisms but does not have an inhibitory effect on the growth of M. 
ulcerans [10].  
Since for cultivation of M. ulcerans a sophisticated laboratory infrastructure is required, 
clinical specimens from BU patients often cannot be processed in a timely manner. It has 
been shown that from tissue specimens transported in semisolid transport medium, positive 
cultures can be obtained even if samples were kept at ambient temperature for more than 
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two months [11]. For FNA samples transported in liquid transport medium containing PANTA 
and processed within 2 weeks, Eddyani et al. further found a sensitivity of in vitro culture of 
17.6 %, which was not significantly lower than the culture positivity rate of 25.0 % obtained 
by culturing  tissue specimens from the same patients [12]. Yeboah-Manu et al. observed 
culture sensitivities of 41.7 % for FNA samples from non-ulcerative lesions and of 43.8 % for 
swab samples if they were transported on ice in transport media containing PANTA and 
processed within 24 hours [13]. The same study also yielded similar results when comparing 
the Petroff and the OA decontamination methods [13]. Further in a subset of samples in the 
same study, 33.3 % of swabs transported dry and processed between seven days and one 
month after collection were culture positive [13]. 
For the current study we set out to determine the best procedure for the cultivation of 
M. ulcerans from swab and FNA samples stored over extended periods of time prior to 
processing. Specifically, the objectives of the current study were to determine how transport 
medium, decontamination method, inoculated media, transport time or other factors 
decrease the contamination rate and increase the chance of primary isolation of M. ulcerans. 
The procedure devised here is suitable for the primary isolation of M. ulcerans strains from 
patients following long delay between sample collection and processing to establish a strain 
collection for research purposes. 
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Materials and Methods 
Patient recruitment and ethical statement 
For the current study samples were collected from BU patients attending health facilities in 
the Mapé Basin of Cameroon [14] between August 2010 and July 2012. Locally patients 
were diagnosed and treatment initiated based on clinical symptoms and if available Ziehl-
Neelsen staining. Samples for laboratory confirmation were collected and processed as 
described below. Ethical clearance for the study was obtained from the Cameroon National 
Ethics Committee (N°041/CNE/DNM/09 and N°172/CNE/SE/2011) and the Ethics Committee 
of Basel (EKBB, reference no. 53/11). Participation was voluntary and all patients who 
participated in the study or their legal guardian provided written informed consent.  
Sample collection, storage and transport 
Prior to the start of medical treatment FNA were collected from patients with non-ulcerative 
lesions and swabs from patients with ulcers. The number of swabs depended on the number 
of lesions, lesion size and clinical judgment. FNA were collected with sterile needles and 
swabs using individually packed sterile cotton swabs. To minimize the handling of needles 
and avoid any dilution of the samples in transport medium, FNA were transferred onto a 
cotton swab immediately after collection. These swabs were then processed the same as the 
swabs collected from ulcers and, in the remainder of the manuscript we refer to all samples 
as swabs. Swabs were stored dry, in 7H9 medium containing PANTA (7H9) or in the 
antibiotics free Amies medium (VWR International); the latter two being semi-solid transport 
media. Sterile 7H9 (Difco Middlebrook, Becton Dickinson and Company) transport medium 
was prepared to contain 0.5 % Agar-Agar (Merck), 0.2 % glycerol (Sigma), 2 % PANTA 
(Becton Dickinson and Company) and 10 % OADC enrichment (Becton Dickinson and 
Company) [11]. Briefly after autoclaving the dissolved 7H9 powder and the agar, the glycerol, 
PANTA and OADC were added and 5ml portions of the still warm medium was filled into 
empty cotton swab tubes (Copan). The transport medium was stored at 4ºC until use. 
Following sample collection, swabs were inserted into the tube containing the transport 
medium and locally stored at 4ºC whenever possible. Due to the remoteness of the BU 
endemic areas in which clinical samples for this study were collected, timely transport to 
adequately equipped laboratories with sufficient capacity was difficult. Therefore at 4-6 
month intervals, samples were transported to the laboratory at the Swiss Tropical and Public 
Health Institute at ambient temperature. Once in the laboratory, swabs were stored at 4ºC 
until processing. 
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PCR, decontamination and primary inoculation 
For DNA extraction and culturing, swabs were transferred to 14 mL McCartney glass bottles 
(Marienfeld, Germany) that were filled approximately to one third with 3 mm diameter glass 
beads (Marienfeld, Germany) and 2-5 mL of sterile phosphate buffered saline (PBS). The 
bottles were vortexed for 1.5 minutes and DNA was extracted from 1 mL of the solution as 
described by Lavender and Fyfe [15]. Extracts were analyzed in duplicate by IS2404 real-
time PCR (qPCR) as previously described [15]. 
Decontamination of 1 mL of the remaining extract in PBS was performed with 1 mL of 1 M 
NaOH for 10 minutes (NaOH_10min), 1 mL of 1 M NaOH for 20 minutes (NaOH_20min), 1 
mL of 5 % OA for 30 minutes (OA_30min) or 1 mL of 5 % OA for 1 hour (OA_1h) at room 
temperature with occasional vortexing. Some but not all extracts were decontaminated with 
multiple decontamination methods in parallel (Additional Table 1). Decontaminated extracts 
were diluted with 20 mL of sterile PBS. The decontaminated samples were centrifuged for 30 
minutes at 3000g, the supernatant decanted and the pellet re-suspended in 0.15 to 0.25 mL 
of sterile PBS. Of the re-suspended pellet, 0.1 mL was transferred to Löwenstein-Jensen (LJ) 
medium slants with glycerol (Becton Dickinson and Company) or the same LJ medium slants 
supplemented with 2 % PANTA (LJ_PANTA). As with the decontamination methods above, 
some but not all re-suspended pellets were inoculated on both media in parallel. 
Culture processing and M. ulcerans identification 
All inoculated cultures were incubated at 30ºC until M. ulcerans growth could be observed. 
Slants were regularly examined and discarded if contamination, i.e. overgrowth with other 
faster growing microorganisms, was detected. All inoculations with no growth were kept for a 
minimum of 25 weeks before discarding. Suspected M. ulcerans growth was confirmed by 
colony PCR using primers MU154 (5’-ggcagttacttcactgcaca-3’) and MU155 (5’-
cggtgatcaagcgttcacga-3’) and amplification for 32 cycles of 30 seconds at 94°C, 30 seconds 
at 60°C and 1 minute at 72°C. PCR products were resolved in a 1.5 % agarose gel. 
Statistical analysis 
To identify factors that affect the rate of contamination and recovery of M. ulcerans primary 
cultures, three sets of univariate and multivariate statistical analyses, one with all 
inoculations and two with subsets, were performed. The factors investigated included: 
transport medium, decontamination method, inoculation media, swab qPCR Ct value, patient 
qPCR result, the time from sampling to inoculation and the number of weeks before 
diagnosis as reported by the patient. The first analysis identified differences between 
inoculations that did not contaminate versus those that did result in contamination (non-
contamination vs. contamination). This analysis aimed at identifying factors that affect 
contamination of cultures of samples taken from lesions clinically suspected of BU, 
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independent of the presence of M. ulcerans on the swab. Specifically, the data set used for 
this analysis included both qPCR positive and negative swabs and inoculations with any of 
the three possible outcomes: M. ulcerans growth, contamination with another 
microorganisms or no growth. Swabs with a negative qPCR result in this data set were 
assigned a Ct value of 76.80 (reciprocal of the midpoint between zero and the minimum of 
1/Ct). These qPCR negative swabs were included in the analysis to investigate general 
factors that affect contamination of wound exudates and if the presence of M. ulcerans 
affects the rate of contamination. In the second analysis, a subset of inoculations was 
analyzed to identify factors that affect M. ulcerans growth (M. ulcerans growth vs. no growth). 
All inoculations with no realistic probability of resulting in M. ulcerans growth, i.e. 
contaminated inoculations and inoculations from swabs that were qPCR negative were 
excluded from this analysis. Finally in the third analysis, we studied factors that affected the 
recovery of M. ulcerans if some inoculations resulted in contamination (M. ulcerans growth 
vs. contamination or no growth). This subset included all inoculations originating from qPCR 
positive swabs independent of their outcome, i.e. also including swabs for which growth may 
have been undetectable because of overgrowth by other microorganisms. In this third 
analysis, the outcomes “no growth” and “contamination” were grouped together as the 
undesired outcome. Workflows of the swabs included in the three data sets are shown in 
Figure 1 and the numbers of samples decontaminated with two decontamination methods in 
parallel are listed in Additional Table 1. 
For the identification of factors that contribute to the outcomes studied, generalized linear 
mixed models with patient identification and identification of each individual swab as random 
effects were used. Factors included in the one-to-one analysis were: transport medium, 
decontamination method, inoculation medium, swab qPCR Ct value, per patient qPCR result, 
time from sampling to inoculation and the duration of the disease before diagnosis. Factors 
that individually had a p-value of the association of less than 0.2 were included in the 
multivariate analyses. The software SAS (SAS Institute, Cary, USA; release 9.3), RStudio 
(RStudio, Boston, USA, version 0.95.262) and R (The R Foundation for Statistical 
Computing; version 2.15.1) were used to perform the analyses. 
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Results 
Factors affecting the rate of contamination  
In total 443 swabs, collected from 73 qPCR confirmed and 22 non-confirmed patients were 
included in the analysis for factors affecting the rate of contamination. Of all these swabs, 
302 were qPCR positive with an average Ct value of 28.09 (Figure 1A). Of the 1125 culture 
inoculations from these swabs, 7.8 % (88/1125) resulted in M. ulcerans growth. The 88 M. 
ulcerans culture positive inoculations originated from samples collected from 31 patients, 
which corresponds to a per patient positivity of 32.6 % (Table 1). Further 52.5 % (591/1125) 
of the inoculations yielded no growth and 39.6 % (446/1125) resulted in contamination. The 
median time to detection of contamination was 5.0 (IQR = 4.0 to 11.0) days (Table 1). One-
to-one analysis was used to identify factors that should be included in the multivariate 
analysis (Additional Table 2). When studying the combined effect of factors on the rate of 
contamination, we found that the transport medium had an overall significant (p-value: 0.008) 
effect on the probability of contamination. Specifically, swabs transported dry had a 57.7 
times lower probability of contamination compared to swabs transported in Amies medium 
(Table 2). We found no significant difference in terms of the rate of contamination between 
swabs transported in 7H9 or Amies medium. As also shown in Table 2, there was no overall 
significant difference (p-value: 0.266) in the rate of contamination between the four 
decontamination methods evaluated here. The inoculated culture medium on the other hand 
significantly (p-value: <0.001) influenced the rate of contamination, with cultures on LJ having 
a 3.8 (1/0.264) times higher probability of contamination than cultures inoculated onto 
LJ_PANTA. The multivariate analysis further showed that there was a significant (p-value: 
0.007) interaction between transport medium and the number of days from sampling to 
inoculation (Table 2). Finally, both an increase in the Ct value of the swab (p-value: 0.236) 
and the storage time from sampling to inoculation (p-value: 0.606) did not have a significant 
effect on the rate of contamination of the cultures (Table 2). Overall, this analysis to identify 
conditions that were best suited to prevent contamination of M. ulcerans primary cultures 
suggested that swabs should be stored dry, any of the evaluated decontamination methods 
can be used, cultures should be inoculated onto LJ_PANTA and neither the Ct value of the 
IS2404 qPCR nor the time from sampling to inoculation had a significant effect on the rate of 
contamination. 
Factors affecting the rate of M. ulcerans recovery in primary culturing 
To identify factors that affect the recovery of M. ulcerans, 440 inoculations from 220 qPCR 
positive swabs originating from 66 qPCR positive patients were analyzed. Only the subset of 
swabs with a realistic probability of resulting in M. ulcerans growth, as defined in Material and 
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Methods above, were used for this analysis. The average Ct value of the swabs was 27.9. Of 
all the inoculations included in the analysis, 88 inoculations of exudates collected from 31 
patients resulted in M. ulcerans growth and the rest yielded no growth. This corresponds to a 
per inoculation positivity rate of 20.0 % (88/440) and a per patient positivity rate of 47.0% 
(31/66). Because it was not possible to determine if the contaminated inoculations could 
have resulted in M. ulcerans growth, they were not included in this analysis (Materials and 
Methods; Table 1). The median time to detectable M. ulcerans growth was 67.0 (IQR = 55.0 
to 105.2) days (Table 1). One-to-one analyses were again used to identify factors to be 
included in the multivariate analysis (Additional Table 3). In this multivariate analysis, we 
found that the transport medium had an overall significant effect (p-value: <0.001) on the 
probability of M. ulcerans growth (Table 3). Specifically, swabs transported dry had a 97.7 % 
reduced chance (p-value < 0.001) of M. ulcerans growth compared to samples transported in 
Amies medium (Table 3). Between swabs transported in Amies or 7H9 medium no significant 
difference was found, although transport in Amies medium had a tendency to increase the 
chance of M. ulcerans recovery (odds ratio for transport in 7H9: 0.304; Table 3). Further in 
the multivariate analysis there was no significant difference in the chance of M. ulcerans 
recovery between the decontamination methods evaluated (p-value: 0.519) and inoculation 
on either LJ or LJ_PANTA (p-value: 0.216). However, with an increase of the Ct value by one 
unit, the probability of M. ulcerans growth was reduced by 12.1 % (p-value: 0.044; Table 3, 1 
- OR) and with every 10 extra days of storage between sampling and inoculation, the 
probability of M. ulcerans growth decreased significantly (p-value: 0.001) by 45.9 %. Our 
analysis further detected a moderately significant (p-value: 0.074) interaction between the 
transport time and the transport medium, with Amies medium having the best chance of M. 
ulcerans growth for an increase in transport time by 10 days.  
Overall, the analysis to evaluate factors that affect the recovery of M. ulcerans revealed that: 
i) storage in either Amies or 7H9 medium was significantly better than keeping swabs dry; ii) 
none of the decontamination methods tested had a significantly better effect on the growth of 
M. ulcerans and iii) the M. ulcerans recovery was not affected by inoculation of samples onto 
media containing PANTA. On the other hand, the analysis showed that both a one unit 
increase in the Ct value of the IS2404 qPCR and a 10 day increase in the turnover time of 
the samples had a significantly negative effect on the rate of M. ulcerans recovery. 
M. ulcerans recovery versus no growth or contamination 
For the identification of factors that affect M. ulcerans recovery in a scenario where some 
cultures are contaminated, 700 inoculated cultures from 302 qPCR positive swabs (average 
Ct value of 28.09) taken from 72 qPCR positive patients were analyzed. As shown in Table 
1, 88 inoculations collected from 31 patients of the total 700 inoculations resulted in M. 
ulcerans growth. This corresponded to a per patient positivity rate of 43.1 %. Further, 37.1 % 
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(260/700) of the inoculations were contaminated and 50.3 % (352/700) did not result in any 
growth. The observed culture positivity rate corresponded to a per patient culture positivity of 
43.1 %. Analysis of these inoculations in a multivariate analysis showed, that transport 
medium had a significant effect (p-value: 0.019) on the recovery of M. ulcerans (Table 4). 
Specifically, swabs transported in Amies medium showed the best recovery rate of M. 
ulcerans, although not significantly better than 7H9 medium (95% CI of OR: 0.269 - 1.415). 
As also seen in the analysis for non-contamination (Table 2) and M. ulcerans growth (Table 
3), the decontamination methods evaluated here did not significantly differ in their effect on 
the chance of M. ulcerans recovery (p-value: 0.295; Table 4). On the other hand the use of 
the inoculated media had a significant (p-value: 0.003) impact on the chance of M. ulcerans 
growth, with the use of LJ as compared to LJ_PANTA reducing the probability of M. ulcerans 
growth by 65.5 %. As further shown in Table 4, a one unit increase in the Ct value away from 
the mean Ct value of the inoculated swabs decreased the chance of M. ulcerans recovery by 
10.8 % (p-value: 0.011). Furthermore, consistent with the analysis of factors affecting M. 
ulcerans growth (Table 3), the time span from sampling to inoculation significantly (p-value: 
0.006) reduced the chance of M. ulcerans isolation, with a decrease of 19.1 % for every 10 
extra days of storage compared to the mean storage time of 80.2 days (Table 4, Figure 2). 
As shown in Figure 2, the predicted probability of M. ulcerans recovery decreased from 61.2 
% at zero days of storage to 26.8 % within 70 days of storage. Specifically for swabs with a 
qPCR Ct value of 27.8, that were transported in Amies medium, decontaminated using 
NaOH for 10 minutes and inoculated onto LJ with PANTA, a probability of M. ulcerans growth 
of 61.2 % can be expected if samples were stored for zero days. If the samples are stored for 
50 or 100 days, the predicted probability decreases to 35.3 % and 15.9 % respectively. 
Overall our analysis of the sample set consisting of only qPCR positive swabs but including 
all possible outcomes of the inoculations, showed that either of the moist transport media 
increased the chance of M. ulcerans recovery compared to samples kept dry. None of the 
decontamination methods yielded superior results and M. ulcerans culturing was favored on 
PANTA supplemented LJ medium. Further the analysis showed that both a one unit increase 
in the Ct value of the IS2404 qPCR and a 10 day increase in the turnover time of the 
samples negatively impacted the chance of M. ulcerans isolation.  
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Discussion 
In the present study we evaluated the effect of various factors on the rate of M. ulcerans 
primary isolation from clinical specimens to develop a method for M. ulcerans recovery from 
samples collected from very remote BU endemic areas. For this, we examined three sets of 
inoculations, i) to identify factors that reduce the rate of contamination of the primary 
cultures, ii) to determine which factors increase the rate of M. ulcerans recovery in a scenario 
where none of the cultures are contaminated and iii) to evaluate the effect of factors in the 
realistic setting where some M. ulcerans growth will be missed due to the contamination of 
cultures. 
In a study on IS2404 PCR positive tissue biopsies which were stored for up to 26 weeks in 
semi-solid transport medium, Eddyani et al. were able to achieve a culture positivity rate of 
45.2 %. This showed that the establishment of an M. ulcerans strain collection from remote 
BU endemic areas from tissue samples is possible [11]. Other studies using either tissue 
biopsies or swab and FNA samples and shorter transport times have also reported culture 
positivity rates of about 50 % with the rest of the cases, although clinically diagnosed and 
PCR confirmed, remaining culture negative [6, 13, 16, 17]. In a study comparable to the 
present analysis, Eddyani et al. cultured M. ulcerans from FNA that were stored for two 
weeks before processing, a per sample positivity rate of 17.6 % was achieved [12]. In spite of 
long storage intervals prior to processing, we have achieved here a per PCR–reconfirmed-
sample positivity rate of 23.5 %, corresponding to a PCR-reconfirmed-patient M. ulcerans 
culture positivity rate from swab and FNA samples of 43.1 %. Given the similarity in these M. 
ulcerans recovery rates in several studies employing different clinical specimens and 
approaches, the reason for lack of growth of M. ulcerans from certain patients should be 
further investigated [18]. 
To increase M. ulcerans recovery rates, Yeboah-Manu et al. have suggested collecting and 
processing multiple swab or FNA samples per patient. To increase the chance of culture 
positivity, we have ensured that lesion exudates were collected from all around ulcers. 
Further, we collected and processed several (median = 4; IQR = 2 to 6) swabs from most 
patients and this repeated sampling did indeed affect the rate of recovery of M. ulcerans per 
patient. Only considering qPCR positive swabs, we observed a significant difference (p-value 
0.003) in the number of swabs collected from culture positive patients (median: 5; IQR: 3 to 6 
swabs) versus the number of swabs collected from culture negative patients (median: 2; IQR: 
1 to 5 swabs). Based on these results, we recommend the collection of up to five swab 
samples per patient prior to treatment start to increase the probability of recovering the 
infecting M. ulcerans strain. 
 Results     Chapter 2 73 
 
In both our analyses for M. ulcerans growth and for contamination of cultures, there was no 
significant difference between swabs transported in 7H9 or Amies medium. However, based 
on the lower costs of Amies transport medium compared to the 7H9 medium (approximately 
0.7 USD per Amies swab and 2.8 USD per 7H9 swab with PANTA and OADC), we 
recommend the use of Amies medium for the transport of swabs collected from BU patients. 
In our analysis, the number of days for which samples were stored did not significantly affect 
the rate of contamination of the inoculated cultures but longer storage did significantly reduce 
the rate of M. ulcerans recovery (Tables 3 and 4, Figure 2). This is contrary to a previous 
report of culturing from tissue biopsies which found that that storage time did not affect the 
rate of M. ulcerans recovery [11]. M. ulcerans may thus survive better if transported in the 
context of a tissue biopsy than as swab sample. As can be expected, the Ct value of the 
IS2404 qPCR had a significant effect on the rate of M. ulcerans recovery (Tables 3 and 4). 
On the other hand, neither the qualitative nor the quantitative qPCR result of a swab nor the 
BU status, i.e. the overall patient qPCR result, had a significant effect on the rate of 
contamination of the primary cultures in the one-by-one or the multivariate analysis (Table 2 
and Additional Table 2). In line with a recent report on secondary infections of BU lesions 
[19], this finding does not support the assumption that BU lesions are less prone to 
contamination with secondary microorganisms than other wounds [20]. 
In our analysis there was no significant difference between the four decontamination 
methods evaluated, although in the univariate analysis for M. ulcerans growth, NaOH for 10 
minutes appeared to outperform the other decontamination options with borderline 
significance (p-value: 0.076, Additonal Table 3). Since 10 min NaOH is also the quickest 
decontamination method, we therefore suggest this one to be used. 
Our analysis of M. ulcerans growth vs. contamination or no growth (Figure 1C), showed that 
the use of LJ_PANTA compared to LJ had a significant positive effect (p-value: 0.003) on the 
rate of recovery of M. ulcerans. This is similar to what has been found by Yeboah-Manu et al. 
where M. ulcerans recovery was also significantly improved (p-value < 0.001) on LJ_PANTA 
compared to LJ alone [13]. 
By evaluating a small set of swabs, Yeboah-Manu et al. have previously been able to show 
that culturing from dry cotton swabs is feasible [13]. In our study we have confirmed this 
finding. However the chance of M. ulcerans recovery from swabs stored dry is reduced by 
75.2 % compared to swabs transported in Amies (Table 4) and in our analysis dry swabs 
only achieved a per patient culture positivity rate of 13.1 %. 
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Conclusions 
In conclusion, our results show that primary culturing of M. ulcerans from cotton swabs after 
long turnover time is possible. Based on our findings we suggest that this type of samples 
should be transported in Amies medium, that they should be decontaminated in 0.5 M NaOH 
for 10 minutes and that cultures should be inoculated onto LJ medium supplemented with 2 
% PANTA. Furthermore, multiple samples (approximately 5) should be collected from each 
patient and only the PCR positive swabs should be inoculated for culturing.  
Overall, the here identified method can help to establish M. ulcerans strain collections from 
very remote BU endemic areas. An increased number of available M. ulcerans strains from 
all endemic areas will be a valuable resource for studies to increase our understanding of 
pathology, transmission and many other aspects of BU. 
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Figures 
 
 
Figure 1: Workflow for swabs included in the statistical analysis. 
The complete set of M. ulcerans primary culturing inoculations was used to identify factors 
that affect the rate of contamination (non-contamination vs. contamination; A). A subset of 
the inoculations was used to identify factors that influence the growth of M. ulcerans in the 
absence of any contamination (M. ulcerans growth vs. no growth; B) and a second subset 
was used to identify factors that affect M. ulcerans growth if some of the inoculations resulted 
in contamination (M. ulcerans growth vs. contamination or no growth; C). The number of 
swabs collected as well as the transport media used and the storage time are shown. 
Further, the number of qPCR positive swabs with their average Ct value are given and the 
numbers of decontaminations as well as inoculations performed are shown. Finally the 
number of total inoculations in each of the data sets is indicated. 
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Figure 2: Predicted probabilities for M. ulcerans growth. 
Based on the M. ulcerans growth vs. no growth or contamination model the probability of M. 
ulcerans growth was predicted as a function of transport time for samples transported in 
Amies medium, decontaminated with NaOH for 10 minutes, inoculated onto LJ medium 
supplemented with PANTA and if the Ct value of the qPCR was 27.8. Mean predicted 
probability of the M. ulcerans growth rate and 95% confidence intervals are shown. 
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Supplementary Material 
Additional Table 1: Number of samples decontaminated with multiple 
decontamination methods in parallel 
Decontamination method* Non-
contamination 
vs. 
contamination 
M. ulcerans 
growth vs. no 
growth 
M. ulcerans 
growth vs. 
contamination 
or no growth 
NaOH_10 and OA_30min 19 3 13 
NaOH_10 and OA_1h 87 44 86 
NaOH_20 and OA_30min 61 25 33 
OA_1h and OA_30min 70 23 32 
* Number of clinical samples decontaminated with the combinations of decontamination methods 
indicated for the three set of samples analysed.
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Additional Table 2: Association§ between non-contamination of M. ulcerans 
cultures and each of the factors of interest 
Factor Value of factor Odds 
ratio§ 
95% CI odds 
ratio 
Overall 
effect (p-
value) 
Transport Medium 7H9 0.840 0.462 - 1.527 <0.001 
 dry 24.314 13.268 - 
44.555 
 
  Amies (ref. level)  1.000   
Decontamination 
medium 
OA_1h 0.853 0.465 - 1.567 0.021 
 OA_30min 0.749 0.396 - 1.414  
 NaOH_20min 1.777 0.860 - 3.673  
 NaOH_10min (ref. level) 1.000   
Inoculation media LJ 0.441 0.307 - 0.634 <0.001 
 LJ_PANTA (ref. level) 1.000   
Swab qPCR Ct value for an increase in 1 unit Ct 0.990 0.978 - 1.002 0.119 
Patient qPCR result negative 0.799 0.379 - 1.682 0.554 
 positive (ref. level) 1.000   
Time from sampling 
to inoculation 
for an increase in 10 day 1.402 1.282 - 1.534 <0.001 
Weeks before 
diagnosis* 
for an increase by 1 week 0.992 0.976 - 1.007 0.285 
§ Adjusted for random effects of the patient and swab identification. 
* Information as reported by the patient.
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Additional Table 3: Association§ between M. ulcerans growth and each of the 
factors of interest. 
Factor Value of factor Odds 
ratio§ 
95% CI odds 
ratio 
Overall 
effect 
p-value 
Transport medium 7H9 0.343 0.099 - 1.192 <0.001 
 dry 0.004 0.001 - 0.015  
  Amies (ref. level) 1.000   
Decontamination 
medium 
OA_1h 0.373 0.135 - 1.032 0.076 
 OA_30min 0.396 0.136 - 1.157  
 NaOH_20min 0.229 0.071 - 0.734  
  NaOH_10min (ref. level) 1.000   
Inoculation media LJ 0.510 0.239 - 1.089 0.082 
 LJ_PANTA (ref. level) 1.000   
Swab qPCR Ct value for an increase in 1 unit 
Ct 
0.947 0.868 - 1.033 0.216 
Time from sampling 
to inoculation 
for an increase in 10 day 0.621 0.522 - 0.738 <0.001 
Number of days of 
treatment before 
sampling 
for an increase in 1 day 1.033 0.965 - 1.106 0.343 
Weeks before 
diagnosis* 
1 week 1.002 0.976 - 1.029 0.865 
§ Adjusted for random effects of the patient and swab identification. 
* Information as reported by the patient.
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Abstract 
Background: Mycobacterium ulcerans is the causative agent of the necrotizing skin disease 
Buruli ulcer (BU), which has been reported from over 30 countries worldwide. The majority of 
notified patients come from West African countries, such as Côte d’Ivoire, Ghana, Benin and 
Cameroon. All clinical isolates of M. ulcerans from these countries are closely related and 
their genomes differ only in a limited number of single nucleotide polymorphisms (SNPs). 
Methodology/Principal Findings: We performed a molecular epidemiological study with 
clinical isolates from patients from two distinct BU endemic regions of Cameroon, the Nyong 
and the Mapé river basins. Whole genome sequencing of the M. ulcerans strains from these 
two BU endemic areas revealed the presence of two phylogenetically distinct clonal 
complexes. The strains from the Nyong river basin were genetically more diverse and less 
closely related to the M. ulcerans strain circulating in Ghana and Benin than the strains 
causing BU in the Mapé river basin. 
Conclusions: Our comparative genomic analysis revealed that M. ulcerans clones diversify 
locally by the accumulation of SNPs. Case isolates coming from more recently emerging BU 
endemic areas, such as the Mapé river basin, may be less diverse than populations from 
longer standing disease foci, such as the Nyong river basin. Exchange of strains between 
distinct endemic areas seems to be rare and local clonal complexes can be easily 
distinguished by whole genome sequencing. 
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Author Summary 
Buruli ulcer (BU) is a progressively necrotizing disease of the skin, caused by infection with 
Mycobacterium ulcerans. BU occurs very focally with highest incidence in West Africa. The 
mode of transmission and the nature and role of potential environmental reservoirs are 
currently not entirely understood. In this study we sequenced whole genomes of sets of M. 
ulcerans case isolates from two BU endemic regions in Cameroon. We identified two distinct 
phylogenetic lineages, which directly correlated with the two endemic regions. Furthermore, 
we showed that the genetic diversity of M. ulcerans is higher in the older endemic region of 
Cameroon (Nyong river basin) compared to the more recently emerged infection focus in the 
same country (Mapé river basin). Together, our results demonstrate that M. ulcerans is 
developing local clonal complexes by the accumulation of single nucleotide polymorphisms 
(SNPs) and that these complexes often remain confined to individual endemic foci. The gene 
encoding for rpoB, which is known to harbour drug resistance mutations against rifampicin in 
M. tuberculosis, was not affected by SNPs in any of the analysed M. ulcerans strains. 
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Introduction 
Buruli ulcer (BU), the third most common mycobacterial disease affecting humans after 
tuberculosis and leprosy, is caused by Mycobacterium ulcerans [1]. The disease is 
characterized by progressive necrosis of the skin and subcutaneous tissue, leading to 
sometimes extensive ulcerations. Even though standard antibiotic treatment for eight weeks 
with rifampicin and streptomycin, as it is currently recommended by the World Health 
Organization (WHO), is highly effective in killing the bacterium, quite a number of patients 
still require surgery for wound debridement and/or skin grafting and can remain with scarring 
and disabilities [2]. BU has been reported from over 30 countries worldwide but has its 
highest incidence in West Africa, where it occurs very focally in rural areas, which are 
associated with wetlands, marshes and riverine zones [3].  
The distinct pathology of M. ulcerans infections is mainly attributed to mycolactone, a 
macrolide exotoxin produced by the mycobacteria [4]. Mycolactone is highly toxic to 
mammalian cells and is also believed to have immunomodulatory functions [5]. The 
polyketide synthases required to produce this potent toxin are encoded as three large genes 
on a giant virulence plasmid, pMUM001, whose acquisition represents a crucial step in the 
divergence of M. ulcerans from its progenitor M. marinum [6,7]. Further hallmarks of M. 
ulcerans evolution include the proliferation of two distinct insertion sequence (IS) elements 
(IS2404 and IS2606), the accumulation of a large number of pseudogenes and considerable 
genome downsizing. These findings indicate that M. ulcerans has recently passed through 
an evolutionary bottleneck and is adapting to a new and more stable environment [7]. This 
new niche is suspected to be aerobic, osmotically stable, dark and possibly extracellular. 
Production of the immunosuppressive toxin mycolactone and the loss of a set of highly 
immunogenic proteins [8] may represent an adaptation to an environment that is screened by 
an immune system.  
Possums, an Australian marsupial species, seem to be especially susceptible to the disease 
and may function as an animal reservoir in BU endemic foci of Victoria, Australia. However, 
attempts to identify an animal reservoir in Africa have not been successful to date [9,10]. 
Therefore it is assumed that there may be other environmental reservoirs of M. ulcerans in 
association with stagnant water bodies. Contact with such wetlands is a known risk factor for 
contracting BU, and patients may become infected through microtrauma of the skin or 
inoculation by an unknown insect vector [3]. M. ulcerans DNA has been detected by IS2404 
specific PCR in environmental samples, but the cultivation of the slow growing mycobacteria 
from such samples is exceptionally difficult and has only succeeded once so far [11,12]. 
Therefore it remains unclear what relevance the presence of DNA in the environment has 
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and how M. ulcerans is transmitted. For a long time the highly clonal population structure of 
M. ulcerans represented a major obstacle for molecular epidemiological studies. 
Conventional typing methods such as restriction fragment length polymorphism, multilocus 
sequence typing and variable number tandem repeat analysis provide insufficient resolution 
[13]. To date the best typing resolution was attained with single nucleotide polymorphism 
(SNP) typing assays [14]. With this method Röltgen et al. were able to demonstrate focal 
transmission in the Densu river basin of Ghana [14]. Furthermore, with an extended set of 
SNPs sufficient phylogenetic signal could be obtained to reconstruct recent evolutionary 
events in M. ulcerans on a continental scale [15]. A drawback of this method is, however, 
that it requires prior knowledge of the relevant SNPs. 
With its decreasing costs, whole genome sequencing (WGS) is now replacing SNP typing for 
M. ulcerans. Here we report on a genomic epidemiological study aimed at inferring 
evolutionary patterns of M. ulcerans in two BU endemic regions of Cameroon (the Mapé and 
the Nyong river basins) by using WGS combined with fine-scale geographic information on 
the origin of the patients from which the M. ulcerans strains were isolated. 
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Materials and Methods 
Ethical statement and patient recruitment 
Samples for this study were collected from patients recruited between August 2010 and July 
2012 in the Mapé river basin of Cameroon [16] and at the district hospital in Ayos in southern 
Cameroon [17]. Ethical clearance for the collection and processing of samples was obtained 
from the Cameroon National Ethics Committee (N°041/CNE/DNM/09, N°006/CNE/SE/2010, 
and N°172/CNE/SE/2011), the Ethics Committee of the Heidelberg University Hospital, 
Germany (N°ISRCTN72102977) and the Ethics Committee of Basel (EKBB, reference n. 
53/11). Participation was voluntary and all patients who participated in the study or their legal 
guardian provided written informed consent. 
M. ulcerans cultivation 
Prior to the start of medical treatment, cotton swabs were collected from each patient for 
diagnosis of M. ulcerans disease by quantitative polymerase chain reaction (qPCR) targeting 
the M. ulcerans specific IS2404 [18] and for cultivation of the bacteria. Wound exudates in 
phosphate buffered saline (PBS), that were produced from cotton swabs for DNA extraction 
as described by Lavender and Fyfe [19], were decontaminated as described by Bratschi et 
al. [20] and cultures initiated on Löwenstein-Jensen (LJ) medium slants (with glycerol; 
Becton Dickinson and Company) and/or LJ medium slants supplemented with 2 % PANTA. 
Inoculated cultures were incubated at 30°C until growth could be observed. Detected growth 
was confirmed to be M. ulcerans by colony PCR using primers MU154 (5’-
ggcagttacttcactgcaca-3’) and MU155 (5’-cggtgatcaagcgttcacga-3’) and amplification for 32 
cycles of 30 seconds at 94°C, 30 seconds at 60°C and 1 minute at 72°C. PCR products were 
resolved in a 1.5 % agarose gel. Confirmed M. ulcerans cultures were expanded on 7H10 
agar plates (Becton Dickinson and Company) until enough bacteria could be harvested for 
DNA extraction as described below. 
DNA extraction 
M. ulcerans DNA for WGS was extracted as described by Käser et al. [21]. Briefly, M. 
ulcerans bacteria were transferred from 7H10 agar plates into a 1.5ml screw-cap tube and 
suspended in lysis buffer (15 % sucrose, 50 mM Tris (pH8.5) and 50 mM EDTA). After 
Incubation with lysozyme for 1h at 37°C, sodium dodecyl sulfate (SDS) and proteinase K 
(PK) were added and the bacteria lysed with a tissue homogenizer (Precellys24, Bertin 
Technologies) in tough micro-organism lysis tubes containing beads (Bertin Technologies). 
DNA from lysate supernatant was extracted by the Phenol-chlorophorm / Ethyl alcohol 
(EtOH) method [21]. Amount and purity of the extracted mycobacterial DNA was assessed 
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with a Qubit 2.0 Fluorometer according to the manufacturer’s protocol (Qubit dsDNA HS 
Assay Kit, Invitrogen). 
Whole genome sequencing 
All processing and sequencing of genomic DNA was performed by the core sequencing 
teams at the Wellcome Trust Sanger Institute. All samples were sequenced as multiplexed 
libraries using Illumina HiSeq 2000 analyzers on 75-bp paired-end runs as described by 
Harris et al. [22]. 
Read alignment and SNP detection 
Variation, in the form of SNPs, was detected using a mapping approach. The paired-end 
Illumina reads were mapped against the M. ulcerans reference genome of the strain Agy99 
(accession number CP000325) and against the M. ulcerans Agy99 pMUM001 plasmid, with 
an insert size ranging from 50 to 400 bp using SMALT version 0.7.4 
(http://www.sanger.ac.uk/resources/software/smalt/) with a word length of 13 and skip size of 
1. The maximum insert size was 1000, the minimum insert size was 50, resulting, on 
average, in a 25x depth coverage for more than 92.1 % of the reference genome. The default 
mapping parameters recommended for reads were employed, except for the minimum score 
required for mapping, which was increased to 30 to make the mapping more conservative. 
Candidate SNPs were identified using SAMtools [23] mpileup as previously described [24]. 
Base calls for all isolates were filtered to remove those at sites with a SNP quality score 
below 30, where the called based was in less than 75 % of mapped reads on each strand, or 
where fewer than two reads mapped to each strand. SNPs called in repetitive regions of the 
M. ulcerans reference genome (737,280 bp) were excluded from the analysis and only the 
SNPs mapped in the core genome (4,894,326 bp) were used to construct the phylogenetic 
tree. Repetitive regions were defined as exact repetitive sequences of ≥20 bp in length, 
identified using rep repeat-match [25]. If 10 % of the genomes under study had an 
ambiguous base in a called SNP, these positions were removed from the analysis. The 
information on the potentially problematic regions is provided in S1 Table. 
Phylogenetic analyses 
A maximum-likelihood phylogenetic tree was generated from the whole genome sequences 
based on the SNPs called by SMALT. Published M. ulcerans genomes from strains isolated 
in Ghana (NM14_01, NM49_02, NM54_02, NM43_02, Agy99), Benin (Mu_06-3845, Mu_06-
3846, Mu_07-1082) and the M. marinum genome (Mu_06-3844) of an isolate from Belgium 
were included in the analysis [13]. The M. marinum genome was used to root the tree. In 
total 91 strains were included in this study (S2 Table). Separate maximum-likelihood trees for 
the plasmid and the chromosome were reconstructed based on one M. marinum genome 
and 53 M. ulcerans genomes. The M. ulcerans genomes include 45 Cameroonian isolates 
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with each patient being represented by one strain. Maximum-likelihood phylogenetic trees 
were constructed using RAxML v7.0.4 und a general time-reversible (GTR) substitution 
model with γ correction for among-site rate variation. Support for nodes on the trees was 
assessed using 100 bootstrap replicates.   
SNP pairwise distance 
To compute the pairwise distance based on the genome wide SNP count between the 
isolates we used MEGA6 [26]. The average pairwise SNP distances per genome within the 
lineages were plotted using software package R (http://www.r-project.org/) and statistical 
significance was assessed by applying the Wilcoxon rank sum test. 
Nucleotide diversity 
Genetic diversity was assessed by calculating the average pair-wise nucleotide differences 
per site (Pi) for both main lineages of M. ulcerans in Cameroon, using the program VariScan 
[27]. We calculated the nucleotide diversity for 1.5 kb non-overlapping windows. 
Median joining networks 
We produced two median joining networks using Network 4.6.1.2 [28], based on 107 variable 
nucleotide positions from 34 isolates of the Mapé river basin and 117 variable nucleotide 
positions from 11 isolates of the Nyong river basin. For the analysis of the association 
between geographic and genetic distances of the sampled populations we performed a 
Mantel test using the function “mantel” asking for the Pearson’s product –moment correlation 
with 999 permutations in the R package “vegan” [29]. We did this for two sets of matrices, a 
smaller subset of 11 samples corresponding to the Nyong isolates, and the entire set of 33 
samples corresponding to the Mapé isolates. 
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Results 
M. ulcerans phylogeny in Cameroon 
We sequenced the genomes of 82 M. ulcerans strains isolated from 45 IS2404 qPCR 
confirmed Cameroonian BU patients. Patients were identified between 2010 and 2012 and 
came from two geographically separated BU endemic regions of Cameroon, the Mapé and 
the Nyong river basins. Prior to treatment, ulcerative lesions were sampled with a cotton 
swab for laboratory confirmation of the clinical diagnosis, primary isolation of the disease 
causing organism and WGS of the isolated M. ulcerans strains.  
The mapping of the obtained Illumina sequencing reads against the reference strain resulted 
in an average coverage of 380 reads per position per genome. We reconstructed the 
phylogenetic relationship among 45 Cameroonian (one strain per patient), five Ghanaian and 
three Beninese M. ulcerans isolates based on 26,740 variable nucleotide positions, rooting 
the tree using a published M. marinum genome (Fig. 1). The phylogenetic tree showed a 
very strong geographical structure. The chromosome tree of the Cameroonian M. ulcerans 
isolates showed two distinct lineages, the first one containing all the Nyong river basin 
isolates (Nyong lineage) and the second one all the isolates from the Mapé region (Mapé 
lineage). The Mapé river basin isolates were more closely related to a set of published 
genomes [13] of Ghanaian and Beninese isolates that we included in the analysis, than to 
the Nyong lineage. The two Cameroonian clonal complexes differed in altogether 828 SNPs 
shared by all members of the respective lineages (Fig. 1). 
The plasmid phylogeny reflected the topology of the M. ulcerans chromosome phylogenetic 
tree (Fig. 1), supporting the hypothesis of a unique acquisition of the plasmid during the 
emergence of M. ulcerans [30] followed by parallel evolution between the chromosome and 
the plasmid. 
Genetic diversity among the Cameroonian isolates 
We analysed the genetic diversity within the two Cameroonian geographical lineages 
separately (Fig. 2). The genetic diversity observed for the Nyong river basin isolates (median 
pairwise SNP difference = 26.2 SNPs) was significantly higher (p-value < 0.0001) than for 
the Mapé basin isolates (median pairwise SNP difference = 7.6 SNPs). Furthermore, an 
analysis of the pairwise geographic distance of seven isolates from the Eastern Nyong river 
basin (approximately 1090 km2) and of four isolates from Western Nyong (approximately 
625km2) still yielded values that were higher (median 24 and 36 pairwise SNP difference) 
than for the Mapé isolates (Fig. 2). The higher genetic diversity thus does not seem to be 
related to the broader geographical distribution for the Nyong river basin isolates 
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(approximately 8600 km2) compared to the Mapé river basin isolates (approximately 6400 
km2) (Fig. 3, A2 and B2). These results were also reflected in the phylogenetic tree, where 
branch lengths were longer for the Nyong river basin strains than for the Mapé river basin 
isolates (Fig. 1). The gene encoding for rpoB, which is known to harbour drug resistance 
mutations against rifampicin in M. tuberculosis [31], was not affected by SNPs in any of the 
M. ulcerans strains analysed here. 
When analysing the nucleotide diversity distribution along the chromosome by calculating the 
average nucleotide pairwise diversity per site (Pi) for both lineages, 99.9 % of the genome 
was found to be highly conserved (S1 Fig.). However, the average nucleotide diversity per 
site for the Nyong river basin lineage was 3.2 times higher than for the Mapé river basin 
lineage (4.10e-6 versus 1.3e-6). The regions of the genome with higher nucleotide diversity 
(0.375e-4 and 1.25e-4, respectively) seemed randomly distributed across the chromosome for 
both lineages (S2 Fig.) and the gene content of these regions varied between the two 
Cameroonian lineages, comprising affected genes of diverse functionalities (S3 Table). 
Phylogeographic analysis of the Cameroonian M. ulcerans isolates  
In order to analyse the distribution of genetic variants within the endemic areas, we 
reconstructed median joining networks for the sequenced strains and mapped the places of 
residence of the patients from which the strains originated (Fig. 3). 
The network of the Mapé river basin isolates had a star structure with two isolates (BP130 
and BP140) at the centre. All the other isolates were connected to this centre and separated 
by three to nine SNPs. While the SNP distance between the two central strains was zero, the 
geographical distance between the corresponding residence places of the two corresponding 
patients was 19.5 km. A total of four clusters were distinguished in the network: blue formed 
by two isolates, green and yellow formed by three isolates each and the red cluster as a 
complex structure formed by nine strains. The strains belonging to the red cluster shared two 
SNPs, the green ones also two SNPs, the yellow ones four and the blue ones shared three 
SNPs. All the grey strains were not forming clusters and differed by 1 to 11 SNPs from the 
central strains. In the network of the Nyong river basin isolates we observed only three 
clusters formed by three (green), seven (red) and one strain (blue). The isolates from the red 
cluster shared six SNPs, while the isolates from the green one shared only two SNPs. 
Overall, for both BU endemic areas in Cameroon we did not find a clear correlation between 
the genetic networks and the geographic distribution of the houses where the patients lived 
in the year prior to the onset of BU disease (Fig. 3). Statistical analysis with the Mantel test 
for the smaller subset of Nyong samples resulted in a positive and marginally significant 
correlation between the geographic and genetic distances (r = 0.2785, p-value = 0.054), 
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whereas the test performed for the Mapé set of isolates resulted in a small non-significant 
negative correlation (r = -0.04774, p-value = 0.676). 
Rate of acquisition of SNPs 
In the course of this genomic epidemiological study we obtained from three patients isolates 
from two or three different time points during the course of their disease (Table 1). When 
comparing the SNP diversity between the isolates from the same patient, only one SNP 
difference was observed between two sequential isolates (Table 1). The affected gene 
(MUL_1383) encoded for a hypothetical protein and the detected mutation was synonymous. 
No SNP difference was observed between two strains isolated from two distant ulcers of one 
patient (Table 1). 
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Discussion 
Due to the limitations of conventional typing methods for the differentiation of strains 
belonging to the highly monomorphic African M. ulcerans population, use of WGS was 
suggested to reach sufficient analytical depth for molecular epidemiology studies [32]. Here 
our comparative genomic analysis of strains from two geographically separated BU endemic 
areas of Cameroon, the Mapé and the Nyong river basins, identified two phylogenetically 
distinct lineages of M. ulcerans. These data support previous findings that the spread of local 
clonal lineages between endemic areas only rarely occurs [13,14]. In a previous IS element - 
SNP based typing study most strains from the central region of Cameroon had the same 
SNP types as strains from neighbouring Gabon. The IS element - SNP type found in a strain 
from the Mapé river basin was also present across entire Central and West-Africa leading to 
the hypothesis that this lineage represents the founder of the other observed IS element - 
SNP types [15]. Our WGS analysis showed that the strains from the Mapé river basin are in 
fact more closely related to the M. ulcerans strain circulating in Ghana and Benin than the 
strains belonging to the Nyong river basin lineage. Additional WGS data with strains from all 
BU endemic African countries are required to shed more light on the spread and evolution of 
M. ulcerans in Africa and the origin of the locally observed two distinct Cameroonian 
lineages. 
Analysis of the pairwise SNPs distance and nucleotide diversity distribution revealed a lower 
genetic diversity among the Mapé river basin strains than among the Nyong river basin 
strains. Epidemiological data suggest that M. ulcerans has expanded in the Mapé river area 
more recently than in the Nyong river basin. Descriptions of BU cases in the Nyong river 
basin exist since 1969 [17]. In contrast, clinically suspected cases of BU in the Mapé river 
area have been reported first only in 2004 [33]. While the disease may have preexisted 
there, epidemiological data strongly indicate that BU incidence has recently increased in the 
Mapé river basin [16,33]. Recent expansion of a clone may thus explain the more limited 
genetic diversity of the M. ulcerans lineage present in the Mapé river basin. It was 
speculated, that this expansion was associated with environmental changes caused by the 
damming of the Mapé river in 1989 [16,33]. Although it has been shown that cases associate 
more with the Mbam river as opposed to the Mapé dam directly [11,16], damming may have 
had an indirect effect on groundwater level and stagnant water bodies in the area. 
We have compared the genome sequences of strains isolated at different time points over 
the course of the BU infection of three patients. In only one case, we detected a single SNP 
in one of the isolates compared to the strain isolated earlier from the same patient. It is not 
possible to conclude whether this observed single polymorphism is related to a re-infection 
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by a variant strain or to a point mutation that occurred either in the patient or during the in 
vitro cultivation. However, these data support the expectation of a low mutation rate in M. 
ulcerans. 
Our analysis shows that WGS is an important tool for studying the local diversity and 
population structure of M. ulcerans in endemic areas and for resolving the evolutionary 
history of the pathogen. A combination of phylogenetic analysis with geographical 
information on the patient’s home at the time of disease onset did not reveal a clear 
distribution pattern of the genetic variants. This may in part be related to the limited 
resolution of the comparative genomic analysis performed here. Resolution of the WGS 
typing could be further increased by inclusion of repetitive regions of the genome and the 
virulence plasmid that we so far excluded from the analysis, such as the IS2404 and PE/PPE 
regions. On the other hand, our sero-epidemiological analyses have provided evidence that 
exposure to M. ulcerans does not primarily occur at the homes of patients [34], but may 
rather be associated with more peripheral environmental water contact sites. Furthermore, 
for patients from the Mapé river basin it has been found that many of them move over long 
distances (in some cases >15 km) from their homes towards the Mbam river for their farming 
activities [11,16]. For genomic epidemiology studies it may therefore be necessary to 
establish detailed individual movement and environmental water contact patterns to follow 
the spatial-temporal spread of genetic variants. 
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Figure 1: Phylogenetic reconstruction of Africa M. ulcerans strains. 
Maximum-likelihood phylogenetic tree based on 26,740 variable nucleotide positions across 
53 M. ulcerans strains by RAxML. The tree was rooted using M. marinum (Mu_06-3844) as 
outgroup. The geographical origin of the strains is indicated to the right of the tree and 
branches are coloured according to the region of isolation of the strains. Bootstrap values 
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higher than 50 % are shown along the branches. The insert shows the pMUM plasmid SNP 
tree based on 21 SNPs with the topology matching the corresponding chromosome-based 
tree. 
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Figure 2: SNP pairwise distance between isolates from the same lineage.  
The variation in the average SNP pairwise distance per genome for each lineage (Mapé and 
Nyong river basin strains) is shown in a box plot, with circles representing outlier sequence 
pairs. Two sub-areas of the Nyong river basin: the Eastern Nyong river basin and Western 
Nyong river basin, which are each smaller than the Mapé river basin area, are additionally 
shown. Statistical significance was assessed with the Wilcoxon rank sum test. 
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Figure 3: Phylogeographic analysis of M. ulcerans in the Mapé and Nyong river 
basins of Cameroon. 
Detailed information about the places of residence of the patients for the year before the 
onset of BU disease was collected from all patients from whom M. ulcerans was isolated. 
Micro-evolutionary diversity of M. ulcerans at the two BU endemic sites is shown in panel A1 
(Mapé river basin) and panel B1 (Nyong river basin). Median joining networks using 117 
variable single nucleotide positions among whole genome sequences of M. ulcerans isolates 
from the Mapé river basin and 107 positions in isolates from the Nyong river basin area are 
depicted. Branch lengths correspond to the number of SNP differences, circle sizes 
correspond to the number of isolates and circle colours correspond to the sub-clusters 
defined. Black circles indicate median vectors (mv) and are hypothetical genotypes. Panels 
A2 (Mapé river basin) and B2 (Nyong river basin) show the geographic localization of the 
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patient’s residences with the locations colour coded according to the lineages shown in panel 
A1 and B1. When isolates of two patients were exactly the same, the respective homes of 
the patients are connected by a line. Major towns in the areas are indicated by black 
squares. 
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Supplementary Material 
Supplementary Table 1: Potentially problematic regions for SNP calling 
identified by repeat-match. 
Please use the link provided with the actual publication. 
Supplementary Table 2: Mapping statistics and metadata for the bacterial 
isolates used in the study. 
Isolate Accession 
Number 
Pellet 
Type 
Year Country District Match_to
_ref 
Yield 
Matching_kb 
BP33 ERR350089 bulk 2010 Cameroon Bankim 95.4 358,752 
BP134 ERR350149 bulk 2012 Cameroon Bankim 94.7 386,185 
BP132 ERR350148 bulk 2012 Cameroon Nwa 95.1 375,389 
BP117 ERR350137 bulk 2012 Cameroon Bankim 95 347,643 
BP129 ERR350145 bulk 2012 Cameroon Bankim 94.6 452,945 
BP140 ERR350153 bulk 2012 Cameroon Bankim 94.1 451,221 
BP130 ERR350146 bulk 2012 Cameroon Malantouen 94.6 451,126 
BP139 ERR350151 bulk 2012 Cameroon Bankim 94.8 369,387 
BP144 ERR350156 bulk 2012 Cameroon Bankim 93.8 358,116 
BP143 ERR350154 bulk 2012 Cameroon Malantouen 95.5 433,066 
BP146 ERR350158 bulk 2012 Cameroon Foumban 95.5 369,167 
BP141 ERR350155 bulk 2012 Cameroon Bankim 94.2 355,503 
BP150 ERR350160 bulk 2012 Cameroon Bankim 95.5 355,612 
BP148 ERR350159 bulk 2012 Cameroon NA 95.1 361,366 
BP46 ERR350095 bulk 2011 Cameroon Malantouen 95.1 399,657 
BP52 ERR350098 bulk 2011 Cameroon Malantouen 94.9 399,164 
BP89 ERR350124 single 2011 Cameroon Malantouen 94.5 366,566 
BP72 ERR350112 bulk 2011 Cameroon Bankim 93.3 427,248 
BP83 ERR350119 single 2011 Cameroon Bankim 95.4 438,866 
BP100 ERR350127 bulk 2011 Cameroon Bankim 93.7 425,243 
BP31 ERR350087 bulk 2011 Cameroon Malantouen 94.9 403,037 
BP40 ERR350093 bulk 2011 Cameroon Malantouen 95.1 344,030 
BP66 ERR350106 bulk 2011 Cameroon Malantouen 95.1 422,133 
BP81 ERR350117 single 2011 Cameroon Malantouen 95.1 363,826 
BP87 ERR350123 single 2011 Cameroon Malantouen 94.5 354,147 
BP20 ERR350079 bulk 2011 Cameroon Yoko 95.1 359,093 
BP50 ERR350097 single 2011 Cameroon Yoko 93.3 406,405 
BP28 ERR350085 bulk 2011 Cameroon Bankim 95.6 340,807 
BP21 ERR350080 bulk 2011 Cameroon Malantouen 94.9 354,131 
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BP62 ERR350104 bulk 2011 Cameroon Malantouen 95.1 191,466 
BP65 ERR350105 bulk 2011 Cameroon Malantouen 95.2 376,201 
BP70 ERR350110 bulk 2011 Cameroon Malantouen 94.7 439,510 
BP45 ERR350094 bulk 2011 Cameroon Bankim 94.8 355,521 
BP105 ERR350129 single 2011 Cameroon Bankim 95.8 415,398 
BP68 ERR350108 bulk 2011 Cameroon Bankim 94.6 330,494 
BP127 ERR350144 single 2011 Cameroon Bankim 94.9 417,149 
BP24 ERR350082 bulk 2011 Cameroon Bankim 94.9 357,606 
BP69 ERR350109 bulk 2011 Cameroon Bankim 94.7 417,625 
BP108 ERR350130 single 2011 Cameroon Bankim 95.5 400,877 
BP48 ERR350096 bulk 2011 Cameroon Bankim 94.2 415,040 
BP67 ERR350107 bulk 2011 Cameroon Bankim 94.9 366,190 
BP114 ERR350134 bulk 2011 Cameroon Bankim 93.4 401,856 
BP116 ERR350136 bulk 2011 Cameroon Bankim 94.7 375,683 
BP131 ERR350147 bulk 2011 Cameroon Malantouen 94.4 386,429 
BP115 ERR350135 bulk 2011 Cameroon Bankim 94.4 388,573 
BP120 ERR350139 bulk 2011 Cameroon Bankim 94.9 331,099 
BP119 ERR350138 bulk 2011 Cameroon Yoko 95.3 399,766 
BP137 ERR350150 NA 2011 Cameroon Malantouen 94.9 416,258 
BP38 ERR350091 bulk 2010 Cameroon Bankim 94.9 357,979 
BP76 ERR350114 single 2010 Cameroon Bankim 94.6 441,493 
BP75 ERR350113 bulk 2010 Cameroon Bankim 94.7 427,529 
BP84 ERR350120 single 2010 Cameroon Bankim 95 405,420 
BP126 ERR350143 single 2010 Cameroon Bankim 95.3 84,645 
BP55 ERR350100 bulk 2010 Cameroon Bankim 95.2 361,665 
BP94 ERR350125 bulk 2010 Cameroon Bankim 95.8 357,855 
BP22 ERR350081 bulk NA Cameroon Mbalmayo 95.7 382,036 
BP86 ERR350122 single NA Cameroon Mbalmayo 96.1 431,925 
BP27 ERR350084 bulk NA Cameroon Mfou 95.6 296,495 
BP29 ERR350086 bulk NA Cameroon Mfou 96 335,712 
BP34 ERR350090 bulk NA Cameroon Mfou 95.6 452,999 
BP39 ERR350092 bulk NA Cameroon Mfou 95.4 375,911 
BP58 ERR350101 bulk NA Cameroon Mfou 95.5 359,868 
BP6 ERR350076 bulk NA Cameroon Mfou 95.7 353,664 
BP78 ERR350115 single NA Cameroon Mfou 95.8 380,280 
BP32 ERR350088 bulk NA Cameroon Ayos 95.4 380,516 
BP25 ERR350083 bulk NA Cameroon Ayos 95.9 326,183 
BP53 ERR350099 bulk NA Cameroon Ayos 95.3 380,115 
BP79 ERR350116 single NA Cameroon Ayos 95.6 380,813 
BP82 ERR350118 single NA Cameroon Ayos 94.5 386,405 
BP8 ERR350077 bulk NA Cameroon Ayos 95.6 393,378 
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BP112 ERR350133 bulk NA Cameroon Ayos 95.4 361,027 
BP113 ERR350157 bulk NA Cameroon Ayos 95.5 382,611 
BP104 ERR350128 single NA Cameroon Ayos 95.6 426,105 
BP110 ERR350132 single NA Cameroon Ayos 95.8 397,694 
BP59 ERR350102 bulk NA Cameroon Ayos 95.4 384,369 
BP71 ERR350111 bulk NA Cameroon Ayos 95.7 416,769 
BP121 ERR350140 bulk NA Cameroon Mbalmayo 95.6 335,505 
BP5 ERR350075 bulk NA Cameroon Abong Mbang 95.6 363,269 
BP85 ERR350121 single NA Cameroon Abong Mbang 96.3 388,938 
BP109 ERR350131 single NA Cameroon Ayos 95.2 375,262 
BP60 ERR350103 bulk NA Cameroon Ayos 94.7 396,155 
BP99 ERR350126 bulk NA Cameroon Mbalmayo 94.8 467,194 
BP138 ERR350152 bulk 2011 Cameroon Bankim 95.2 363,763 
NM 
14_01 
SRR073310 NA 2001 Ghana Ga District 99.8 159,537 
NM 
43_02 
SRR073314 NA 2002 Ghana Ga District 99.8 156,814 
NM 
54_02 
SRR073313 NA 2002 Ghana Ga District 99.8 157,658 
NM 
49_02 
SRR073312 NA 2002 Ghana Ga District 99.8 149,352 
Mu_06-
3845 
ITM001441 NA 2000 Benin Houedja 91.6 80,435 
Mu_06-
3846 
ITM971116 NA 1997 Benin Lalo 91.0 69,676 
Mu_07-
1082 
ITM030216 NA 2003 Benin Adjohoun 90.8 69,823 
Mu_06-
3844 
ITM063844 NA 2006 Belgium  89.3 210,427 
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Supplementary Table 3: Areas across the genomes with high Pi. 
Area Pi Region Genes product SNPs 
Mapé 2.674E-
04 
38001..40900  MUL_0040  transcriptional regulatory protein 
(Whib-like), WhiB5 
3S 
Mapé 1.72E-04 4907201..4910100 MUL_4425  monooxygenase, wich function 
probably is involved in cellular 
metabolism 
1S 
Nyong 
basin 
2.91E-04 159201..162100 MUL_0156  conserved hypothetical protein 1S 
Nyong 
basin 
2.91E-04 652901..655800 MUL_0630 conserved hypothetical 
membrane protein 
1STOP 
    MUL_0631 conserved hypothetical 
membrane protein 
1N 
      MUL_0632  3-oxoacyl-[acyl-carrier-protein] 
synthase III FabH 
1N 
Nyong 
basin 
3.39E-04 4821301..4824200 MUL_4346  multi-functional enzyme with 
acyl-CoA-reductase activity 
AcrA1_1 
1N, 3S 
Nyong 
basin 
4.36E-04 293401..296300  MUL_0288 conserved hypothetical protein 3N 
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Figure S1: Distribution of chromosomal nucleotide diversity statistics. 
Pi calculated on non-overlapping 1,500 pair sliding windows. Plots were drawn using the R 
density function. 
 
 
Figure S2: Nucleotide diversity (Pi) values along the length of the chromosome. 
Chromosomes are represented linearly, using the coordinate system of the respective 
reference genomes with 0 on the far left (and far right). 
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Abstract 
Background: Buruli ulcer, caused by infection with Mycobacterium ulcerans, is a chronic 
ulcerative neglected tropical disease of the skin and subcutaneous tissue that is most 
prevalent in West African countries. M. ulcerans produces a cytotoxic macrolide exotoxin 
called mycolactone, which causes extensive necrosis of infected subcutaneous tissue and 
the development of characteristic ulcerative lesions with undermined edges. While cellular 
immune responses are expected to play a key role against early intracellular stages of M. 
ulcerans in macrophages, antibody mediated protection might be of major relevance against 
advanced stages, where bacilli are predominantly found as extracellular clusters. 
Methodology/Principal Findings: To assess whether vaccine induced antibodies against 
surface antigens of M. ulcerans can protect against Buruli ulcer we formulated two surface 
vaccine candidate antigens, MUL_2232 and MUL_3720, as recombinant proteins with the 
synthetic Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion. The 
candidate vaccines elicited strong antibody responses without a strong bias towards a TH1 
type cellular response, as indicated by the IgG2a to IgG1 ratio. Despite the cross-reactivity of 
the induced antibodies with the native antigens, no significant protection was observed 
against progression of an experimental M. ulcerans infection in a mouse footpad challenge 
model.  
Conclusions: Even though vaccine-induced antibodies have the potential to opsonise the 
extracellular bacilli they do not have a protective effect since infiltrating phagocytes might be 
killed by mycolactone before reaching the bacteria, as indicated by lack of viable infiltrates in 
the necrotic infection foci. 
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Author Summary 
Buruli ulcer is a slow progressing ulcerative disease of the skin and subcutaneous tissue that 
is most prevalent in West African rural communities. Mycobacterium ulcerans, the causative 
agent of the disease, produces a toxin called mycolactone, which is held responsible for the 
extensive tissue damage seen in advanced Buruli ulcer lesions. To date, no effective vaccine 
against the disease exists and it is unclear to what extent antibodies against cell surface 
antigens of M. ulcerans play a role in protection. To assess whether vaccine induced 
antibodies against cell surface proteins can protect against Buruli ulcer, we formulated two 
surface vaccine candidate antigens, MUL_2232 and MUL_3720, as adjuvanted recombinant 
proteins and investigated their protective potential in a mouse model of M. ulcerans infection. 
Despite the induction of strong antibody responses against the surface molecules and cross-
reactivity of the induced antibodies with the antigens in their native context, we did not 
observe protection against the disease. While the vaccine-induced antibodies could opsonize 
the extracellular bacilli, infiltrating phagocytes might be killed early by mycolactone. 
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Introduction 
Buruli ulcer (BU) is a neglected tropical disease of the skin and subcutaneous tissue reported 
from over 30 countries worldwide. BU is most prevalent in West African countries like Cote 
d’Ivoire, Cameroon, Benin and Ghana [1,2]. Mycobacterium ulcerans, the causative agent of 
BU, produces a macrolide exotoxin called mycolactone, which is responsible for extensive 
necrosis of infected subcutaneous tissue leading to the development of large ulcerative 
lesions, if not treated at an early stage [3]. While extensive surgical removal of the diseased 
tissue has been the only treatment approach for a long time, since 2004 the WHO 
recommends eight weeks of combination chemotherapy with rifampicin and streptomycin [4]. 
This change in treatment strategy has substantially decreased both the amount of surgery 
required for treatment of extensive skin lesions as well as recurrence rates [5–7]. 
Nevertheless, BU has remained a huge socioeconomic burden in endemic regions of Africa. 
Affected populations are typically living in rural regions with limited access to health care 
services and limited financial resources, frequently resulting in delayed health care seeking 
and presentations with large ulcerative lesions, which take long time to heal [8,9].  
Sero-epidemiological studies have shown that active BU only develops in some of the people 
exposed to M. ulcerans [10,11]. Together with reports on spontaneous healing of BU lesions 
[12,13] and the fact that the risk for young adults to develop BU is much smaller than for 
children [14], this observation suggests that development of protective immunity against BU 
is possible [15]. However, it is not clear which immune effector functions are important for 
protection. Cellular immunity is expected to play a key role in the early intracellular growth 
phase of M. ulcerans in macrophages [16–18]. However, induction of TH1 responses by 
vaccination with Bacillus Calmette-Guérin (BCG) or a mycolactone negative M. ulcerans 
strain conferred only transient protection in an experimental mouse infection model [19]. 
Likewise, BCG vaccination seems to lead to cross-reactive immunity to severe forms of BU 
in clinical trials [20,21], but the BCG mediated induction of cellular response was not able to 
protect completely from M. ulcerans disease in either mice or humans [19–21]. In advanced 
BU lesions, in which clusters of extracellular bacilli dominate, antibodies against surface 
proteins of M. ulcerans may be of major importance for conferring protection [18,22,23]. In 
order to study this hypothesis, two M. ulcerans surface antigens, MUL_2232 and MUL_3720, 
were chosen in this study as vaccine candidate antigens. MUL_2232, the 18 kDa small heat 
shock protein of M. ulcerans, is an immunodominant cell wall associated protein with a 
homologue found in M. leprae, but not in M. bovis or M. tuberculosis [10]. MUL_3720 is a 22 
kDa molecule with a predicted N-terminal lectin domain and a C-terminal peptidoglycan-
binding domain with a putative role in cell attachment and cell-cell interaction [24] that is 
highly expressed on the surface of the bacilli [25]. 
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Within the framework of a collaborative project funded by the European Commission 
(BuruliVac) our goal was to assess whether vaccine induced antibody responses against 
surface proteins of M. ulcerans are protective against BU. Here we present immunogenicity 
studies of MUL_2232 and MUL_3720 formulated as adjuvanted recombinant proteins with 
Alum, Sigma adjuvant (a squalene oil-in-water emulsion containing Monophosphoryl Lipid A 
(MPL) and synthetic trehalose dicorynomycolate) or EM048 (glucopyranosyl lipid adjuvant-
stable emulsion (GLA-SE) adjuvant system [26,27]). Further, we assessed the potential of 
the induced immune responses to confer protection against experimental infection in a 
murine M. ulcerans infection model. 
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Materials and Methods 
Ethical statement 
All animal experiments performed were approved by the animal welfare committee of the 
Canton of Basel (authorization number 2375) and the Canton of Vaud (authorization number 
2261) and were conducted in compliance with the Swiss animal protection law. Infection 
experiments with M. ulcerans were conducted under Biosafety-level-3 conditions at the École 
polytechnique fédérale de Lausanne (EPFL). 
Expression and purification of recombinant M. ulcerans proteins 
The potential protein vaccine candidate antigens MUL_2232 (GenBank accession number 
4550596) and MUL_3720 (GenBank accession number 4553013) of M. ulcerans Agy99 were 
ordered as codon optimized genes for expression in human cells (GenScript) and received in 
pUC57 plasmids. Expression of the antigens as recombinant proteins in E. coli was achieved 
with the pET28a expression system (Novagen, modified to contain an ampicillin selection 
cassette). Briefly, restriction sites required for further cloning were attached by the use of 
specifically designed primers for amplification of the codon optimized sequences by 
polymerase chain reaction (PCR). Primer sequences for MUL_22232 amplification were 5’-
TTCCTTCATATGCTGATGAGAACCGACCCTTTTAGA-3’ and 5’-
TTCCTTGCGGCCGCTCAAGCCTCAATCACTTCGGGA. Primer sequences for MUL_3720 
amplification were 5’-TTCCTTCATATGAGCGATACTCTGACTGAAGGACAG-3’ and 5’-
TTCCTTGCGGCCGCGCTCAAGGAATAGTCAGGACCTCT-3’. PCR products were cut by 
the restriction enzymes NdeI and NotI (New England Biolabs) and subsequently ligated into 
pET28 to attach an N-terminal 6xHis-tag. After propagation of the generated plasmids in 
Top10 E. coli (Invitrogen), control restriction and sequencing of the plasmids ensured 
selection of appropriate clones for expression of the proteins. Protein expression was 
induced in E. coli BL21(DE3) strains (Invitrogen) by addition of 1 mM isopropyl 
thiogalacoside (Calbiochem) for 4 h at 37°C in lysogeny broth (LB) medium supplemented 
with Ampicillin. After screening for high level recombinant protein expression by analysis of 
small induced cultures, larger amounts of recombinant proteins were produced by selected 
expression clones.  
Protein lysates were produced by dilution of the bacterial pellet in PBS, the addition of 
lysozyme and sonication. After removal of cellular debris by centrifugation, the 6xHis-tagged 
recombinant proteins were purified by nickel-nitrilotriacetic acetic (Ni-NTA) metal-affinity 
chromatography. Proteins were eluted with increasing concentrations of imidazole and the 
integrity and purity of proteins was assessed by SDS-page separation and Coomassie Blue 
staining (S1 Fig). Final concentrations of the produced recombinant proteins rMUL2232 and 
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rMUL3720 were determined by BCA assay (Pierce) according to the manufacturer’s 
instructions. 
Adjuvant formulations 
Oil-in-Water formulated TLR-4 agonist (GLA-SE, EM048) was produced by the Infectious 
Disease Research Institute (IDRI) [26,27]. EM048 was mixed with recombinant protein in 
PBS to a final concentration of 50 µg/ml EM048 and 200 µg/ml recombinant protein. Sigma 
adjuvant system (Sigma) was reconstituted according to the manufacturer’s instructions and 
combined with recombinant protein to a final concentration of 200 µg/ml recombinant protein. 
Imject Alum (Thermo Scientific) was mixed with recombinant protein according to the 
manufacturer’s instructions to a final volume ratio of Imject Alum to immunogen of 1:1 and a 
final concentration of 200 µg/ml recombinant protein. 
Immunization of mice 
Immunogenicity of the described vaccine formulations was studied in 8 week old female 
BALB/c mice (Janvier). Groups of five mice were immunized three times by the 
subcutaneous (s.c.) route in the scruff of the neck with 100 µl of the adjuvanted proteins in 
three week intervals. Prior to the first immunization as well as before every new immunization 
mice were bled by the tail vein and serum gained by centrifugation of the blood in SST 
Microtainer tubes (Becton, Dickinson and Company). An additional blood collection was 
performed three weeks and six months after the last immunization. 
Enzyme-linked immunosorbent assays (ELISA) 
Serum immunoglobulin G (IgG) antibody titers were determined by ELISA on recombinant 
protein with all incubation steps performed at room temperature (RT). 10 µg/ml of rMUL2232 
or rMUL3720, respectively, were coated on ELISA plates (Maxisorp; Nunc) by incubation 
overnight. After blocking with 5% skim milk/PBS for 1 hour, plates were incubated with 
dilution series of sera from immunized mice in 0.5% skim milk/PBS for two hours, washed 
and incubated with alkaline phosphatase-conjugated goat anti-mouse monoclonal antibody 
(mAb; Sigma) as secondary antibodies for 1 hour. Plates were washed prior to development 
with p-nitrophenyl phosphate (Sigma) as substrate. The optical density (OD) of the reaction 
product was measured at 405 nm with a microplate absorbance reader (Sunrise Absorbance 
Reader; Tecan). The threshold for endpoint titer determination was defined as the double of 
the mean measurements plus the mean standard deviation of a dilution series done without 
primary antibody and a dilution series done with pre-bleed serum. Individual serum dilution 
series were approximated with sigmoidal dose-response curves and the reciprocal dilution of 
the intersection between the curve and the threshold was defined as individual endpoint titer 
(GraphPad Prism software, Graph-Pad Software Inc.).  
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For the determination of IgG subclasses, ELISA was performed as described above with the 
use of subclass specific alkaline phosphate-conjugated secondary antibodies (Southern 
Biotech).  
Western blot analysis 
According to the manufacturer’s instructions, 10 µg of M. ulcerans whole cell lysate was 
loaded on a prefabricated 4-12% gradient gel (NuPAGE Novex 4-12% Bis-Tris Gel; 
Invitrogen) with MES running buffer under reducing conditions. A dry-blotting system (iBlot; 
Invitrogen) was used to electrophoretically transfer the separated proteins to nitrocellulose 
membranes, which were subsequently blocked in 5% skim milk/PBS over night at 4°C. 
Membranes were cut into strips and individually incubated with appropriate dilutions of serum 
of immunized mice in 1% skim milk/0.05% Tween20 / PBS for 1 hour at RT. After several 
washing steps in 1% skim milk/0.05% Tween20/PBS, a HRP-conjugated goat anti-mouse 
IgG γ-chain mAb (Southern Biotech) was used as secondary antibody and incubated for 1 
hour at RT. Excess antibody and skim milk residuals were washed away with PBS and blots 
were then developed using ECL Western blotting detection reagents (ECL Western blotting 
Substrate; Pierce).  
For the determination of the Western blot endpoint titers, individual dilution series of sera 
were processed as described above. Development of the entire set of strips by the ECL 
system was done on one single film. Development time was chosen as the shortest time 
needed for detecting a specific signal in at least one strip for every serum dilution, e.g. lowest 
dilution, and for every dilution series of individual sera at least one strip with no specific 
signal, e.g. highest dilution. Western blot endpoint titers were defined as the reciprocal value 
of the last dilution that yielded a specific band in Western blotting on the film.  
Immunofluorescence assays on paraffin embedded M. ulcerans 
Immunofluorescence assays with sera of immunized mice on paraffin embedded M. ulcerans 
bacteria were performed as previously described [25]. Briefly, African M. ulcerans isolates 
were embedded into paraffin, cut into 3 µm thin sections and mounted on Superforst Plus 
glass slides (Thermo Scientific). Sections were then deparaffinised, rehydrated and pre-
treated with 1mM EDTA buffer pH=8 for epitope retrieval as described for tissue sections in 
immunohistochemistry [28]. Unspecific binding was prevented by incubation of the bacteria in 
1.5% goat serum in PBS for 1 hour at RT. Appropriately diluted mouse mAbs specific for 
MUL_2232 and MUL_3720 were used as primary antibodies. Detection of the specific 
binding of primary antibodies was done with an Alexa488 labelled secondary goat anti-
mouse total IgG (H+L) antibodies (Life Technologies). Image acquisition was performed on a 
confocal laser microscope (Carl Zeiss, Axiovert 200M).  
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Active immune protection experiments in mice 
Active immune protection experiments were conducted with groups of eight female 8 weeks 
old BALB/c mice. Mice were immunized twice s.c. in the scruff of the neck with 100 µl of the 
adjuvanted proteins in three week intervals. Three weeks after the second immunization and 
prior to infection with M. ulcerans, mice were bled by the tail vein and successful 
immunization was verified by testing the sera for specific antibodies in ELISA and Western 
blotting as described above. All M. ulcerans infection experiments were conducted under 
BSL-3 conditions. 
The M. ulcerans strain S1013 used for the experimental infection of mice was isolated in 
2010 from the ulcerative lesion of a Cameroonian BU patient [29]. Bacteria were cultivated in 
BacT/ALERT medium (Biomerieux) for six weeks, recovered by centrifugation and diluted in 
sterile PBS to 125 mg/ml wet weight. Mice were infected with 1.5 x 106 (high dose) or 1.5 x 
105 (low dose) bacteria in PBS into the left hind foot pad three weeks after the last 
immunization.  
The course of the infection was followed by weekly measurements of the foot pad thickness 
with a caliper. At days 63 (high dose) and 87 (low dose) after experimental infection, mice 
were euthanised, blood samples harvested through cardiac puncture and foot pads 
aseptically removed for enumeration of M. ulcerans bacteria or histopathology. Mouse foot 
pads designated for enumeration of M. ulcerans bacteria were dipped in 70% ethanol, dried 
under the laminar flow, cut into four pieces with a scalpel and transferred to reinforced hard 
tissue grinding tubes (MK28-R, Precellys) containing 750 µl of BacT/ALERT medium. Tissue 
homogenization was performed with a Precellys 24-Dual tissue homogenizer (3 x 20 s at 
5000 rpm with 30 s break), the lysate was transferred to a clean tube and the lysis tube still 
containing tissue residuals refilled with additional 750 µl of BacT/ALERT medium. The 
remains were homogenized a second time as described above and the individual two lysates 
were pooled [30].  
DNA from 100 µl of a 1:50 dilution of the foot pad lysate in PBS was extracted as described 
by Lavender and Fyfe [31]. Extracted DNA was then analysed for insertion sequence (IS) 
2404 by quantitative (q) PCR as previously described [31]. For graphic representation of the 
results, cycle threshold (Ct) values were converted into genome copy numbers per foot pad 
by applying a standard curve established for IS2404 by Fyfe et al. [32]. 
Histopathology 
Mouse foot pads designated for histopathological analysis were removed above the ankle 
and immediately transferred to 10% neutral-buffered formalin solution (approx. 4% 
formaldehyde, Sigma) for fixation during 24 hours at room temperature. Subsequently, the 
foot pads were decalcified in 0.6 M EDTA and 0.25 M citric acid for 12 days at 37°C and 
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transferred to 70% ethanol for storage and transport. Foot pad samples were dehydrated and 
embedded into paraffin. 5 µm thin sections were cut, deparaffinised, rehydrated, and stained 
with Haematoxylin/Eosin (HE, Sigma, J.T. Baker) or Ziehl-Neelsen/Methylene blue (ZN, 
Sigma) according to WHO standard protocols [33]. Stained sections were mounted with 
Eukitt mounting medium (Fluka). Pictures were taken with a Leica DM2500B microscope or 
with an Aperio scanner. 
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Results 
GLA-SE adjuvanted recombinant M. ulcerans protein formulations elicited 
specific antibody responses 
The two M. ulcerans vaccine candidate antigens MUL_2232 and MUL_3720 were expressed 
as 6xHis-tagged recombinant proteins in E. coli and purified via a Ni-NTA column (S1 Fig). 
Mice were immunized three times with either 20 µg of MUL_2232 or MUL_3720 formulated 
with the human-compatible GLA-SE adjuvant EM048. Alum and Sigma adjuvant were used 
as control adjuvants. ELISA with mouse sera on the respective recombinant proteins showed 
that all formulations elicited robust antigen specific serum IgG responses (Fig 1) dominated 
by IgG1 and only a minor proportion of IgG3 (Fig 2, A1 and B1).  
Western blotting analyses of sera against M. ulcerans lysates showed specific bands of the 
expected molecular weight of MUL2232 and MUL3720 (Fig 3A, S2 Fig, A). Sera of 
immunized mice also recognized M. ulcerans bacteria in an indirect immunofluorescence 
assay (IFA) performed on paraffin embedded M. ulcerans bacteria (Fig 3B, S2 Fig, B). For 
both target antigens the previously demonstrated surface localization [25] was confirmed. Six 
months after the last immunization, antibody responses in all groups of immunized mice had 
dropped significantly. However, specific antibody titres were still higher than in the pre-
immune sera and sufficient to elicit signals in Western blotting analyses (Fig 2, A3 and B3). 
Assessment of protectivity of the vaccine induced antibody responses in an 
experimental M. ulcerans infection mouse model 
Given that antigens formulated with the human-compatible EM048 elicited higher total IgG 
responses after two injections and with similar IgG1, but higher IgG2a, IgG2b, IgG3 antibody 
levels compared to formulation with Alum, we determined the protective potential of these 
vaccine formulations in an experimental M. ulcerans infection mouse model. Because the 
increase of total IgG titers after a third immunization was not significant (Fig 1), groups of 
eight mice were immunized twice with rMUL3720/EM048. Three weeks after the second 
immunization mice were infected into the left hind foot pad with an inoculum of 1.5 x 106 
(high dose) or 1.5 x 105 (low dose) of M. ulcerans bacilli. The course of the infection was 
followed by weekly measurements of the foot pad thickness with a caliper. Mice in all groups 
infected with the high dose of bacteria showed first signs of inflammation and foot pad 
swelling seven weeks after infection (Fig 4, A). Swelling gradually increased over time, until 
mice had to be euthanised at day 63 and the bacterial load was determined by qPCR (Fig 4, 
B). Compared to the amount of M. ulcerans DNA that was contained in the inoculum, a 
roughly 250 times increase had occurred both in immunized and control animals during the 
63 days of infection (Fig 4, B). 
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Histopathological analysis of representative foot pads revealed the presence of oedema (Fig 
5, B1, B4) and slight infiltration at the site of infection (Fig 5, B6) as well as at the heel of the 
foot pad (Fig 5, B2). Acid fast bacilli (AFB) were found at all sites where infiltration occurred 
(Fig 5, B3, B5, B7). 
In mice infected with the low dose inoculum, foot pad swelling started seven to eight weeks 
after infection (Fig 4, A) and the increase in M. ulcerans DNA content was about 9500 fold in 
87 days. Also with the lower challenge dose no difference in bacterial load was observed 
between immunized and control immunized animals (Fig 4, B). Large clumps of AFB were 
found in all infected foot pads irrespective of the immunization status of the mice (Fig 5, C1 - 
C2, D1. AFB occurred in clumps (Fig 5, C2), organized within filamentous structures 
principally located in oedematous tissue (Fig 5, C3, D3) and in close contact with infiltrating 
cells (Fig 5, D2). Similarly, rMUL2232/EM048 did not induce any protective effect (S3 Fig).  
M. ulcerans infection failed to boost immunization-induced antibody responses 
Antibody titers in immunized mice before infection (S4 Fig) and after 63 days of infection 
were directly compared to elucidate whether the immunization-induced antibody responses 
were increased by exposure to the target antigens in the native context of the infecting bacilli. 
No booster effect was observed after infection with the high dose inoculum of M. ulcerans 
(Fig 6, A1 and A2). On the contrary, both ELISA and Western blotting analyses 
demonstrated a significant drop in specific antibody titres after infection (Fig 6, B). 
Furthermore, neither non-immunized nor control-immunized animals raised a specific 
antibody response against rMUL2232 (Fig 6, A1) or rMUL3720 (Fig 6, A2) and Western 
blotting analyses of these control sera revealed a profound lack of any M. ulcerans specific 
antibody responses in the course of infection (Fig 6, B).  
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Discussion 
Currently, there is no highly effective vaccine against the mycobacterial diseases 
tuberculosis, leprosy and BU available. BCG was originally developed as a vaccine against 
tuberculosis, but, dependent on the study site, a protective efficacy ranging from 20% to 90% 
was also observed against leprosy [34,35]. Similarly, BCG was found to offer a short-lasting 
protection of 47% against BU in a controlled clinical trial in Uganda [20], reconfirming results 
of a previous smaller trial [36]. However, case-control studies have failed to provide evidence 
of a lasting protective effect of routine BCG vaccination against BU [37–39]. Yet in M. 
ulcerans mouse infection models any other vaccine candidate has so far outperformed the 
effectiveness of BCG [18].  
As a partner in the collaborative research project BuruliVac, we seeked to assess the 
potential to develop a protein based subunit vaccine against BU. Here we report results 
obtained with two cell surface exposed M. ulcerans proteins formulated with the adjuvant 
EM048. In spite of the development of robust humoral immune responses, none of the 
vaccination formulations tested conferred protection in the experimental M. ulcerans mouse 
foot pad infection model.  
Choosing potential protective antigens for the inclusion into a protein subunit vaccine against 
BU was difficult, since the nature of protective immune responses against the disease is 
unclear. Given the mainly extracellular location of M. ulcerans in advanced lesions, the 
choice of surface exposed proteins seemed most attractive. Additionally, M. ulcerans specific 
proteins were of preference, because it was already observed that proteins from the closely 
related pathogens M. bovis and M. leprae were not very effective in conferring cross-
protectivity, despite high sequence homology [40,41]. We have chosen MUL_2232 for its 
known surface localization, its strong immunogenicity and its missing homolog in M. 
tuberculosis [10]. The second candidate, MUL_3720, was identified in a screen for potential 
diagnostic antigens conducted in our laboratory [24]. Homologs of MUL_3720 are absent in 
other mycobacterial pathogens prevalent in BU endemic areas. Furthermore, it is highly 
expressed and most importantly it is located on the surface of M. ulcerans [25].  
In light of current literature available on protective immunity to BU we have chosen to 
formulate the selected antigens with the human compatible adjuvant GLA-SE. GLA is a 
synthetic Toll-like receptor 4 agonist, that has been demonstrated to confer potent adjuvant 
activity for various antigens [26,42–44] when formulated with a squalene based oil-in-water 
stable emulsion (SE). While SE is an adjuvant on its own, the addition of GLA biases the 
induced cell mediated immunity (CMI) toward a TH1 type immune response, an observation 
made for several antigens tested so far [42,45]. However, formulations of the recombinant 
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proteins rMUL2232 and rMUL3720 with EM048, the specific GLA-SE adjuvant used in this 
study, did not lead to such a clear shift of CMI towards TH1. Yet compared to Alum, which is 
still the adjuvant most commonly used in human vaccines, EM048 induced significantly 
higher antibody titres with both recombinant proteins investigated. All mice immunized with 
adjuvanted recombinant protein vaccine-candidates and later challenged with M. ulcerans 
had mounted strong specific antibody responses, which were cross-reactive with the 
antigens in the native context on the bacterial cell surface. Nevertheless, these mice were 
not protected from disease. Opsonisation of the bacteria by the immunization-induced 
antibodies may not lead to protection, since the clusters of the extracellular M. ulcerans 
found in advanced BU lesions are imbedded in necrotic tissue. Infiltrating macrophages are 
therefore not able to reach the bacteria, since infiltrating cells seem to be killed by 
mycolactone before reaching the infection foci. On the other hand, it is not completely ruled 
out that antibodies against other target structures may be protective. Neutralizing antibodies 
against the poorly immunogenic macrolide toxin mycolactone for example could potentially 
confer protection against disease. The fact that the response of immunized mice was not 
boosted upon progressive infection with M. ulcerans could hint to another obstacle for 
vaccine development against BU. The apparent general lack of antibody responses in non-
immunized challenged control mice that was observed by us and others [23] is surprising, 
and requires further investigation. A number of studies have reported systemic T-cell anergy 
in patients with BU, but development of antibody responses against M. ulcerans was 
detected in a majority of patients [10,46–48].  
In the framework of this study we have developed methods to evaluate the protective 
capacity of candidate vaccines in the M. ulcerans mouse footpad infection model. The fact 
that we did not see protection in immunized animals could have many explanations; including 
insufficient bias towards a TH1 type of CMI. Most likely immunization with only one antigen is 
generally not sufficient for protection against disease. Considering that vaccination with a 
mycolactone deficient mutant strain of M. ulcerans did not lead to full protection in the mouse 
model [19], the development of a multivalent subunit vaccine may be the right strategy to 
pursue. 
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Figures 
 
 
Figure 1. Immunogenicity of recombinant protein/EM048 formulation in 
comparison to commercially available adjuvants for mice. 
Groups of five BALB/c mice were immunized three times in three week intervals with 20 µg of 
rMUL2232 (A) or rMUL3720 (B) formulated with Alum, Sigma Adjuvant or EM048. Serum 
three weeks after every immunization (I1, I2 and I3) was analysed in ELISA on the respective 
recombinant protein. Depicted are individual endpoint IgG titers as determined in one single 
ELISA, the mean (line) ± standard deviation. Overall statistical significance was calculated by 
Kruskal-Wallis test per immunization time point (A: PI1 = 0.0029, PI2 and PI3 = ns.; B: PI1 = 
0.0009, PI2 = 0.0029, PI3 = ns.). Individual statistical differences between groups were 
assessed by the Dunn procedure and are depicted if detected (* p ≤ 0.05; ** p ≤ 0.01). 
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Figure 2. Assessment of Immunoglobulin G subclasses and the longevity of 
antibody responses induced by immunization. 
Immunoglobulin G (IgG) subclasses were determined in serum collected three weeks after 
the third immunization with rMUL2232 (A1) and the indicated adjuvant or rMUL3720 (B1) and 
the indicated adjuvant. ELISA on recombinant protein was performed with secondary 
antibodies specific for four IgG subclasses: IgG1 (black), IgG2a (dark grey), IgG2b (light 
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grey), IgG3 (very light grey). Depicted are the mean individual endpoint IgG titers determined 
in one single ELISA (bar), and the standard deviation (error bar). Overall statistical 
significance was calculated by Kruskal-Wallis test (A1: PIgG1 = ns., PIgG2a = 0.0396, PIgG2b = 
ns., PIgG3 = 0.0375; B1: PIgG1 = ns., PIgG2a = 0.0029, PIgG2b = 0.0431, PIgG3 = ns.). Individual 
statistical differences between groups were assessed by the Dunn procedure and are 
depicted if detected (* p ≤ 0.05). 
The ratio of IgG2a to IgG1 was determined for individual animals accordingly (A2 and B2). 
Depicted are the individual values, the mean IgG2a to IgG1 ratio (bar) and the standard 
deviation (error bar). Overall statistical significance was calculated by Kruskal-Wallis test (A2: 
P = ns.; B2: P = 0.0001). Individual statistical differences between groups were assessed by 
the Dunn procedure and are depicted if detected (** p ≤ 0.01). 
Total IgG titers in individual immunized mice three weeks (t1) and six months (t2) after the 
third immunization were compared by Western blotting on M. ulcerans lysate. Depicted are 
individual Western blot endpoint titers and the median per group (line) for rMUL2232 
immunized animals (A3) and rMUL3720 immunized animals (B3). Statistical significance was 
assessed by Mann-Whitney test and is depicted if detected (* p ≤ 0.05; ** p ≤ 0.01). 
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Figure 3. Cross reactivity of the immune sera with M. ulcerans. 
(A) Groups of five BALB/c mice (m1 – m5) were immunized three times in three week 
intervals with 20 µg of rMUL2232 formulated with Alum, Sigma Adjuvant or EM048. Serum 
three weeks after every immunization (I1, I2 and I3) was analysed by Western blotting on M. 
ulcerans lysate. Monoclonal anti-MUL_2232 antibody (mAb) served as positive control, pre-
bleed (pb) serum or no primary antibody (nc) as negative controls.  
(B) Sera from three weeks after the third immunization with rMUL2232 and indicated 
adjuvant were used for indirect immunofluorescence staining on paraffin embedded M. 
ulcerans bacteria with an Alexa488 labelled secondary antibody. Pre-bleed serum did not 
stain the bacteria. Sera of immunized mice (a mix of sera from five individual mice per group) 
did reveal surface staining similar to the staining achieved with anti-MUL_2232 monoclonal 
antibody (mAb). 
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Figure 4. Evaluation of the protective potential of immunization with 
rMUL3720/EM048 formulation in a M. ulcerans infection mouse model. 
Groups of eight BALB/c mice were immunized twice with 20 µg of rMUL3720/EM048 or PBS 
alone as infection control. Three weeks after the last immunization mice were challenged 
with a high dose or a low dose of M. ulcerans (inoculum) into the left hind foot pad. Infection 
was followed by measuring foot pad thickness with a caliper (A) until mice were euthanized 
at day 63 after infection (high dose, H1) or at day 87 after infection (low dose, H2). Depicted 
is the mean foot pad thickness (diamond/circle) ± standard deviation of the differently 
immunized groups. (B) Bacterial load in infected foot pads was determined by qPCR for six 
mice per group. Depicted are individual measurements as genome copies per foot pad, the 
mean (line) ± standard deviation. 
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Figure 5. Histopathological evaluation of mouse footpads following M. ulcerans 
infection.  
Histological sections of foot pads from M. ulcerans-infected mice were stained with 
Haematoxylin/Eosin (A, B1 - B7) or Ziehl-Neelsen/Methylene blue (ZN) (C1 - C4, D1 - D4). 
Histological sections of one lymph node were stained with ZN (E1 – E3). 
Mice challenged with a high dose of M. ulcerans developed typical signs of infection in the 
mouse foot pad model until day 63 after infection. Compared to a control foot pad (A) the 
infected foot pad of a representative immunized mouse (B1) showed necrosis and infiltration 
interspersed with AFB at the ankle (B2, B3) as well as at the base of the foot (B6, B7). 
Oedema was marked on top of the foot pad (B4) where bacteria were also found (B5). 
Immunized mice (C1) as well as control mice (D1) challenged with a lower dose of M. 
ulcerans developed strong infection foci until day 87 after infection. AFB appeared as big, 
dense clumps (C2) or in close association with infiltrating cells (D2) towards the heel of the 
infected foot pads as well as in the middle of the foot (C1, D1). AFB were also present in 
oedematous tissue in the upper half of the foot (D3) and appeared in filamentous 
organization (C3). 
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Figure 6. Evaluation of the booster effect of M. ulcerans infection on the pre-
existing antibody response in rMUL3720/EM048 immunized and subsequently 
infected mice. 
(A1) Serum of six BALB/c mice immunized with rMUL2232/EM048 prior to infection (before 
infection) with M. ulcerans was compared to serum of the same animals after 42 days of 
infection (after infection) in ELISA on rMUL2232. Control immunized animals had received 
PBS/EM048 or only PBS prior to infection. Depicted are individual endpoint IgG titers as 
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determined in one single ELISA, the group mean (line) ± standard deviation. Statistical 
significance was calculated by the Student’s t- test (** p ≤ 0.01). 
(A2) Serum of eight BALB/c mice immunized with rMUL3720/EM048 prior to infection with M. 
ulcerans was compared to serum of the same animals 63 days after infection with M. 
ulcerans bacteria in ELISA on rMUL3720. Control immunized animals (control) had only 
received PBS prior to infection. Depicted are individual endpoint IgG titers as determined in 
one single ELISA, the mean (line) ± standard deviation. Statistical significance was 
calculated by the Student’s t- test (**** p ≤ 0.0001). 
(B) Serum of six BALB/c mice (m1 – m6) immunized with rMUL3720/EM048 prior to infection 
with M. ulcerans (a) was compared to serum of the same animals after 42 days of infection 
(b) by Western blotting on M. ulcerans whole cell lysate. Monoclonal anti-MUL_3720 
antibody (mAb) served as positive control, pre-bleed (pb) serum or no primary antibody (nc) 
as negative controls. 
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Supplementary Material 
 
 
S1 Figure. Two M. ulcerans candidate vaccine antigens expressed as 
recombinant proteins in E. coli. 
Indicated amounts of rMUL2232 (A) or rMUL3720 (B) were resolved on SDS-page and 
stained with Coomassie blue. 
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S2 Figure. Cross reactivity of immune sera with M. ulcerans. 
(A) Groups of five BALB/c mice (m1 – m5) were immunized three times in three week 
intervals with 20 µg of rMUL3720 formulated with Alum, Sigma Adjuvant or EM048. Serum 
after every immunization (I1, I2 and I3) was analysed by Western blotting on M. ulcerans 
lysate. Monoclonal anti-MUL_3720 antibody (mAb) served as positive control, pre-bleed (pb) 
serum or no primary antibody (nc) as negative controls. (B) Sera from three weeks after the 
third immunization with rMUL3720 and indicated adjuvant were used for indirect 
immunofluorescence staining on paraffin embedded M. ulcerans bacteria with an Alexa488 
labelled secondary antibody. Pre-bleed serum did not stain the bacteria. Sera of immunized 
mice (a mix of sera from five individual mice per group) did reveal surface staining similar to 
the staining achieved with anti-MUL_3720 monoclonal antibody (mAb). 
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S3 Figure. Evaluation of the protective potential of immunization with 
rMUL2232/EM048 formulation in a M. ulcerans infection mouse model. 
Groups of six BALB/c mice were immunized twice with 20 µg of rMUL2232/EM048, 
PBS/EM048 or PBS alone as infection control. Three weeks after the last immunization mice 
were challenged with M. ulcerans (inoculum) into the left hind foot pad. Infection was 
followed by measuring foot pad thickness with a caliper (A1) until mice were euthanized at 
day 42 after infection. Depicted is the mean foot pad thickness (diamond/dot) ± standard 
deviation of the differently immunized groups. (A2) Bacterial load in infected foot pads was 
determined by qPCR for five mice per group. Depicted are individual measurements as 
genome copies per foot pad, the mean (line) ± standard deviation. 
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S4 Figure. Reactivity of immune sera on M. ulcerans lysate.  
Groups of eight BALB/c mice were immunized twice with 20 µg of rMUL3720/EM048 or PBS 
only as infection control. Serum prior to infection with M. ulcerans was analysed by Western 
blotting on M.ulcerans lysate. Monoclonal anti-MUL_3720 antibody (mAb) served as positive 
control, pre-bleed (pb) serum or no primary antibody (neg) as negative controls. C1 and C2 
each represent a mix of sera of eight mice immunized with PBS only. 
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Abstract 
Buruli ulcer, caused by infection with Mycobacterium ulcerans, is a necrotizing disease of the 
skin and subcutaneous tissue, which is most prevalent in rural regions of West African 
countries. The majority of clinical presentations seen in patients are ulcers on limbs that can 
be treated by eight weeks of antibiotic therapy. Nevertheless, scarring and permanent 
disabilities occur frequently and Buruli ulcer still causes high morbidity. A vaccine against the 
disease is so far not available but would be of great benefit if used for prophylaxis as well as 
therapy. In the present study, vesicular stomatitis virus-based RNA replicon particles 
encoding the M. ulcerans proteins MUL2232 and MUL3720 were generated and the 
expression of the recombinant antigens characterized in vitro. Immunisation of mice with the 
recombinant replicon particles elicited antibodies that reacted with the endogenous antigens 
of M. ulcerans cells. A prime-boost immunization regimen with MUL2232-recombinant 
replicon particles and recombinant MUL2232 protein induced a strong immune response but 
only slightly reduced bacterial multiplication in a mouse model of M. ulcerans infection. We 
conclude that a monovalent vaccine based on the MUL2232 antigen will probably not 
sufficiently control M. ulcerans infection in humans. 
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Author Summary 
Infection with Mycobacterium ulcerans can lead to a slow progressing, ulcerative disease of 
the skin and underlying soft tissue called Buruli ulcer. The disease is most prevalent in rural 
African communities with limited access to health care facilities. The most efficient means to 
prevent the disease, a vaccine against Buruli ulcer is not available to date. In the present 
study we investigated the immunogenicity and protective potential of a single cycle virus 
system expressing the two M. ulcerans antigens MUL2232 and MUL3720. Immunization of 
mice with those vesicular stomatitis virus replicon particles led to the induction of humoral as 
well as cellular immune responses in the immunized animals. Subsequent challenge 
experiments in a mouse model of M. ulcerans infection demonstrated only a limited reduction 
of bacterial burden in mice immunized with a prime-boost approach with MUL2232. Most 
probably, a vaccine formulation with only one antigen will not be able to provide protection 
against Buruli ulcer in humans. 
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Introduction 
Mycobacterium ulcerans causes Buruli ulcer (BU), a disease of the skin and underlying 
subcutaneous tissue, which is reported from over 30 countries worldwide [1]. BU is most 
prevalent in West African countries and mainly affects children less than 15 years of age, 
living in remote, rural areas [2]. The natural reservoir of M. ulcerans has not been identified 
so far and also the mode of transmission of this pathogen remains unclear [3].  
M. ulcerans produces a macrolide exotoxin called mycolactone, which induces apoptosis in 
mammalian cells and leads to the typical clinical presentation of ulcerative BU skin lesions 
after the overlying epidermis has collapsed [4]. Non-ulcerative forms of the disease are 
nodules or papules, oedema and plaques [5]. BU was traditionally treated by wide surgical 
excision of the affected skin and skin grafting if necessary. Since 2004, treatment of patients 
for eight weeks with the antibiotics rifampicin and streptomycin is recommended as standard 
therapy by the World Health Organization (WHO) [6]. Even though the use of antibiotics has 
reduced recurrence rates to less than 2% [7–9], patients are often left with scars and lifelong 
disabilities [10]. A vaccine against BU would therefore be of high value to prevent and treat 
the disease [11].  
As opposed to M. tuberculosis and M. leprae, which are both intracellular pathogens for 
which T helper 1 (TH1) cellular immune responses are essential for infection control [12], M. 
ulcerans is found in extracellular clumps in the necrotic subcutaneous skin tissue of 
advanced lesions. However, there is evidence for an initial intracellular stage in 
macrophages during the early phase of infection [13,14]. Correlates of protection have not 
been identified, and in particular it is not known, whether antibodies specific for surface 
antigens of M. ulcerans have protective activity [15].  
Vaccination with Bacille Calmette-Guérin (BCG) seems to confer a transient protection from 
BU and a shorter duration of ulcers [16–18]. In a mouse model of M. ulcerans infection, 
vaccination with either BCG or a mycolactone-negative M. ulcerans mutant strain delayed 
the onset of foot pad swelling [19,20]. A limited protective efficacy has also been achieved 
with monovalent DNA-based protein subunit vaccine formulations targeting either the 
mycolyl-transferase antigen (Ag) 85A from M. bovis or M. ulcerans [21,22] or mycolactone 
polyketide synthase domains that are encoded on the giant M. ulcerans plasmid pMUM001 
[23]. 
Vesicular stomatitis virus (VSV) is a member of the virus family Rhabdoviridae and has a 
non-segmented single-stranded RNA genome of negative polarity. VSV is transmitted by 
insects and causes a vesicular-like disease in livestock and Flu-like symptoms in humans. 
The VSV seroprevalence is very low in the human population, indicating that human 
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infections are rare. The non-persisting replication of VSV in the cytosol of the host cell, low 
virulence and low pre-existing immunity in humans, and the option of simple genetic 
manipulation [24] has recommended VSV as viral vector system for vaccination [25,26]. 
Several VSV-based vaccines for protection against viral and bacterial pathogens have been 
generated in recent years and have been evaluated in a number of animal models [27–30]. 
More recently, single-cycle VSV vectors have been developed, which lack the genetic 
information for the VSV glycoprotein G and are complemented with this protein in trans. 
Although these VSVΔG vectors are restricted to a single round of infection, they were shown 
to be as immunogenic as propagation-competent VSV vectors [31]. 
In the present study we used this safe vaccine vector platform to characterize the 
immunogenicity of two M. ulcerans protein antigens. In view of the mainly extracellular nature 
of M. ulcerans, we chose antigens known to be highly expressed on the surface of the 
bacteria. The 18 kDa small heat shock protein (MUL2232) was identified amongst the most 
immunodominant antigens expressed by M. ulcerans when serum responses from people 
living in endemic areas were analysed [32]. A homologue of MUL2232 was found in the 
genome of M. leprae but neither in M. bovis nor in M. tuberculosis. Similar to the M. leprae 
homologue, MUL2232 is associated with the cell wall fraction of M. ulcerans [32,33]. The 
second antigen chosen, MUL3720, is a 21 kDa protein with a putative lectin and a 
peptidoglycoan-binding domain that does not have homologues in M. leprae or M. 
tuberculosis [34,35]. It is highly expressed by M. ulcerans and may play a role in cell 
attachment and cell-cell interactions [35], making it a candidate antigen for vaccine 
development. We generated recombinant single-cycle VSV vectors encoding the selected 
antigens individually and analysed their expression in mammalian cell lines. We further 
analysed the immunogenicity of the generated VSV vectors and evaluated two short 
immunization protocols. Finally, we investigated the protective potential of such immunization 
schemes in an experimental mouse model of M. ulcerans infection. 
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Materials and Methods 
Ethics statement 
All animal experiments were conducted in compliance with the Swiss animal protection law 
and approved by the animal welfare committee of the Canton of Basel (authorization number 
2375) and the Canton of Vaud (authorization number 2657). 
Cells 
Baby hamster kidney 21 (BHK-21) cells were obtained from the German Cell Culture 
Collection (DSZM, Braunschweig). Cells were grown in Earle’s minimal essential medium 
(MEM, Life Technologies) supplemented with 5% foetal bovine serum (FBS, Biowest). BHK-
G43, a transgenic BHK-21 cell line expressing the VSV G protein in an inducible manner, 
was maintained as described previously [36]. Murine L929 fibroblasts (ATCC, The Global 
Bioresource Center) were cultivated in RPMI medium (Gibco) supplemented with 10% foetal 
calf serum (FCS, Sigma), 2 mM glutamine (Gibco) and 0.05 mM β-mercaptoethanol (Gibco). 
Generation of recombinant vesicular stomatitis virus replicon particles 
expressing M. ulcerans codon optimized antigens 
The potential protein vaccine candidate antigens MUL_2232 (GenBank accession number 
4550596) and MUL_3720 (GenBank accession number 4553013) of M. ulcerans Agy99 were 
ordered as codon optimized genes for expression in humans (GenScript) and received in 
pUC57 plasmids. For generation of recombinant VSV replicon particles (VRPs), codon 
optimized target antigens were amplified by PCR and inserted into the pVSV*ΔG plasmid 
using single MluI and BstEII restriction sites upstream and downstream of the fourth 
transcription unit, replacing the VSV G gene [37]. Sequence integrity of the resulting 
plasmids was confirmed by Sanger sequencing. Recombinant VRPs were generated as 
described previously [38]. In brief, BHK-G43 cells were infected with recombinant MVA-T7 
virus expressing T7 RNA polymerase [39]. Subsequently, the infected cells were transfected 
with plasmids driving T7 RNA polymerase-mediated expression of the VSV proteins N, P, 
and L, and with pVSV*ΔG(MUL2232) or pVSV*ΔG(MUL3720) driving T7 RNA polymerase-
mediated transcription of VSV antigenomic (negative-sense) RNA. Expression of the VSV G 
protein was induced by adding mifepristone (Sigma) to the cell culture medium. At 24 hours 
post transfection cells were detached with trypsin and seeded along with an equal number of 
fresh BHK-G43 cells into T-75 flasks. Cells were then incubated at 37°C for another 24 hours 
in the presence of mifepristone. Cell culture supernatant was clarified by low-speed 
centrifugation and by passage through a 0.2 µm pore filter. The VRPs in the clarified cell 
culture supernatant were further propagated on mifepristone-induced BHK-G43 cells and 
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stored at -70°C. VRPs were titrated on BHK-21 cells taking advantage of the eGFP reporter 
protein. 
Western blot analysis 
Detection of vaccine antigens in VRP-infected cells 
Equal numbers of confluent L929 fibroblasts were infected with VRPs at a multiplicity of 
infection (MOI) of 10 for 6 hours at 37°C. Cells were washed with ice-cold phosphate 
buffered saline (PBS; Sigma) and harvested for lysis. Protein lysates of both the soluble and 
insoluble fraction of the cells were produced with a cell fractionation kit (Abcam) according to 
the manufacturer’s instructions. Equal amounts of protein lysates as well as M. ulcerans 
lysate in an appropriate dilution were resolved on prefabricated 4-12% gradient gels 
(NuPAGE Novex 4-12% Bis-Tris Gel; Invitrogen) with MES running buffer (Invitrogen) 
according to the manufacturer’s directions. A dry-blotting system (iBlot; Invitrogen) was used 
to transfer proteins to nitrocellulose membranes. Membranes were blocked and specific 
proteins detected with in house anti-MUL2232 or anti-MUL3720 mouse mAbs followed by 
HRP-conjugated goat anti-mouse IgG γ-chain mAb (Southern Biotech, 1030-05). Blots were 
developed using ECL Western blotting detection reagents (ECL Western blotting Substrate; 
Pierce). 
Cross-reactivity of the elicited antibodies in mouse sera with the native antigen in M. 
ulcerans lysate 
10 µg of M. ulcerans whole cell lysate was resolved on a one well prefabricated 4-12% 
gradient gel (NuPAGE Novex 4-12% Bis-Tris Gel; Invitrogen) with MES running buffer 
according to the manufacturer’s instructions. The blocked membrane was subsequently cut 
into thin strips that were individually incubated with appropriate dilutions of serum of 
immunized mice for 2 hours. Secondary antibody and development were performed as 
described above.  
Immunofluorescence analyses 
For indirect immunofluorescence analysis, BHK-21 cells were grown on 12 mm diameter 
cover slips (2 x 105 cells/well) and infected with VRPs (106 infectious units/well) for 6 hours at 
37°C. Cells were fixed with 3% paraformaldehyde (PFA) and washed with PBS containing 
0.1 M of glycine. The cells were permeabilized with 0.25% (v/v) Triton X-100 and 
subsequently incubated for 1 hour with anti-MUL2232 or anti-MUL3720 mAbs in appropriate 
dilutions in 1% bovine serum albumin (Sigma). For detection of antigen-bound primary 
antibodies, cells were incubated with an Alexa Flour 546 labelled anti-mouse IgG secondary 
antibody (1/500; Molecular Probes, A-11018). The cells were washed with distilled water, 
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embedded in Mowiol 4-88 (Sigma) mounting medium, and analyzed with a Leica TCS SL 
confocal microscope and LCS software (Leica Microsystems AG, Glattbrugg, Switzerland). 
ELISA on recombinant protein 
ELISA plates (Maxisorp; Nunc) were coated with 10ug/ml purified recombinant MUL2232 
(rMUL2232) or MUL3720 (rMUL3720) protein produced in Escherichia coli [40]. After 
blocking, plates were incubated with serially diluted sera from immunized mice. Alkaline 
phosphatase-conjugated goat anti-mouse antibody (Sigma) was used as secondary antibody 
and p-nitrophenyl phosphate (Sigma) served as substrate. The optical density (OD) of the 
reaction product was measured at 405 nm with a microplate reader (Sunrise Absorbance 
Reader; Tecan). The threshold for endpoint titer determination was defined as the double of 
the mean measurements plus the mean standard deviation of a dilution series done without 
primary antibody and a dilution series done with pre-bleed serum. Individual serum dilution 
series were approximated with sigmoidal dose-response curves and the reciprocal dilution of 
the intersection between the curve and the threshold was defined as individual endpoint titer.  
Mouse immunization studies 
All animal studies were conducted in 8 weeks old female BALB/c mice (Janvier). VRPs (107 
fluorescence-forming units) were either applied subcutanously (s.c.) in the neck (for 
evaluation of the vaccination protocol) or intramuscularly (i.m.) into the right caudal tight 
muscle using a volume of 100 µl or 30 µl, respectively. When several immunizations were 
conducted, injections were performed in three week intervals. For prime-boost vaccination 
regimen, 30 µg of non-adjuvanted recombinant protein were applied s.c. into the neck. Blood 
was collected from the tail vein prior to every immunization as well as 5/6 and 14 days after 
the protein boost. Serum was prepared by centrifugation of the blood in SST Microtainer 
tubes (Becton, Dickinson and Company). 
Analysis of cellular immune responses 
Immunized mice were euthanized 3 weeks after the second immunization. Heart blood was 
collected and spleens were aseptically removed and homogenized by passing through a 70 
µm cell strainer (BD Falcon). Cells were then pelleted and red blood cells lysed by incubating 
the pellet in red blood cell lysing buffer (Sigma) for 1 minute. Remaining cells were washed 
several times with stemline T-cell expansion medium (Sigma) supplemented with 4mM L-
Glutamine (Gibco), 1% Pen-Strep (Gibco), 2.5 ug/ml Amphotericin B (Sigma) and 0.05 mM 
β-mercaptoethanol (Gibco) and finally adjusted to 4 x 106 white blood cells/ml. 7.2 x 105 cells 
per well were incubated in round-bottom microwell plates (BD Falcon) in a humidified CO2 
incubator and stimulated with Concanavalin A (2 µg/ml, Sigma) as positive control or 
recombinant proteins at 5 µg/ml. Supernatants were harvested after 24h for Interleukin 2 (IL-
2) and 96h for Interleukin 10 (IL-10) and Interferon gamma (IFNγ) assays and stored frozen 
156 Results     Chapter 5 
 
at -20°C until analysis for the selected cytokines. Amount of cytokines in supernatants was 
determined with Quantikine ELISA kits for IL-2, IL-10 and IFNγ (R&D Systems). 
Challenge infection experiments 
The M. ulcerans strain (S1013) used for the experimental infection of mice was isolated in 
2010 from the ulcerative lesion of a Cameroonian BU patient [2]. Bacteria were cultivated for 
6 weeks in Bac/T medium (Biomerieux), recovered by centrifugation, and suspended in 
sterile PBS to 125 mg/ml wet weight corresponding to 2.8 x 105 CFU/ml as determined by 
plating serial dilutions on 7H9 agar plates (Difco). Three weeks after the last immunization, 
mice were infected with 30 µl of M. ulcerans suspension (1/100 of the stock solution in PBS) 
into the left hind foot pad. Development of the infection was followed by weekly 
measurements of the foot pad thickness with a caliper. At day 60 after experimental infection, 
mice were sacrificed and foot pads aseptically removed for enumeration of M. ulcerans 
bacteria or histopathology. Draining inguinal lymph nodes of designated animals were 
removed and fixed in formalin as well. All M. ulcerans infection experiments were conducted 
under BSL3 conditions. 
Colony forming unit (CFU) plating and enumeration of bacterial load by real-
time PCR (qPCR) 
Mouse feet designated for enumeration of M. ulcerans bacteria were immediately removed 
above the ankle after euthanasia, shortly dipped into 70% ethanol, then dried under the 
laminar flow, cut in 4 pieces with a scalpel and transferred to 750 µl of Bac/T medium in 
reinforced hard tissue grinding tubes (MK28-R, Precellys). Tissue homogenization was 
performed with a Precellys 24-Dual tissue homogenizer (3 x 20 s at 5000 rpm with 30 s 
break), the lysate was transferred to a new tube and the lysis tube still containing tissue 
remains was refilled with 750 µl of Bac/T medium. The remains were homogenized a second 
time and the two lysates pooled. 
CFU plating 
250 µl of the foot pad lysate was decontaminated with 0.5 M NaOH as described previously 
[41]. The pellet of decontaminated lysate was dissolved in 500 µl of Bac/T medium and 
appropriate dilution series plated on 7H9 agar plates. Following 150 days of incubation at 
30°C colonies were counted and the concentration of bacteria expressed as CFU. 
DNA extraction and qPCR 
DNA from 100 µl of a 1 to 50 dilution of the foot pad lysate in PBS was extracted as 
described by Lavender and Fyfe [42]. Extracted DNA was analysed for IS2404 by qPCR as 
previously described [42]. Ct values were converted into genome copy numbers per foot pad 
by applying the standard curve established for IS2040 by Fyfe et al. [43]. 
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Histopathology 
Mouse feet designated for histopathological analysis were removed above the ankle and 
immediately transferred to 10% neutral-buffered Formalin solution (approx. 4% 
formaldehyde, Sigma) for fixation during 24 hours at room temperature. Subsequently, the 
feet were decalcified in 0.6 M EDTA and 0.25 M citric acid for 12 days at 37°C and 
transferred to 70% ethanol for storage and transport. The samples were dehydrated and 
embedded into paraffin. 5 µm thin sections were cut, deparaffinised, rehydrated, and stained 
with Haematoxylin/Eosin (HE, Sigma, J.T. Baker) or Ziehl-Neelsen/Methylene blue (ZN, 
Sigma) according to WHO standard protocols [44]. Stained sections were mounted with 
Eukitt mounting medium (Fluka). Pictures were taken with a Leica DM2500B microscope or 
with an Aperio scanner. 
Statistical analysis and image processing 
Differences of bacterial load in infected foot pads were statistically analysed by the Mann-
Whitney test using Graph Pad Prism (Version 6.03). Results of cytokine production were 
subjected to log10 transformation and subsequently analysed with SAS software (SAS 
Institute, Cary, USA, release 9.3) using linear mixed models adjusted for random effects. 
Image processing and picture panel assembly was performed with Photoshop software 
(Adobe Photoshop CS6 Extended, version 13.0.1). 
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Results 
Expression of the M. ulcerans vaccine candidate antigens MUL2232 and 
MUL3720 by cells infected with recombinant virus replicon particles 
Candidate vaccines were generated by replacing the VSV glycoprotein G gene with the M. 
ulcerans genes MUL2232 or MUL3720 (Fig. 1, A). In order to ease virus detection and 
titration, the coding sequence for the enhanced green fluorescent protein (eGFP) was 
inserted as an additional transcription cassette downstream of the M. ulcerans genes. The 
recombinant viruses VSV*ΔG(MUL2232) and VSV*ΔG(MUL3720) as well as the control virus 
VSV*ΔG, which only contained the eGFP gene in place of the VSV surface glycoprotein G 
(Fig. 1, A), were produced and propagated in the helper cell line BHK-G43 providing the VSV 
G protein in trans. As expected from other studies with similar constructs, the trans-
complemented particles were able to infect a variety of different mammalian cell lines but 
were unable to release progeny viruses [27,45]. We thus refer to them as to virus replicon 
particles (VRPs). 
In order to study the expression of MUL2232 and MUL3720 in infected cells, BHK-21 cells 
were infected with the three different VRPs generated and analysed by using MUL2232 and 
MUL3720-specific mouse monoclonal antibodies (mAbs) in immunofluorescence microscopy. 
Both antigens accumulated in the cytosol of the infected BHK-21 cells (Fig. 1, B1 and B2). 
While in the immunofluorescence analysis MUL2232 appeared to be expressed at lower 
levels than MUL3720, staining intensities in Western blotting analyses were comparable for 
both proteins (Fig.1, C). MUL2232 was mainly detected in the soluble fraction of infected 
L929 fibroblasts and to a smaller part in the insoluble fraction (Fig. 1, C1) while MUL3720 
was found in the soluble fraction only (Fig. 1, C2). Both proteins co-migrated with the 
corresponding proteins in M. ulcerans lysate according to the predicted molecular mass (Fig. 
1, C). 
Immunization of mice with virus replicon particles induces M. ulcerans cross-
reactive antibody responses 
To characterize the immune responses elicited by the recombinant VRPs, we compared 
different immunization regimens in BALB/c mice. Humoral immune responses were 
assessed by ELISA on immobilized recombinant protein. Sub-cutaneous (s.c.) administration 
of 107 VRPs did not lead to measureable antibody responses against the target antigens 
(Fig. 2, A and B). However, when VSV*ΔG(MUL2232) was given i.m., Immunoglobulin (Ig) G 
antibodies were elicited in all immunized animals. In contrast, only some mice produced 
antibodies following i.m. immunization with VSV*ΔG(MUL3720) (Fig. 2, A and B). Therefore 
induction of antibodies solely by i.m. immunization with VSV*ΔG(MUL3720) was no longer 
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pursued in subsequent experiments. Independently of the route of administration, both VRPs 
primed the immune system, as demonstrated by the fast humoral immune response to an 
adjuvant-free booster immunization (s.c.) with 30 µg of the corresponding recombinant 
protein (Fig. 2, A and B). Six days after the booster injection, antibody titers were generally 
higher in mice primed i.m. than in mice primed s.c. (Fig. 2, A and B). Therefore, only the i.m. 
route was employed for VRP administration in subsequent experiments. In addition, a dose 
of 107 VRPs per immunization was generally used. 
In a next step, we assessed the potential of a shorter prime-boost immunization strategy by 
immunizing the animals only once i.m. with VSV*ΔG(MUL2232) or VSV*ΔG(MUL3720) and 
three weeks later with 30 µg of rMUL2232 or rMUL3720 via the subcutaneous route in the 
absence of adjuvant. Five days after the rMUL2232 boost, the ELISA IgG titers were only 
marginally higher than those observed prior to the boost, but increased further in the 
subsequent two weeks (Fig. 3, A). On the other hand, administration of rMUL3720 led to high 
antibody titers already eight days after the boost (Fig. 3, C). Importantly, the elicited 
antibodies were not only cross-reactive with the recombinant proteins produced in E. coli but 
also with the target proteins expressed by M. ulcerans, as demonstrated by Western blotting 
on M. ulcerans lysate (Fig. 3, B and D).  
To evaluate whether this immunization regimen would also elicit antigen-specific cellular 
immune responses, antigen-specific cytokine secretion of spleen cells was studied in vitro 
after primary immunization of mice with VSV*ΔG(MUL2232) and a second immunization with 
either rMUL2232 or VSV*ΔG(MUL2232). Three weeks after the second immunization, spleen 
cells were stimulated with either rMUL2232 or the unrelated rMUL3720 as control. 
Stimulation with Concanavalin A (ConA) served as positive control for confirming the viability 
of the cultured spleen cells. The stimulated cell culture supernatants were analysed by 
ELISA for the production of the TH1 cytokine Interferon gamma (IFNγ) (Fig. 4, A), the 
pleiotropic [46] cytokine Interleukin 2 (IL-2) (Fig. 4, B) and the TH2 cytokine Interleukin 10 (IL-
10) [47] (Fig. 4, C). Overall, no marked difference in terms of cytokine production was 
observed between the two immunization schedules. In both cases all three cytokines were 
produced in significantly higher amounts when cultured spleen cells were stimulated with the 
corresponding rMUL2232 antigen. In contrast, stimulation with the unrelated antigen 
rMUL3720 or mock stimulation had no significant effect (Fig. 4). The most pronounced 
response was found for IL-10 (Fig. 4, C), indicating a slight polarization towards a TH2 type 
response. The same experimental setup with VSV*ΔG(MUL3720) was not successful due to 
technical problems. 
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Vaccination has no marked inhibitory effect on bacterial proliferation in an 
experimental BU mouse model 
In a last step, we explored the protective efficacy of the VRP-based immunization in an 
experimental M. ulcerans infection model. Groups of six BALB/c mice were immunized 
according to the VSV*ΔG(MUL2232)/rMUL2232 prime-boost regimen or two times i.m. with 
VSV*ΔG(MUL2232). Respective control groups were immunized either with the control VRP 
VSV*ΔG and an rMUL2232 boost (prime-boost control) or twice with VSV*ΔG (Fig. 5). Three 
weeks after the last immunization, the left hind foot pad of the mice was infected with 8.4 x 
103 M. ulcerans bacilli. The slowly progressing infection was followed by weekly 
measurements of the thickness of the infected foot pads with a caliper (Fig. 5, A). To 
determine the bacterial multiplication, mice were euthanized at day 60 after infection and foot 
pads either processed for histopathological analysis or lysed for enumeration of M. ulcerans 
by standard CFU plating. Quantification was additionally performed by an adapted qPCR 
method, suitable for the detection of bacterial proliferation in mouse foot pads over the 
course of the infection (Fig. 5, C). No differences in the kinetics of footpad swelling were 
observed between immunized mice and the respective control animals (Fig. 5, A). However, 
60 days post infection the number of CFU per foot pad was slightly but significantly lower in 
animals immunized with the VRP prime-protein boost regimen as compared to the prime-
boost control immunized animals (Fig. 5, B). Quantification of M. ulcerans DNA in the 
footpads by insertion sequence (IS) 2404 specific qPCR yielded similar results, i.e. a slight 
but significant reduction in bacterial multiplication caused by the VRP prime-protein boost 
immunization, but not by two subsequent immunization with VRPs (Fig. 5, B and D). The 
same experiment with MUL3720 VRPs did not result in any difference between immunized 
and control groups (S2 Figure). 
A histopathological analysis of representative foot pads confirmed the findings of a slight 
reduction of bacterial burden in the VSV prime-protein boost immunized animals as 
compared to the prime-boost control animals. The non-infected right foot pads served as 
control and appeared completely normal (Fig. 6, A1) with intact muscle tissue (Fig. 6, A2) 
and no apparent oedematous changes (Fig. 6, A3). In comparison, the infected left foot pads 
of control mice showed typical histopathological signs of BU with strong oedema (Fig. 6, B1 
and B4), necrotic sole of foot (Fig. 6, B2), and inflammatory infiltration and extensive 
haemorrhages all over the foot pad (Fig. 6, B3). Ziehl-Neelsen/Methylene blue (ZN) staining 
revealed large clumps of acid fast bacilli (AFB) (Fig. 6, C1), not only located where they were 
initially injected, but also more towards the heel of the foot (Fig. 6, C2) and in the 
oedematous tissue in the upper part of the foot pad (Fig. 6, C5). AFB were associated with 
remains of infiltrating immune cells (Fig. 6, C3) and were also found as fibrous structures in 
completely necrotic tissue (Fig. 6, C4). In animals that received a VRP prime-protein boost 
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immunization, a trend towards a reduction in the number of AFB clusters was observed (Fig. 
6, D1). Furthermore, AFB appeared to be more often in close contact with infiltrating cells or 
were found intracellular (Fig. 6, D3).   
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Discussion 
Despite substantial control efforts and improvements in treatment and diagnosis, the 
socioeconomic impact of BU on affected communities remains high. Long treatment 
regimens with daily i.m. injections in rural settings of West Africa, late reporting to health 
facilities, scarring and resulting permanent disabilities create high morbidity that could be 
prevented by a vaccine against M. ulcerans. Although no such vaccine is available at the 
moment, reports on self-healing in patients with early stages of the disease [48,49] as well as 
sero-epidemiological studies in BU-endemic countries [32,50] indicate that the human 
organism is in principle capable of inducing a protective immune responses against BU. 
Furthermore, protein subunit vaccination approaches have demonstrated partial protection in 
a BU mouse infection model [21,22,51]. 
In the present study, we used a viral replicon particle system for delivering M. ulcerans 
protein antigens to the immune system. Immunization with a high number of VRPs induced 
M. ulcerans specific antibody responses with i.m. application being superior to s.c. 
application. Our VRP prime-recombinant protein boost regimen not only induced a humoral 
but also a cellular immune response. This is in line with previous work showing that VRPs 
are able to trigger humoral as well as cellular immune responses [52]. 
The bacterial proteins MUL2232 and MUL3720 were chosen as vaccine antigens because 
previous work suggested that these antigens are not only highly immunogenic but also 
associated with the outer surface of M. ulcerans [32,34,35]. Therefore, the strong humoral 
immune response observed following immunization of mice was expected to allow antibody-
mediated opsonization of the bacteria with consequent enhanced phagocytosis, complement 
activation, or antibody-dependent cellular cytotoxicity. While we did not observe vaccination-
induced reductions in foot pad swelling in our murine M. ulcerans infection model, 
assessment of the bacterial load by qPCR as well as CFU plating revealed a slight, but 
significant reduction in bacterial multiplication in VRP prime-protein boost immunized mice. 
While measurement of foot pad swelling over time is a parameter that can be followed 
without euthanizing mice [53,54], our results illustrate that foot pad swelling not necessarily 
reflects the extent of bacterial proliferation. 
Despite a slight inhibitory effect on bacterial proliferation, immunization with only one target 
antigen in a VRP prime-protein boost regimen was not sufficient to confer full protection 
against the experimental infection. Several factors, like the choice or number of antigens 
included into the VRPs, could have let to this negative result. Since it is not known, which 
immune effector functions are relevant for protection against M. ulcerans disease [15], it is 
not clear whether lack of a strong TH1-polarisation is of major relevance for the failure to 
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achieve a strong protective efficacy with the immunization regimens tested. One of the 
advantages of the replicon system lies in the ability of VSV to tolerate incorporation of long 
stretches of foreign DNA into its genome [25,26]. As a modular system, it offers the 
possibility to design a multivalent subunit vaccine by combining several M. ulcerans proteins 
in one replicon. Furthermore the versatility of the system allows to engineer the location of 
the expressed protein in the infected cell, or to target specific immune cells by including 
genes for co-stimulatory molecules or receptors to be expressed on the surface of the 
infected cells [25]. Here we have demonstrated that RNA replicon particles are a very good 
delivery system for mycobacterial antigens, which is in particular encouraging future 
development of VRP-based multivalent subunit vaccines. 
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Figures 
 
 
Figure 1: Expression of M. ulcerans proteins by VRP-infected cells. 
(A) Genome maps of recombinant VSV: The genome of VSV encodes for the nucleoprotein 
N, phosphoprotein P, matrix protein M, glycoprotein G, and the large RNA polymerase L. In 
VSV*ΔG, the glycoprotein G coding region was replaced by the coding sequence for eGFP. 
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In VSV*ΔG(MUL22332) and VSV*ΔG(MUL3720), the VSV G gene was replaced by the M. 
ulcerans genes MUL2232 and MUL3720, respectively. The reporter protein eGFP is encoded 
by an additional transcription cassette located downstream of the M. ulcerans genes. (B) 
BHK-21 cells were infected with the indicated replicons and indirect immunofluorescence 
analysis performed with mAbs specific for MUL2232 (B1) or MUL3720 (B2) (red 
fluorescence). The infection of cells with VRPs is indicated by eGFP expression (green 
fluorescence). Scale bar equals 30 µm. (C) Equal numbers of L929 fibroblasts were infected 
with the indicated VRPs at a MOI of 10. At 6 hours post infection, the cells were harvested 
and protein lysates of the soluble (s) and insoluble (i) fraction analysed by Western blotting 
for expression of M. ulcerans antigens using mAbs specific for MUL2232 (C1) and MUL3720 
(C2), respectively. 
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Figure 2: Comparison of immunization routes. 
Groups of five female BALB/c mice were sequentially immunized with VSV*ΔG(MUL2232) 
(A) or VSV*Δ(MUL3720) (B) via the sub-cutaneous (grey dots) or intra-muscular (black dots) 
route. Prior to every new immunization, blood was taken and serum analysed by ELISA on 
the corresponding recombinant proteins (rMUL2232 or rMUL3720). After the third 
immunization, all mice were boosted (s.c) with the VRP correspondent, non-adjuvanted 
recombinant protein. Endpoint total IgG titers were determined for individual animals in one 
single ELISA. Mean values (line) ± standard deviations are shown. 
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Figure 3: Induction of antigen-specific antibodies by a short prime-boost 
immunization protocol. 
Female BALB/c mice (n = 5) were immunized once with VSV*ΔG(MUL2232) or 
VSV*ΔG(MUL3720) and boosted with rMUL2232 or rMUL3720 three weeks later. Control 
animals (n = 5 and n = 3) were immunized with empty replicon prior to recombinant protein 
boost three weeks later. (A) Analysis of serially diluted immune sera by ELISA on 
immobilized rMUL2232. Mean values (dot) ± standard deviations are shown. (B) Western 
blotting analysis on M. ulcerans lysate using the indicated immune sera taken three weeks 
after protein boost. (C) Analysis of serially diluted immune sera by ELISA on immobilized 
rMUL3720. Mean values (dot) ± standard deviation are shown. (D) Western blotting analysis 
on M. ulcerans lysate using the indicated immune sera taken two weeks after protein boost. 
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Figure 4: Analysis of cellular immune responses. 
Female BALB/c mice (n = 5) were immunized once with VSV*ΔG(MUL2232) (i.m.) and 
boosted with rMUL2232 (s.c., prime-boost) or were immunized with VSV*ΔG (i.m.) and 
boosted with rMUL2232 (s.c., prime-boost control). Alternatively, the animals were 
immunized twice with either VSV*ΔG(MUL2232) (2 x VRP) or the control vector VSV*ΔG (2 x 
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empty VRP). Three weeks after the final immunization, mice were euthanized. Spleen cells 
were taken into culture and stimulated with either Concanavalin A (ConA), rMUL2232, 
rMUL3720 or left unstimulated (medium). Levels of secreted cytokines were determined by 
commercially available ELISA kits at 24 hours (IL-2, B) and 96 hours (IFNγ, A; IL-10, C) after 
stimulation. Mean values (bar) ±  standard deviations for 5 mice tested are shown and 
expressed as log10 (pg/ml). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001 (p – value 
adjusted for random effects in a linear mixed model). Ns equals non-significance. # Due to 
high non-specific rMUL3720 stimulation presumably caused by contaminants in the 
recombinant protein preparation, values were normalized to those of a non-immunized group 
of mice and z-values are depicted for all stimulations except ConA. 
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Figure 5: Infection of immunized mice with M. ulcerans. 
Groups of six immunized, female BALB/c mice were infected by s.c. injection of M. ulcerans 
suspension (30 µl) into the left hind foot pad. (A) Development of the infection was followed 
by weekly measurements of the foot pad thickness with a caliper. The mean foot pad 
thickness (dot) ± standard deviation is shown for each animal group. (B) At day 60 after 
infection, mice were sacrificed and the number of M. ulcerans bacilli in foot pads determined 
by classical CFU plating. (C) Quantification of M. ulcerans in foot pad lysates by IS2404 
specific qPCR. Genome equivalents are shown. (D) Determination of M. ulcerans genome 
equivalents in immunized and infected mice. * p ≤ 0.05 (Mann-Whitney test). 
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Figure 6: Histopathological analysis of mouse foot pads following infection 
with M. ulcerans. 
Histological sections of foot pads from M. ulcerans-infected mice were stained with 
Haematoxylin/Eosin (A1-A3, B1-B4) or Ziehl-Neelsen/Methylene blue (ZN) (C1-C5, D1-D3). 
The right, non-infected foot pad showed no swelling (A1), intact muscle tissue (A2) and 
absence of oedema in the upper part of the foot (A3). As opposed to this, the left foot of a 
mouse immunized with VSV*∆G/rMUL2232 (prime-boost control) was strongly swollen 60 
days post infection (B1). Cellular infiltration and beginning necrosis of the tissue was 
explicitly strong at the base of the foot pad, where bacteria were injected (B2) and muscle 
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fibres started to become destroyed (B3). The upper part of the foot is highly oedematous 
(B4). Staining of the same foot pad for AFB revealed large amounts of bacteria in close 
contact to infiltrating immune cells at the base of the foot (C3). Appearance of AFB in the 
destroyed muscle tissue (C4). Big clumps of bacteria were also found towards the ankle of 
the foot (C2) and in the oedematous tissue in the upper half of the foot pad (C5). The foot 
pad of a mouse immunized with VSV*ΔG(MUL2232)/rMUL2232 (prime-boost) contained 
large amounts of AFB (D1) which were less spread in the whole foot pad. Intracellular AFB 
were frequently observed (D3). 
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Supplementary Material 
 
 
S1 Figure: Infection of immunized mice with M. ulcerans (MUL3720 
immunizations). 
Groups of six immunized, female BALB/c mice were infected into the left hind foot pad with 
30 µl of M. ulcerans suspension (s.c.). (A) Development of the infection was followed by 
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weekly measures of the foot pad thickness with a caliper. Depicted is the mean foot pad 
thickness (dot) ± standard deviation of the individual differently immunized groups. (B) At day 
60 after infection, mice were sacrificed and the number of M. ulcerans bacilli in foot pads 
determined by classical CFU plating. (C) Determination of M. ulcerans genome equivalents 
in immunized and infected mice. 
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Abstract 
Malaria infection with viable Plasmodium falciparum parasites by bites of infected 
mosquitoes under simultaneous drug cover with chloroqine, so called infection-treatment-
vaccination, has been shown to be an effective vaccination strategy in malaria-naïve human 
volunteers. Similarly, infection-treatment-vaccination with infected red blood cells in mouse 
models led to sterile immunity. Thinking further along this line, Plasmodium parasites could 
possibly be used as delivery systems for antigens originating from other disease causing 
agents and cross-protect against several diseases. As part of the evaluation of the potential 
for developing a protein subunit vaccine against Buruli ulcer, an ulcerative disease of the skin 
caused by Mycobacterium ulcerans, we tested an infection treatment vaccination approach 
with genetically modified Plasmodium berghei mouse malaria parasites. We confirmed the 
expression of the chosen protein vaccine candidates of M. ulcerans, MUL3720 and 
MUL4987 (Ag85A), in the generated P. berghei lines and demonstrated the induction of 
potent specific antibody responses by infection of mice under chloroquine cover. However, 
the elicited immune responses were not sufficient to produce solid protection in an 
experimental mouse footpad infection model of Buruli ulcer. 
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Introduction 
Already in 1975 it has been shown that immunization with attenuated whole Plasmodium 
falciparum sporozoites applied by mosquito bites can elicit sterilizing immune protection 
against experimental malaria infection in human volunteers [1]. These and other findings led 
to increased efforts to develop whole parasite-based vaccination as alternative to a subunit 
vaccine against malaria. Recently it has been shown that protection against controlled 
human malaria infection can be achieved by repeated intravenous injection of attenuated, 
cryopreserved P. falciparum sporozoites [2]. More generally speaking, whole parasite 
vaccination approaches can be separated into two key concepts: infection with irradiated or 
attenuated sporozoites or infection with viable parasites under drug cover. Infection with 
viable malaria parasites under drug cover, also called infection – treatment - vaccination 
(ITV), has been shown to be effective in malaria-naive volunteers immunized by bites of 
infected mosquitoes while simultaneously preventing disease with chloroquine prophylaxis 
[3]. In mouse malaria models sterile immunity has also been achieved by infection with 
infected red blood cells (iRBC) under curative drug cover [4,5]. With the goal to address 
whether the subcellular location of an antigen influences the nature and magnitude of 
antigen-specific T-cell responses, Lin et al. recently reported the introduction of the model 
antigen Ovalbumin (OVA) in P. berghei parasites [6]. Whether OVA was expressed on the 
parasitophorous vacuole membrane (PVM) or in the parasite cytosol influenced its 
expression levels as well as the induction and magnitude of parasite-specific T-cell 
responses [6]. For the study presented here we chose to assess whether mycobacterial 
antigens could be expressed instead of OVA and whether such modified P. berghei parasites 
could be used for ITV for a mycobacterial disease. 
Mycobacterium ulcerans, the donor of the heterologous antigens for this study, causes a 
slowly progressing, necrotising disease of the skin and subcutaneous tissue in humans [7]. 
The so called Buruli ulcer (BU) is typically found very focally in rural communities in West 
African countries, but has been reported from more than 30 countries worldwide [8]. Until 
today both the natural reservoir/s as well as the mode(s) of transmission are not clearly 
identified [8,9]. With 8 weeks of daily doses of rifampicin and streptomycin, treatment for BU 
is very long and could potentially be shortened by the use of a vaccine [10]. Furthermore a 
vaccine could prevent the disease and its associated socioeconomic impact on the affected 
population completely. Unfortunately no such vaccine is available at the moment [11]. Little is 
known about correlates of protection in BU patients, although sero-epidemiological studies 
and reports on spontaneous healing indicate the existence of a protective immune response 
[12–16]. Cellular mediated immunity (CMI) of a T-helper 1 (TH1) type was suggested to be 
essential against first intracellular stages of M. ulcerans [11]. However, later in the 
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development of BU, the majority of bacilli are found extracellular in the affected 
subcutaneous tissue [17,18]. Against those stages, the presence of natural- or vaccine-
induced antibodies against surface proteins could be of major importance [19]. In the study 
presented here we focused on the use of Plasmodium parasites in ITV as delivery system for 
the two heterologous protein antigens MUL3720 and MUL4987 of M. ulcerans. We studied 
the humoral immune response induced by ITV and evaluated the protective potential of the 
vaccine formulations in a mouse challenge model. If feasible, the resulting vaccine would be 
one step of many to go towards multi-disease vaccination against malaria and other 
infectious diseases. 
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Materials and Methods 
Ethical Statement 
All animal experiments performed were approved by the animal welfare committee of the 
Canton of Basel (authorization number 1731) and the Canton of Vaud (authorization number 
2657) and were conducted in compliance with the Swiss animal protection law. All infection 
experiments with M. ulcerans were conducted under Biosafety-level-3 (BSL-3) conditions at 
the École polytechnique federal de Lausanne (EPFL). 
Generation of transgenic P. berghei parasites 
P. berghei expressing codon optimized MUL_3720 and MUL_4987 as fusion to the PVM 
protein EXP1/HEP17 (exported protein 1, hepatocyte erythrocyte protein 17 kD) were 
generated as previously described [6]. 
P. berghei immunization of mice by infection and subsequent cure with 
chloroquine 
Mice were infected by the intravenous (i.v.) route with whole blood of a donor mouse 
previously infected with genetically modified Plasmodium berghei by the intra-peritoneal (i.p.) 
route. Donor mouse blood was diluted with sterile phosphate buffered saline (PBS) to contain 
1 % of infected erythrocytes in order to infect every mouse of the experimental group with 2 x 
107 iRBC, ensuing high in group consistency of the infection rate [20]. Treatment of the mice 
was started 48 hours after i.v. infection by administering chloroquine (Sigma) in the drinking 
water (0.288 mg/ml) during fourteen days. To make the water more palatable for the animals, 
glucose at a concentration of 15 mg/ml was additionally added to the drinking water. Three 
weeks after infection with P. berghei, blood collection by the tail vein was performed and 
serum gained by centrifugation of the blood in SST Microtainer tubes (Becton, Dickinson and 
Company). 
Lysates of P. berghei and M. ulcerans 
For production of P. berghei protein lysate, blood of highly infected mice was collected by 
cardiac puncture after euthanasia. iRBC were harvested by centrifugation and washed 
several times with PBS. The pellet of iRBC was dissolved in five times its volume in RIPA 
buffer containing protease inhibitors (cOmplete Mini, EDTA-free, Roche), incubated 15 
minutes on ice and lysate cleared by centrifugation. Total protein content was determined by 
BCA assay (Pierce) according to the manufacturer’s instructions. For protein lysates of M. 
ulcerans, 7.5 ml fully grown culture in BacT/ALERT medium (Biomerieux) was pelleted by 
centrifugation, resuspended in 1 ml PBS and incubated at 85°C for 1h. Bacteria were 
pelleted again, washed in PBS and finally resuspended in 375 µl 1% SDS with protease 
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inhibitors and transferred to lysis tubes (Tough micro-organism lysing tubes, Precellys). Final 
lysis of the bacteria was performed with a Precellys 24-Dual tissue homogenizer (2 x 50 s at 
5000 rpm with 5 s break) and lysate cleared from bacterial debris by centrifugation. Total 
protein content was determined by BCA assay (Pierce). 
Western blotting 
All Western blotting analysis was conducted according to the manufacturer’s instructions on 
prefabricated 4-12% gradient gels (NuPAGE Novex 4-12% Bis-Tris Gel; Invitrogen) with 
MES running buffer. A dry-blotting system (iBlot; Invitrogen) was used to transfer proteins to 
nitrocellulose membranes by electrophoresis. Membranes were blocked in 5% skim 
milk/PBS over night at 4°C. For Western blotting on P. berghei lysates, individual lysates 
were separated on different lines of the gel and the blocked membrane incubated with 
appropriately diluted anti-MUL3720 monoclonal antibody (mAb) or anti-MUL4987 mAb in 1% 
skim milk/0.05 % Tween20/PBS for 1 hour at room temperature (RT). After several washing 
steps in 1% skim milk/0.05% Tween20/PBS, HRP-conjugated goat anti-mouse IgG γ-chain 
mAb (Southern Biotech) was used as secondary antibody and incubated for 1 hour at RT. 
Excess antibody and skim milk residuals were washed away with PBS and blots were then 
developed using ECL Western blotting detection reagents (ECL Western blotting Substrate; 
Pierce). For Western blotting on M. ulcerans lysate, 10 µg of total protein was separated on a 
one well gel, the blocked membrane cut into thin strips and individually incubated with 
appropriate dilutions of serum of immunized mice in 1% skim milk/0.05% Tween20/PBS for 1 
hour at RT. Washing and development were then conducted as described above.  
Expression of recombinant proteins and enzyme linked immunosorbent assays 
(ELISA) 
Expression of the vaccine candidate antigens MUL3720 and MUL4987 (Ag85A) was 
achieved with the pET28a expression system (Novagen, modified to contain an ampicillin 
selection cassette) in E. coli BL21(DE3) strains (Invitrogen) by addition of 1mM isopropyl 
thiogalacoside (Calbiochem) for 4h at 37°C. Purification of the 6xHis-tagged proteins from 
the bacterial pellet in PBS (recombinant MUL3720, rMUL3720) or 8 M Urea (recombinant 
MUL4987, rMUL4987) was done by nickel-nitrilotriacetic acetic (Ni-NTA) metal affinity 
chromatography [21]. Proteins were eluted with increasing concentrations of imidazole and 
decrease of pH respectively, and integrity and purity of proteins assessed by SDS-page 
separation and Coomassie Blue staining (Add Ref. Adj. paper). Final amount of the so 
produced recombinant proteins (rMUL3720 and rMUL4987) was determined by BCA assay 
(Pierce) according to the manufacturer’s instructions. 
Sera of immunized mice were analysed for specific antibodies against the vaccine candidate 
antigens by ELISA on recombinant proteins. All incubation steps were performed at RT. 10 
188 Results     Chapter 6 
 
µg/ml of rMUL3720 or rMUL4987 were coated on ELISA plates (Maxisorp; Nunc) by 
incubation overnight. Plates were first blocked in 5% skim milk/PBS for 1 hour and incubated 
with dilution series of sera from immunized mice in 0.5% skim milk/PBS for two hours. After 
washing the plate with dH2O/0.1% Tween20, alkaline phosphatase-conjugated goat anti-
mouse monoclonal antibody (mAb; Sigma) was incubated for 1 hour. Plates were washed 
again and subsequently developed with p-nitrophenyl phosphate (Sigma) as substrate. The 
optical density (OD) of the reaction product was measured at 405 nm with a microplate 
absorbance reader (Sunrise Absorbance Reader; Tecan). The threshold for endpoint titer 
determination was defined as the double of the mean measurements plus the mean standard 
deviation of a dilution series done without primary antibody and a dilution series done with 
serum taken prior to all immunizations (pre-bleed). Individual serum dilution series were 
approximated with sigmoidal dose-response curves (Graph Pad prism) and the reciprocal 
dilution of the intersection between the curve and the threshold was defined as individual 
endpoint titer. 
Immunofluorescence assays 
Infected parasites cultures were stained for immunofluorescence analysis (IFA) as previously 
described [22]. Briefly, whole blood of infected mice was harvested and iRBC fixed with 4% 
formaldehyde/0.01% glutaraldehyde and permeabilized with 0.1% Triton X-100. Staining was 
performed with anti-MUL3720 mAb as primary antibody and Alexa 568 labelled donkey anti-
mouse IgG (Invitrogen) as secondary antibody. Pictures were acquired with a Zeiss LSM 700 
confocal microscope (Carl Zeiss GmbH, Jena, Germany). Immunofluorescence assays with 
sera of immunized mice on paraffin embedded M. ulcerans bacteria were performed as 
previously described [23]. Briefly, African M. ulcerans isolates were embedded into paraffin, 
cut into 3 µm thin sections and mounted on Superforst Plus glass slides (Thermo Scientific). 
Sections were deparaffinised, rehydrated and pre-treated with 1mM EDTA buffer pH=8 for 
epitope retrieval as described for tissue sections in immunohistochemistry [24]. Unspecific 
binding was prevented by incubation of the bacteria in 1.5% goat serum in PBS for 1 hour at 
RT. Appropriately diluted mouse mAbs specific for MUL3720 and MUL4987 were used as 
primary antibodies. Detection of the specific binding of primary antibodies was achieved with 
an Alexa488 labelled secondary goat anti-mouse total IgG (H+L) antibody (Life 
Technologies). Image acquisition was performed on a applied precision widefield Delta 
Vision microscope (Olympus IX71).  
M. ulcerans infection 
Groups of 15 female, seven weeks old BALB/c mice (Janvier) were immunized by P. berghei 
infection and subsequent chloroquine cure via drinking water as described above. Four 
weeks after ITV mice were challenged with 2.4 x 102 colony forming unit (CFU) M. ulcerans 
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(S1013, [25,26]) into the left hind foot pad. For infection bacteria were cultivated in 
BacT/ALERT medium (Biomerieux) for six weeks, recovered by centrifugation and diluted in 
sterile PBS to 125 mg/ml wet weight. 30 µl of a 1:100 dilution of this stock solution was used 
for infection. Inoculum dose was determined by CFU plating on 7H9 agar plates. 
The course of infection was followed by weekly measurements of the foot pad thickness with 
a caliper. At day 39 after infection (time point 1, T1) five mice per experimental group were 
euthanized and all foot pads analysed for bacterial load by qPCR. At day 49 after infection 
(time point 2, T2) a total of seven mice per experimental group were euthanized. Four foot 
pads were analysed for bacterial load and three processed for histopathological analysis. 
The remaining three mice were euthanized at day 63 (time point 3, T3) and all analysed for 
bacterial load by qPCR. When mice were euthanized, blood was collected by cardiac 
puncture and foot pads aseptically removed. Foot pads designated for histopathological 
analysis were immediately transferred to 10% neutral-buffered Formalin solution (approx. 4% 
formaldehyde) for fixation during 24 hours at RT. Foot pads designated for enumeration of M. 
ulcerans bacteria were dipped in 70% ethanol, dried under the laminar flow and cut into four 
pieces with a scalpel. After transfer to reinforced hard tissue grinding tubes (MK28-R, 
Precellys) foot pads were homogenized in 750 µl of 7H9 medium (Becton, Dickinson and 
Company). Tissue homogenization was performed with a Precellys 24-Dual tissue 
homogenizer (3 x 20 s at 5000 rpm with 30 s break), the lysate was transferred to a new tube 
and the lysis tube still containing tissue remains refilled with additional 750 µl of 7H9 
medium. The remains were homogenized a second time and the correspondent two lysates 
pooled.  
Quantification of bacterial load by qPCR and CFU plating 
For enumeration of bacteria in the foot pad lysate, DNA from 100 µl of a 1:40 dilution of the 
foot pad lysate in PBS was extracted as described by Lavender and Fyfe [27]. Extracted 
DNA was then analysed for insertion sequence (IS) 2404 qPCR as previously described [27]. 
For graphic representation of the results, cycle threshold (Ct) values were converted into 
genome copy numbers per foot pad by applying the standard curve established for IS2404 
by Fyfe et al. [28]. Extractions were done two times from independent foot pad lysate 
dilutions, qPCR performed in one run and the average of the two Ct values taken for 
conversion into genome copy numbers per foot pad. For enumeration of bacteria by CFU 
plating, 250 µl of foot pad lysate was decontaminated with 0.5 M NaOH as described 
previously [29]. The pellet of decontaminated lysate was dissolved in 500 µl of 7H9 medium 
and appropriate dilution series plated on 7H9 agar plates. Following 250 days of incubation 
at 30°C colonies were counted and the concentration of bacteria expressed as CFU.  
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Histopathology 
Formalin fixed foot pads were decalcified in 0.6 M EDTA and 0.25 M citric acid for 12 days at 
37°C and transferred to 70% ethanol for storage and transport. The samples were 
dehydrated and embedded into paraffin. 5 µm thin sections were cut, deparaffinised, 
rehydrated, and stained with Haematoxylin/Eosin (HE, Sigma, J.T. Baker) or Ziehl-
Neelsen/Methylene blue (ZN, Sigma) according to WHO standard protocols [30]. 
Immunohistochemical staining was performed as previously described [31]. Stained sections 
were mounted with Eukitt mounting medium (Fluka). Pictures were taken with a Leica 
DM2500B microscope or with an Aperio scanner. 
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Results 
Genetically modified P. berghei parasites express M. ulcerans vaccine 
candidate antigens 
Coding sequences for the two protein vaccine candidate antigens MUL3720 and MUL4987 of 
M. ulcerans were introduced into the chromosome of P. berghei parasites. Expressed as 
fusion protein to HEP17 this strategy resulted in parasite lines cl2205 (MUL_3720::Hep17) 
and cl2224 (MUL_4987::Hep17), for which the M. ulcerans antigens were expected to be 
located on the PVM surrounding the parasites in the iRBC. Additionally, two parasite lines in 
which the candidate antigens are C-terminally tagged with the fluorescent protein mCherry 
and are expressed under the control of the strong hsp70 promoter were generated. The 
resulting parasite lines cl2222 (MUL_3720::mCherryhsp70) and cl2225 
(MUL4987::mCherryhsp70) were expected to express the proteins in the parasite cytosol. 
Western blotting analyses on lysates of the genetically modified parasites confirmed the 
expression of MUL3720 in cl2205 (Fig. 1A, left panel) and of MUL4987 in cl2224 (Fig. 1A, 
right panel). Both proteins were detected only in the lysate of the correspondently modified P. 
berghei clone (Fig. 1A). Due to their nature as fusion proteins with HEP17, both proteins had 
an increased size compared to their counterparts expressed by M. ulcerans or the respective 
recombinant proteins (Fig. 1A). Expression of MUL3720 in the parasite line cl2222 was also 
confirmed by Western blot analyses (Fig. 1B) but no signal was obtained for MUL4987 
expression in cl2225. 
Although for both target proteins mouse monoclonal antibodies (mAb) were available to 
visualize the expression of the target protein by the P. berghei parasites in fixed RBC from 
infected mice by IFA, only staining with anti-MUL3720 mAb was successful (Fig. 1C). RBC 
infected with cl2205 showed a clear staining of the PVM as a dotted ring around the parasite 
(Fig. 1C, top panel row). Cl2222 showed the expression of MUL3720 in the parasite vacuole 
(Fig. 1C, middle panel row), whereas the genetically non-modified P. berghei strain ANKA 
showed no staining.  
Immunization with genetically modified P. berghei under chloroquine coverage 
leads to specific antibody responses 
In a pilot study, female NMRI mice were immunized twice by ITV with 2 x 107 P. berghei 
iRBC. Both times curative administration of chloroquine via the drinking water was initiated 
when parasitemia had reached around 1 %. Six weeks after the first and ten days after the 
second ITV sera of immunized mice was analysed for specific antibody responses by ELISA 
on the respective recombinant protein. One round of ITV resulted in specific antibody 
responses against antigens expressed on the PVM (Fig. 2A, cl2205; 2B, cl2224) but no 
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responses were observed when antigens were expressed in the parasite cytosol (Fig. 2A, 
cl2222; 2B, cl2225). Antibody responses were not significantly boosted by a second round of 
ITV (Fig. 2A and B). Sera of animals immunized twice by ITV with the control parasite strain 
ANKA slightly reacted in ELISA on rMUL3720 but not on rMUL4987.  
Based on these results we only applied one ITV in subsequent M. ulcerans challenge 
experiments in BALB/c mice. Animals of this mouse strain immunized with cl2205 also 
mounted a strong antibody response against rMUL3720 as seen in ELISA with serum from 
three weeks after ITV (Fig. 3, A1). In comparison, antibody responses against rMUL4987 in 
cl2224 immunized mice were weaker and more heterogeneous (Fig. 3, B1 and B2). Control 
mice infected with genetically unmodified parasites (ANKA) as well as non-infected animals 
did not mount a specific antibody response against the recombinant antigens. Western 
blotting analysis with the individual sera on lysate of M. ulcerans and IFA on paraffin 
embedded bacteria revealed cross-reactivity of the elicited antibodies with MUL3720 and 
MUL4987 expressed by the mycobacteria (Fig. 3, A2 and B2, C1 and C2). Moreover, the 
analysis confirmed the more variable humoral immune response against MUL4987. None of 
the control mice developed antibodies cross-reactive with the two M. ulcerans target proteins 
(Fig. 3, A2 and B2).  
In comparison to two other delivery systems we had previously used for the same M. 
ulcerans protein antigens [26] (Add Ref. Adjuvant) ITV with genetically modified P. berghei 
induced medium antibody titers (Fig. 4). For both candidate antigens two subsequent 
immunizations with recombinant proteins adjuvanted with GLA-SE (Add Ref. Adjuvant) 
induced the strongest responses, while formulation as virus replicon particles [26] induced 
only marginal titers (Fig. 4). In terms of immunoglobulin (Ig) G subclasses both parasite lines, 
cl2205 and cl2224, induced predominantly IgG1 and IgG2a and the subclass IgG spectrum 
did not change with a second ITV (Supplementary Fig. 1).  
Infection of P. berghei immunized animals with M. ulcerans 
To assess the protective potential of ITV with the genetically modified P. berghei lines 
against M. ulcerans infection, we challenged immunized mice in an experimental infection 
model with 3.5 x 104 M. ulcerans bacilli into the hind left foot pad. The development of the 
infection was followed by weekly measurements of the footpad thickness with a caliper (Fig. 
5A). 39 (T1) and 49 (T2) days after infection randomly selected animals were sacrificed to 
determine the bacterial load in the infected foot pads. Footpad swelling started around day 
28 after infection and gradually progressed over the following five weeks until all remaining 
mice were euthanized at day 63 (T3). Transiently smaller foot pad swelling was observed in 
cl2224 mice compared to the infection control group. This difference was significant at days 
35 (Fig. 5B, p = 0.0074) and 44 (p = 0.0199), but not at day 39 and at later time points. 
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Accordingly, no difference in amount of oedema was detected in the histopathological 
analysis of representative foot pads done at T2 (Supplementary Fig. 2). All animals showed 
cellular infiltration that mainly consisted of neutrophils in close association with acid fast 
bacilli (AFB). In contrast, footpad swelling was significantly increased in mice immunized with 
cl2205 (at day 35, 39 and 49; p = 0.0178, 0.0347 and 0.0006, respectively) or ANKA (at day 
35 and 49; p = 0.0320, and 0.0016, respectively) (Fig. 5B) compared to infection control 
animals. When we determined the bacterial load in the infected foot pads after 39 days (T1), 
49 days (T2) and 63 days (T3) by IS2404 qPCR based quantification of M. ulcerans DNA, 
differences between groups were perceivable but not statistically significant (Fig. 6), which 
was confirmed by the results from CFU plating (Supplementary Fig. 3).  
Comparing total IgG titers in sera collected after ITV with total IgG titers in sera after ITV and 
additional M. ulcerans infection, no booster effect of the infection on animals immunized with 
cl2205 was observed (Fig. 7A). In contrast, a slight significant boost by the exposure to the 
antigen in the native context of an infection was detected in animals that had received cl2224 
by ITV (Fig. 7B). Interestingly, infection alone did not induce antibodies against rMUL3720 
nor rMUL4987 (Fig. 7). 
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Discussion 
Although vaccination by ITV with malaria parasites expressing heterologous antigens is still 
far from application, this approach could serve in the future as multi-disease vaccination. 
Recently it has been demonstrated that the model antigen ovalbumin (OVA) expressed in P. 
berghei parasites induced OVA specific T-cell responses in an ITV approach with infection by 
injection of iRBCs [6]. Along these lines we have demonstrated that P. berghei can serve as 
delivery system for heterologous mycobacterial antigens.  
The subcellular location of the model antigen OVA in the malaria parasites had a strong 
influence on the nature and magnitude of the antigen-specific T-cell responses [6]. 
Expression on the PVM by fusion of OVA to HEP17 led to significantly stronger splenic and 
intracerebral OVA-specific CD8+ and CD4+ T-cell responses than cytosolic OVA expression 
[6]. Similarly, M. ulcerans proteins fused to Hep17 led to more stable expression of the 
candidate antigens and induced significant specific antibody titers in ITV immunized mice as 
compared to cytosolic expression. Protein-dependent effects were additionally observed in 
the presented study, in which both fusion protein expression, as well as the induced humoral 
immune response were stronger in MUL3720::Hep17 expressing parasites than in the 
MUL4987::Hep17 parasites. As expected, the MUL3720::Hep17 fusion protein was 
associated with the PVM; due to lack of a suitable antibody the localisation of the 
MUL4987::Hep17 fusion protein with the PVM could not be reconfirmed.  
ITV induced strong antibody responses that were cross-reactive with the native protein 
antigens on the surface of M. ulcerans cells. Classically, a mouse foot pad model of M. 
ulcerans infection is used to test new drug treatments for Buruli ulcer or study the protective 
potential of new vaccines [32]. In this challenge model mice immunized with unmodified and 
MUL3720-expressing parasites showed a tendency of accelerated swelling and inflammation 
compared to non-immunized mice. This may be related to an unspecific increased 
immunological alert elicited by the malaria infection. Taking into account that immunization 
by ITV enhanced M. ulcerans infection related footpad swelling, the observed delay in 
swelling in mice immunized with MUL4987 expressing parasites may reflect development of 
partial specific immune protection. In line with this observation, also priming with a MUL4987 
(Ag85A) DNA vaccine and boosting with recombinant Ag85A protein has been shown before 
to delay footpad swelling [33,34]. To what extent antibody responses play a role in protection 
against the mainly extracellular M. ulcerans bacilli is not clear [12]. From the data presented 
here, we conclude that antibody responses against MUL3720 and MUL4987 are not of major 
importance in conferring protection. 
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Figures 
 
Figure 1: Expression of the vaccine candidate antigens MUL_3720 and 
MUL_4987 by genetically modified P. berghei parasites. 
(A) Western blot analysis on lysates of different P. berghei lines with mAb’s against 
MUL3720 (left panel) and MUL4987 (right panel). Indicated amounts of lysates of P. berghei 
parasites, M. ulcerans lysate (Mu lysate) and recombinant proteins were loaded. Both 
proteins were expressed by the specific parasite line at the size expected, which due to their 
fusion to P. berghei HEP17 was bigger than the proteins in M. ulcerans lysate or the 
recombinant forms of the proteins. (B) Western blot analysis on lysates of different P. 
berghei lines probed with anti-MUL372 mAb. Indicated amounts of lysates of P. berghei 
parasites, M. ulcerans lysate (Mu lysate) and recombinant proteins were loaded. (C) Indirect 
immunofluorescence staining of red blood cells infected with genetically modified P. berghei 
parasites. Formalin/Glutaraldehyde fixed iRBC were probed with anti-MUL3720 mAb (red) 
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and nuclei stained with DAPI (blue). Infection with the parasite line cl2205 led to expression 
of MUL3720 on the PVM. Control infection with ANKA parasites did not lead to expression of 
MUL3720. Scale bar represents 3 µm. 
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Figure 2: Humoral immune response to two sequential ITVs with different P. 
berghei constructs. 
Female NMRI mice (n = 4 - 5) were immunized by ITV with the indicated P. berghei lines. Six 
weeks after first ITV serum was collected (open symbols) and the procedure was repeated 
(closed symbols). Sera after each ITV were analysed by ELISA on the P. berghei line 
corresponding recombinant protein (A: rMUL3720; B: rMUL4987). Endpoint total IgG titers 
were determined for individual animals in one single ELISA. Mean values (line) ± standard 
deviations are shown. Differences in total IgG endpoint titers after first and second ITV were 
not statistically significant (Wilcoxon Rank-Sum test). 
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Figure 3: Humoral immune response to the chloroquine covered infection with 
modified P. berghei parasites in mice.  
Sera of groups of 15 P. berghei infected and subsequently chloroquine treated, female 
BALB/c mice were analysed by ELISA on rMUL3720 (A1) or rMUL4987 (A2). Serial dilutions 
of sera are shown as mean (dot) ± standard deviation. While strong antibody response upon 
infection with cl2205 was detected in immunized mice (A1) the response upon infection with 
cl2224 was less pronounced (A2). Cross reactivity of the infection-induced antibodies with 
the native antigens was demonstrated by Western blotting on M. ulcerans lysate (B1 and 
B2). Anti-MUL3720 mAb (B1) or anti-MUL4987 mAb (B2) served as positive controls, pre-
bleed (pb) serum or no primary antibody (nc) as negative controls. All but one mouse in the 
cl2205 infected group showed strong specific response against MUL3720 (B1). Antibody 
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response to MUL4987 was specific to the native antigen in Western blotting, but again not 
very pronounced (B2). (C1 and C2) Cross reactivity of the infection-induced antibodies in 
serum of representative animals with surface structures on paraffin embedded M. ulcerans 
bacteria demonstrated in immunofluorescence analysis.  
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Figure 4: Comparison of different delivery systems for MUL3720 and MUL4987. 
Groups of female mice were immunized with standard regimens of different delivery systems 
for the two protein vaccine candidate antigens MUL3720 (A) and MUL4987 (B). Sera were 
analysed two to three weeks after the last immunization. Adjuvant formulation: 20 µg of 
recombinant protein were formulated with GLA-SE/EM048 (Add Ref Adjuvant) and mice 
were immunized twice s.c. in the scruff of the neck in a three week interval. Virus replicon 
particle (VRP): Mice were immunized once intra-muscularly with 107 VSV*ΔG(MUL3720) (A) 
or VSV*ΔG(tPA-MUL4987) (B) and boosted three weeks later with 30 µg of the respective 
non-adjuvanted recombinant protein [26]. P. berghei: one round of ITV with cl2205 (A) or 
cl2224 (B) was done. Endpoint total IgG titers were determined for individual animals in one 
single ELISA per delivery system on recombinant protein. Mean values (line) ± standard 
deviations are shown. 
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Figure 5: Course of infection with M. ulcerans in P. berghei immunized mice. 
(A) Groups of 15 P. berghei immunized, female BALB/c mice were challenged with M. 
ulcerans injected s.c. into the left hind foot pad. Infection was followed by measuring foot pad 
thickness with a caliper until mice were euthanized at day 39 (T1, remaining n = 10), day 49 
(T2, remaining n = 3 (2)) and day 63 (T3). Depicted is the mean foot pad thickness (dot) ± 
standard deviation of the individual differently immunized groups. Foot pad swelling started 
after 4 weeks of infection and progressively increased until mice were euthanized at day 63 
after infection. Differences between immunized groups were highest between day 35 and 
day 49 of infection and are depicted in more detail in (B).  
(B) For infection between day 35 and day 49 foot pad thickness of individual mice per group 
is depicted (dots). Additionally, the mean value (line) ± standard deviation of each group is 
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given. Statistical significance was calculated by the Student’s t- test and is indicated with the 
according p-value when detected. Mice immunized with cl2205 (blue) had a tendency to 
show stronger swelling than non-immunized mice (black) that was always statistically 
significant except at day 44. Mice immunized with cl2222 (red) showed a slight tendency to 
have less swelling than non-immunized mice.  
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Figure 6: Bacterial load in foot pads of P. berghei immunized and M. ulcerans 
infected mice.  
After infection with 3.5 x 104 M. ulcerans (Inoculum) bacterial load in infected foot pads was 
determined by qPCR at three time points during infection: 39 days (T1, n = 5), 49 days (T2, n 
= 4) and 63 days (T3, n = 2 – 3) after infection. Depicted are individual measurements as 
genome copies per foot pad, the mean (line) ± standard deviation. A slight tendency of 
reduction in bacterial load in cl2224 immunized animals is visible at all time points but not 
statistically significant (Kruskal-Wallis test). 
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Figure 7: Vaccination-induced humoral immune responses are not boostered 
by infection with M. ulcerans. 
Groups of 15 P. berghei immunized, female BALB/c mice were challenged with M. ulcerans 
injected s.c. into the left hind foot pad. Sera after ITV before M. ulcerans infection were 
compared to sera of the same animals after at least 39 days of M. ulcerans infection by 
ELISA on the P. berghei line corresponding recombinant protein (A: rMUL3720; B: 
rMUL4987). Endpoint total IgG titers were determined for individual animals in one single 
ELISA. Mean values (line) ± standard deviations are shown. Statistical differences were 
assessed by paired t-test and are shown when detected. * p ≤ 0.05. 
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Supplementary Material 
 
Supplementary Figure 1: Ig subclass distribution in sera of mice after two 
sequential ITVs. 
Female NMRI mice (n = 4 - 5) were immunized by ITV with the indicated P. berghei lines. Six 
weeks after first ITV serum was collected (open symbols) and the procedure was repeated 
(closed symbols). Sera after each ITV were analysed by ELISA on the P. berghei line 
corresponding recombinant protein (A1-A3: rMUL3720; B1-B3: rMUL4987). Ig subclass titers 
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were determined for individual animals in one single ELISA by development with isotype 
specific secondary antibodies. Mean values (line) ± standard deviations are shown. 
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Supplementary Figure 2: Histopathological analysis at T1. 
All scans of representative infected foot pads of each experimental group showed slight 
oedema in the upper part of the foot pad and slight cellular infiltration and necrosis at the 
base of the foot pad (HE). ZN staining revealed AFB in close contact to infiltrating cells and 
cellular debris, which were mainly neutrophils (N-Elastase).  
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Supplementary Figure 3: Bacterial load in foot pads of ITV immunized and M. 
ulcerans infected mice.  
After infection with M. ulcerans (Inoculum) bacterial load in infected foot pads was 
determined by CFU plating at three time points during infection: 39 days (T1, n = 5), 49 days 
(T2, n = 4) and 63 days (T3, n = 2 – 3) after inoculation. Depicted are individual 
measurements as CFU per foot pad, the mean (line) ± standard deviation. 
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Abstract 
Background Buruli ulcer (BU) is a slowly progressing, necrotising disease of the skin 
caused by infection with Mycobacterium ulcerans. Non-ulcerative manifestations are 
nodules, plaques and oedema, which may progress to ulceration of large parts of the skin. 
Histopathologically, BU is characterized by coagulative necrosis, fat cell ghosts, epidermal 
hyperplasia, clusters of extracellular acid fast bacilli (AFB) in the subcutaneous tissue and 
lack of major inflammatory infiltration. The mode of transmission of BU is not clear and there 
is only limited information on the early pathogenesis of the disease available. 
Methodology/Principal findings For evaluating the potential of the pig as experimental 
infection model for BU, we infected pigs subcutaneously with different doses of M. ulcerans. 
The infected skin sites were excised 2.5 or 6.5 weeks after infection and processed for 
histopathological analysis. With doses of 2 x 107 and 2 x 106 colony forming units (CFU) we 
observed the development of nodular lesions that subsequently progressed to ulcerative or 
plaque-like lesions. At lower inoculation doses signs of infection found after 2.5 weeks had 
spontaneously resolved at 6.5 weeks. The observed macroscopic and histopathological 
changes closely resembled those found in M. ulcerans disease in humans. 
Conclusion/Significance Our results demonstrate that the pig can be infected with M. 
ulcerans. Productive infection leads to the development of lesions that closely resemble 
human BU lesions. The pig infection model therefore has great potential for studying the 
early pathogenesis of BU and for the development of new therapeutic and prophylactic 
interventions. 
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Author Summary 
Buruli ulcer caused by Mycobacterium ulcerans infection is a necrotizing disease of the skin 
and the underlying subcutaneous tissue. Since the skin of pigs (Sus scrofa) has striking 
structural and physiological similarities with human skin, we investigated whether it is 
possible to develop an experimental M. ulcerans infection model by subcutaneous injection 
of the mycobacteria into pig skin. Injection of 2 x 106 or 2 x 107 colony forming units of M. 
ulcerans led to the development of lesions that were both macroscopically and 
microscopically very similar to human Buruli ulcer lesions. In particular for the 
characterization of the pathogenesis of Buruli ulcer and of immune defence mechanisms 
against M. ulcerans, the pig model appears to be superior to the mouse foot pad model 
commonly used for the evaluation of the efficacy of chemotherapeutic regimens. 
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Introduction 
Buruli ulcer (BU), caused by infection with Mycobacterium ulcerans, is a human disease of 
the skin primarily affecting subcutaneous fat tissue and leading to ulceration of the overlying 
dermal and epidermal layers [1,2]. The disease is reported from countries worldwide but has 
its highest prevalence in West Africa [3]. Natural reservoirs of M. ulcerans as well as the 
mode(s) of transmission are not clearly identified [3,4]. While for a long time wide surgical 
excision was the only treatment option for BU, since 2004 the World Health Organization 
(WHO) recommends antibiotic therapy with rifampicin and streptomycin for 8 weeks [5]. This 
change in standard treatment has reduced recurrence rates to less than 2% [6–9].  
M. ulcerans produces the polyketide exotoxin mycolactone that is responsible for the 
necrotizing nature of BU [10]. Three distinct non-ulcerative stages of the disease are 
described: subcutaneous, painless and movable nodules or papules, oedema and plaques. 
All three stages may progress to ulceration once the destruction of the subcutis results in 
collapse of the overlying epidermis and dermis [11]. 
Ulcerative BU lesions have been histopathologically well described through the analysis of 
excised tissue from surgically treated patients. Coagulative necrosis, fat cell ghosts and 
epidermal hyperplasia together with the presence of extracellular clusters of acid fast bacilli 
(AFB) in the absence of major inflammatory infiltrates in central parts of the lesions are 
considered hallmarks of the disease and can also be used for histopathological diagnosis 
[12,13]. However, early, pre-ulcerative stages have been described less frequently, because 
in particular in the African BU endemic regions patients are rarely reporting at treatment 
centres during early stages of the disease. Furthermore, with the replacement of surgical 
treatment by chemotherapy, tissue samples are not easily available any longer. Therefore, a 
suitable experimental animal infection model is required to contribute to the understanding of 
early host-pathogen interactions and pathogenesis in BU. 
A range of animal species have been reported of being naturally infected with M. ulcerans 
and of developing ulcerative lesions. These include koalas, possums, cats, dogs and horses 
[14–21]. Except for possums which appear to be unusually susceptible to the disease, these 
animal infections seem to occur only sporadically [22]. Experimental M. ulcerans infections 
have been performed with amphibians, armadillos, rats, mice, guinea pigs and monkeys, with 
a mouse foot pad model being most widely used for studying the efficacy of prophylactic and 
therapeutic interventions [23–29]. Here we propose the pig (Sus scrofa) as experimental M. 
ulcerans infection model, since pigs are closely related to humans in terms of many aspects 
of anatomy and physiology [30,31]. The pig is widely used as a model in dermatological 
studies because pig skin, in contrast to rodent skin, has striking similarities to human skin 
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[32]. Not only the thickness of the epidermis and the dermis are comparable to human skin 
[33], but also the presence of a subcutaneous fat cell layer is favouring the pig model over 
the mouse foot pad model commonly used for analysing BU pathogenesis. Furthermore, the 
porcine immune system reflects the human immune system in many aspects better than the 
murine immune system does [34,35]. For all these reasons we explored here the potential of 
the pig to serve as model for human M. ulcerans infection. 
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Materials and Methods 
Ethical Statement 
All animal experiments described here were approved by the Animal Welfare Committee of 
the Canton of Berne under licence number BE50/11, and conducted in compliance with the 
Swiss animal protection law and with other national and international guidelines. 
Bacteria 
The M. ulcerans strain used in this study was isolated in 2010 from a swab taken from the 
undermined edges of the ulcerative lesion of a Cameroonian BU patient [4]. Five passages of 
the strain after isolation were done in Bac/T medium (Biomerieux) at 30°C. For preparation of 
the inoculum, bacteria were cultivated in Bac/T medium for 6 weeks, recovered by 
centrifugation and diluted in sterile phosphate-buffered saline (PBS) to 375 mg/ml wet weight 
corresponding to 2 x 108 CFU/ml as determined by plating serial dilutions on 7H9 agar 
plates. From this stock solution suspension serial dilutions in PBS were prepared for 
infection. 
Infection and inoculation with synthetic mycolactone A/B 
Specific pathogen-free 2-month-old pigs (Large White) from the in-house breeding unit of the 
Institute of Virology and Immunology (IVI) were kept under BSL3 conditions one week prior 
and during the time of experimental infection. Animals were checked once daily for 
macroscopic signs of infection, had ad libitum access to water and were fed daily with 
complete pelleted food. 
Pigs were infected on both flanks at four to six infection sites with 100 µl of M. ulcerans 
suspension, containing 2 x 107, 2 x 106, 2 x 105, 2 x 104 or 2 x 103 CFU. Injection areas were 
wiped with 70% ethanol and bacterial suspensions injected subcutaneously with a 26G 
needle. Individual infection sites were encircled with a black marker and the labelling 
renewed at least once a week. Animals were euthanized at 2.5 weeks or 6.5 weeks post-
infection and tissue samples taken as described below.  
In addition, the effect of mycolactone was studied directly by injecting 5 µg or 0.5 µg of 
synthetic mycolactone A/B [36] and analysing tissue specimens taken 2.5 weeks later. 
Euthanasia and necropsy 
Pigs were euthanized by intravenous injection of pentobarbital (150 mg/kg bodyweight) and 
subsequent exsanguination. Skin tissue at infection sites was extensively excised with a 
scalpel and scissors, including all layers of the skin down to the fascia, and samples were 
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immediately transferred to 10% neutral-buffered Formalin solution (approx. 4% 
formaldehyde). 
Histopathological analysis 
After fixation samples were transferred to 70% ethanol for storage and transport, dehydrated 
and embedded into paraffin. 5 µm thin sections were cut, deparaffinised, rehydrated and 
directly stained with Haematoxylin/Eosin (HE) or Ziehl-Neelsen/Methylene blue (ZN) 
according to WHO standard protocols [11]. Stained sections were mounted with Eukitt 
mounting medium (Fluka). Pictures were taken with a Leica DM2500B microscope or with an 
Aperio scanner. 
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Results 
Macroscopic appearance of Mycobacterium ulcerans infected pig skin 
In order to assess early effects of the subcutaneous experimental infection of pigs with doses 
of 2 x 103 to 2 x 107 M. ulcerans CFU, injection sites were closely monitored for macroscopic 
changes of the skin. At 2.5 weeks after injection of the bacteria, first changes in colouration 
and thickness of the skin became apparent at the sites inoculated with the highest 
inoculation doses, 2 x 107 and 2 x 106 CFU (Fig. 1, B1). Like nodular BU lesions in humans, 
these early lesions were elevated, movable, firm and palpable. When these skin areas were 
excised 2.5 weeks and 6.5 weeks after infection and vertically cut in half after fixation in 
formalin, roundish yellow structures reflecting coagulative necrosis in the dermis became 
macroscopically apparent (Fig. 1, B2). A belt with reddish colour, reflecting infiltrating cells 
and bleeding into the skin, was observed around the necrotic core. While these structures 
were larger at sites inoculated with a dose of 2 x 107 CFU than at sites inoculated with 2 x 
106 CFU, the general architecture observed with both inoculation doses was similar. At sites 
inoculated with <2 x 105 CFU, no macroscopically visible alterations of the skin were found 
2.5 weeks after infection (Fig. 1, A1 and A2). 
At 6.5 weeks after experimental infection, sites injected with the highest inoculation dose had 
either enlarged to an indurated plaque (Fig.1 E1) or ulcerated (Fig. 1, D1). At sites injected 
with 2 x 106 CFU, nodular lesions were observed that were flatter and less palpable 
compared to those detected 2.5 weeks after infection (Fig. 1, C1). These lesions were 
macroscopically clearly visible in cross sections through the tissue (Fig. 1, C2). Nodular and 
ulcerative lesions exhibited greyish/reddish colour changes in the dermis and subcutis (Fig. 
1, C2 and D2). The plaque lesion developing after injection with 2 x 107 CFU appeared as 
long cord-like structure with a centre made of yellowish necrotic slough, surrounded by 
several layers differing in colouration (Fig. 1, E2).  
Histopathological features of the pig skin 2.5 weeks after experimental 
infection 
Microcopically, infiltrating immune cells were found 2.5 weeks after infection at all sites 
inoculated with ≥2 x 104 CFU (Fig. 2, A1, B1, C1 and D1). As expected from the 
macroscopically observed signs, the most pronounced histopathological alterations were 
associated with the two highest inoculation doses (2 x 107 and 2 x 106 CFU). The non-
ulcerative lesions that developed between the dermis and the underlying muscle tissue 
displaced the fat layer (Fig. 2, A1 and B1) and caused the macroscopically visible elevation 
of the skin (Fig. 1, B1). Microscopically, a necrotic core surrounded by large numbers of 
infiltrating cells and interspersed with fat cell ghosts was observed (Fig. 2, A2 and B2). 
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At sites infected with 2 x 105 CFU, no necrotic core structures but some fat cell ghosts and 
accumulations of infiltrating cells were found (Fig. 2, C1 and C2). The infection with 2 x 104 
CFU caused a small accumulation of infiltrating cells (Fig. 2, D1 and D2) and no signs of 
infection and/or inflammation were observed at sites inoculated with the lowest dose (2 x 103 
CFU).  
Histopathological features of the pig skin 6.5 weeks after experimental 
infection 
At 6.5 weeks after experimental infection, histopathological changes were only found at sites 
that had been injected with 2 x 107 or 2 x 106 CFU. In contrast, the skin appeared macro- and 
microscopically healthy following infection with lower doses of M. ulcerans, exhibiting intact 
epidermis and fat cells, undistorted collagen fibre networks and no marked inflammatory 
infiltration (Fig. 3, D1 and D2). 
Where the infection focus had started to ulcerate, strong infiltration towards the destroyed 
epidermis was observed (Fig. 3, A1 and A2). No AFB were found in this region, indicative for 
loss of the necrotic core with the major burden of AFB through the ulceration (Fig. 3, A2, Fig. 
4, B1 and B2). Small clusters of AFB were found at deeper sites in the tissue, lateral to the 
ulceration site (Fig. 4, B3 - B5). Infiltration and destruction of collagen fibres extended into 
the lower part of the dermis and the upper part of the subcutis, reaching far beyond the area 
where the epidermis was destroyed (Fig. 3, A1), indicating the formation of undermined 
edges (Fig. 3, A2, dotted line).  
The overall architecture of the plaque lesion that had developed resembled the nodular 
stages seen 2.5 weeks after infection, i.e. a necrotic centre was surrounded by layers of 
infiltrating cells (Fig. 3, B1). While large clumps of extracellular AFB were found in the 
necrotic core after injection of 2 x 107 CFU (Fig. 3, B2), AFB were less abundant and 
bacterial clumps smaller when 2 x 106 CFU were used for infection (Fig. 3, C2). Fig. 4A 
depicts the complex architecture of a plaque lesion (2 x 107 CFU dose) with several distinct 
belts of infiltrating cells surrounding a central necrotic core which contained huge clusters of 
AFB but was completely devoid of infiltration (Fig. 4A, Ring 1, A1 and A2). In the surrounding 
ring 2, AFB were scarce and had mostly a beaded appearance. In addition to these single 
AFB, small globi-like clusters of AFB were found, along with Methylene blue stained remains 
of infiltrating cells (Fig. 4A, Ring 2, A3 and A4). Ring 3 contained mostly small infiltrating cells 
that appeared intact, and some acid-fast bacterial debris (Fig.4A, Ring 3, A5 and A6). The 
outermost layer that could be distinguished did not contain AFB and was mainly built by 
macrophages and lymphocytes (Fig. 4A, Ring 4, A7). Hence, the number and integrity of 
AFB decreased from the centre to the periphery of the lesion, whereas the integrity of the 
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cellular infiltration showed an opposite trend, most likely reflecting levels of the cytotoxic 
macrolide mycolactone decreasing from centre to periphery.  
Histopathological resemblance of pig and human BU lesions 
All key features of BU pathology in humans were also found in the experimentally infected 
pig skin. Already 2.5 weeks after infection, coagulative necrosis (Fig. 5, A1), fat cell ghosts 
(Fig. 5, A2) and extracellular clusters of AFB (Fig. 5, A3 and A4) were detected. Slight 
epidermal hyperplasia was already observed at 2.5 weeks and became more pronounced 
6.5 weeks after infection (Fig. 5, A5 - A7). At this time, typical histopathological hallmarks of 
more advanced human BU lesions also emerged in the infected pig skin, namely formation of 
granulomas (Fig. 5, A8) and presence of giant cells (Fig. 5, A9). Not only experimental 
infection with M. ulcerans led to these typical alterations in the skin, but also the injection of 
synthetic mycolactone A/B (Fig. 5B). 
Development of satellite infection foci 
Besides the general histopathological changes, another similarity to findings in human BU 
[37] was observed: the formation of satellite infection foci adjacent to the primary lesion. A 
striking example for this is depicted in Fig. 4B where two satellite foci with small clusters of 
AFB in a necrotic core were found peripheral to the ulcerated main infection focus (Fig. 4B, 
Region 2). Likewise in the plaque lesion depicted in Fig. 4A, clusters of AFB were found near 
the main infection focus (Fig. 4A, Ring 5, A8). 
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Discussion 
Detailed studies on the early pathogenesis of BU in an animal model closely mimicking 
human BU would be very important for a better understanding of host-pathogen interactions 
and the relative importance of different effector functions of the innate and adaptive immune 
system against M. ulcerans. Here we explored the potential of the pig to serve as model for 
human M. ulcerans infection. After having infected pigs subcutaneously with high doses (2 x 
106 or 2 x 107 CFU) of M. ulcerans bacteria, we observed the development of different forms 
of BU lesions (nodules, plaques and ulcers). Macroscopic and histopathological changes 
closely mirrored human BU. Challenge with lower doses (2 x 103 to 2 x 105 CFU) resulted in 
limited tissue destruction and/or infiltration 2.5 weeks after infection, which resolved 
spontaneously until week 6.5. Likewise, the dose of bacteria transmitted may be of critical 
importance for the outcome of a natural M. ulcerans infection in humans. Sero-
epidemiological analyses in human populations living in BU endemic areas have indicated 
that exposure to M. ulcerans often leads to self-resolving, non-symptomatic infections, as 
indicated by development of M. ulcerans specific antibody responses [38,39]. While 
macrophages and other immune cells might be able to eliminate smaller numbers of 
scattered M. ulcerans cells, microcolonies of a critical size may develop a protective cloud of 
mycolactone around them. If the local concentration of the macrolide cytotoxin exceeds a 
certain level, infiltrating cells may be killed before they can reach the bacteria. This leads to 
the characteristic picture of clusters of extracellular AFB located primarily in the necrotic core 
of advanced lesions, which is devoid of living infiltrating immune cells, but contains debris of 
early inflammatory infiltrates [40,41].  
In our study, we observed round elevations of the skin already 2.5 weeks after infection. 
These alterations were firm, movable and clearly palpable and hence displayed the 
characteristic features of human BU nodules [11]. Microscopic investigation of the infected 
skin sites revealed that most histopathological hallmarks of BU had already developed during 
the first 2.5 weeks of infection if 2 x 106 or 2 x 107 CFU of M. ulcerans was used. The 
experimentally induced nodules exhibited a necrotic core containing extracellular AFB 
surrounded by infiltrating cells and fat cell ghosts. Subcutaneous injection of the bacteria led 
to the formation of an infection focus in the lower dermis and subcutis, where it is also 
typically found in human BU [13]. 
In ulcerative human BU lesions AFB are typically focally distributed and not evenly dispersed 
in the affected tissue [37,42]. Ulceration leads to the shedding of necrotic tissue containing 
masses of AFB. Therefore the bacterial burden is usually higher in non-ulcerative lesions 
than in ulcers, where the majority of the remaining AFB reside in the undermined edges of 
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the ulcers. Our histopathological analyses showed, that like in human BU disease [37], 
satellite lesions may develop near the primary lesion. These may emerge from globi-like 
accumulations of AFB originating from bacteria that were internalized and transported to 
distant sites by phagocytic cells. Globi-like accumulations are also found in human BU [43] 
and in experimentally infected mice [44–46]. Again, these microcolonies may have to reach a 
critical size to be able to develop a protective cloud of mycolactone around them. The 
emergence of only small numbers of newly established microcolonies may explain why 
borders of advanced ulcers often appear to be very heterogeneous with respect to disease 
activity with some regions displaying progressive tissue destruction and others showing 
spontaneous healing tendencies.  
At 6.5 weeks after infection with 2 x 106 or 2 x 107 CFU of M. ulcerans, lesions that were still 
closed comprised a necrotic centre containing clumps of AFB surrounded by well stratified 
belts of infiltrating cells. Similarly, lesions consisting of a necrotic core surrounded by an 
inner belt of CD14 positive monocytes/macrophages and a more external belt of CD3 
positive T-cells have been described in human BU [47]. The integrity and number of bacteria 
was decreasing to the outer rim of the lesion. In contrast, the density and integrity of the 
cellular infiltrates decreased towards the necrotic core.  
In the pig model first macroscopic signs of infection (nodules) developed relatively fast after 
injection of a high number of bacteria. For human BU disease in Uganda and Southern 
Australia incubation periods of 4-13 weeks and 5-38 weeks have been estimated, 
respectively [48]. However, incubation periods as short as 2-3 weeks have also been 
described [49]. Despite extensive analyses we did not find bacteria in the tissue with low 
inoculation doses at the 6.5 week time point. Therefore we assume that also at later time 
points lesions would not develop with these low infection doses. It is possible that pigs are 
more resistant to M. ulcerans infection than humans. Consequently, the size of the inoculum 
to achieve productive experimental infection may be higher for pigs than for the natural 
infection of humans. This high experimental inoculation dose may have led to fast 
progression of the disease.  
In conclusion, our findings indicate that the pig is a very good animal model to study many 
aspects of M. ulcerans infection. Pig skin represents a much closer model for human skin 
than murine foot pads, ears or tails with respect to physiology, structure and abundance of 
fat tissue [50]. In addition, the immune system of the pig resembles the human system more 
closely than that of the mouse [34]. In particular the development of new therapeutic and 
prophylactic interventions might benefit from the porcine M. ulcerans infection model.  
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Figures 
 
 
Figure 1: Macroscopic appearance of pig skin infected with M. ulcerans. 
Development of representative lesions 2.5 weeks or 6.5 weeks after subcutaneous infection 
with 2 x 107 (B1, D1 and E1) or 2 x 106 (C1) CFU is depicted and compared to a site left 
uninfected (A1). Excised tissue specimens were fixed and vertically cut in half to visualize 
macroscopically visible alteration in tissue structure (A2 - E2). For high inoculation doses (≥2 
x 106 CFU) the formation of nodules (B1) with necrotic centres was observed already 2.5 
weeks after infection (B2). These yellow centres indicative for coagulative necrosis were 
surrounded by a reddish ring (B2). At 6.5 weeks after infection, these nodules had 
progressed into a small ulcer or a plaque (D1, E1) associated with marked macroscopically 
visible alterations in tissue structure (D2, E2). At sites injected with 2 x 106 CFU nodules with 
greyish discoloration of the dermis had developed 6.5 weeks after injection of M. ulcerans 
(C1, C2). 
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Figure 2: Microscopic appearance of pig skin 2.5 weeks after experimental 
infection. 
Histologic sections stained with HE. Infiltrating cells were found in the fat layer between 
dermis and muscle tissue at sites infected with ≥2 x 104 CFU (A1, B1, C1 and D1). While the 
two highest inoculation doses led to the development of lesions with a necrotic core 
surrounded by strong infiltration (A2, B2), infiltration but no necrotic core was observed when 
doses of 2 x 104 and 2 x 103 CFU were used (C2, D2 insert). Fat cell ghosts were found at 
sites infected with the three highest inoculation doses (A2, B2 and C2). x: necrosis, y: 
infiltration, z: fat cell ghosts. 
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Figure 3: Microscopic appearance of pig skin 6.5 weeks after experimental 
infection. 
Histologic sections stained with Haematoxylin/Eosin (HE) (A1, A2, B1, C1, D1 and D2) or 
Ziehl-Neelsen/Methylene blue (ZN) (B2, C2). At sites injected with 2 x 107 CFU nodules had 
either developed into a small ulcer with destroyed epidermis (z), strong infiltration and 
indications for the development of undermined edges (A1, A2, dotted line) or into a plaque 
with a necrotic core surrounded by infiltrating cells (B1). x: intact epidermis, y: epidermal 
hyperplasia, z: destroyed/missing epidermis. 
The site infected with 2 x 106 CFU showed a similar architecture as the plaque but flatter, 
less organized and with a smaller overall circumference (C1). Both lesions comprised AFB in 
their necrotic cores, either in big clumps (B2) or in smaller numbers and smaller aggregations 
(C2). No signs of infection, inflammation and pathology were observed at sites inoculated 
with 2 x 105 CFU (D1, D2) or less (not shown). 
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Figure 4: Containment of large amounts of AFB in the necrotic core and 
development of satellite microcolonies. 
Histologic sections stained with ZN. A plaque (A) and a small ulcer (B) are shown that 
developed 6.5 weeks after infection with 2 x 107 CFU. The ulcerated lesion was strongly 
infiltrated at the site of ulceration, where no AFB were found (Region 1, B1, B2). Lateral and 
between dermis and muscle tissue infiltrating cells enclosed small necrotic areas (Region 2, 
B3), where AFB were found as satellite microcolonies (B4, B5). The plaque consisted of 
distinct layers of infiltrating cells encasing a necrotic core containing large clumps of bacteria 
(Ring 1, A1, A2). A second and third ring with decreasing bacterial load and integrity and 
increasing integrity of infiltrating cells were layered around this core (Ring 2, A3, A47 and 
Ring 3, A5, A6). A belt of intact cells was surrounding these three inner layers. It did not 
contain any AFB (Ring 4) except for a microcolony peripheral to the main bacterial burden 
(Ring 5, A5). 
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Figure 5: Histophathological hallmarks of Buruli ulcer in experimentally 
infected pig skin. 
Histologic sections stained with Haematoxylin/Eosin (HE) (A1, A2, A5, A6, A7, A8, A9, B1, 
B2 and B3) or Ziehl-Neelsen/Methylene blue (ZN) (A3, A4).  
A: All typical histopathological features of BU in humans were found in infected pig skin. A1: 
necrosis, A2: fat cell ghosts, A3 and A4: extracellular clusters of AFB, A5: healthy epidermis, 
A6: moderate epidermal hyperplasia, A7: strong epidermal hyperplasia, A8: granuloma 
formation, A9: giant cells.  
B: Histopathological changes induced by mycolactone injection. B1: necrosis, B2: fat cell 
ghosts, B3: giant cells. 
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Discussion 
 
WHO currently lists 17 diseases as neglected tropical diseases (NTDs), whereof BU is one of 
four that are caused by bacterial pathogens. All NTDs have in common that they affect the 
world’s poorest people and impair their physical and/or cognitive development and thus 
impede their ability to earn a living [1,2]. Undoubtedly, the acknowledgement of BU as a 
major public health problem by the WHO has substantially increased the research interest for 
the disease, which is reflected in the increased amount of scientific publications on M. 
ulcerans since the “Yamoussoukro Declaration” in 1998 [3,4]. On the other hand, a closer 
look at what we know today about BU and its causative agent M. ulcerans reveals that a 
substantial part of the knowledge originates from the early times of BU research (1960s and 
1970s) and that our knowledge is far from being complete. Major questions, like the main 
environmental reservoir of M. ulcerans, remain unanswered and the exact mode/s of 
transmission of the disease has/have not yet been identified. Consequently, the incubation 
time of BU can only be estimated to be 2 - 3 months [5] and the mechanisms leading to the 
large variety of observed clinical pictures remain incomprehensible. Besides mere ignorance 
concerning certain BU-relevant questions, other aspects imperatively need optimization, 
such as early case detection and simple, highly sensitive and specific diagnostic tools for BU. 
Furthermore extended treatment options, especially treatment beyond antibiotics, remain 
major issues in BU research.  
Within the framework of this thesis, we have tackled some of the unknown aspects of BU by 
establishing a new research site in the remote Mapé basin of Cameroon, where the disease 
has recently emerged [6]. We have studied the epidemiology in this region in detail (Results 
Chapter 1) and laid the foundations for subsequent biomedical studies (Results Chapter 2) 
as well as investigations into identifying transmission patterns by combining whole genome 
sequencing information with geographical data (Results Chapter 3). Furthermore, we have 
elucidated the potential for developing a protein subunit vaccine against M. ulcerans (Results 
Chapters 4 - 6) and established the pig as suitable animal model for studying early BU 
pathology and validating new interventions (Results Chapter 7).  
Buruli ulcer endemic areas: What has been learned from the Mapé dam region 
of Cameroon? 
Already in 1969, one BU endemic region was reported in Cameroon - the Nyong river basin 
located in the south-central region of the country [7,8]. At that time, a total of 47 cases were 
described from an area between the two villages of Ayos and Akonolinga. A cross-sectional 
survey in the same region in 2001 identified a total of 436 cases on clinical grounds, of which 
135 were laboratory confirmed [9]. Reports on BU cases in a second region of Cameroon, 
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the Bankim Health District (HD, Mapé dam region), only emerged recently when Marion et al. 
described the discovery of 195 clinically diagnosed cases over a 2.5 year period from 2007 
onwards [6]. Damming of the Mapé river and the resulting formation of a lake in 1988, was 
suspected to be the cause for the increased incidence of BU in this part of Cameroon. In 
collaboration with the foundation Fairmed, the Bankim HD was established as a new field 
site. As a starting point, a house-by-house survey was conducted in spring 2010, collecting 
epidemiological data of over 48’000 individuals and examining the local population for BU, 
leprosy and yaws (Results Chapter 1). Despite the notion that BU was highly endemic in the 
area, only 25 cases of BU were identified on clinical grounds and only 23 % of them could be 
reconfirmed by IS2404 qPCR. Although this survey strategy can be successful for detecting 
cases in remote communities, which are otherwise not discovered by the health care system, 
we would recommend another approach for future studies. Only selected communities 
should be chosen based on epidemiological data for maximising the cost-benefit ratio.  
On the other hand, the exhaustive survey performed for initiating a new field site in a new BU 
endemic area did yield much more information than “just” newly discovered BU cases. The 
awareness for BU and the acceptance of the local control program in the population was 
certainly increased. This is reflected in the total number of new BU cases that were identified 
by passive case finding during the 27 months following the survey. A steady flow of patients 
from the Bankim HD as well as from surrounding HDs reported to the district hospital, were 
clinically diagnosed, laboratory confirmed and received treatment (Results Chapter 1).  
The survey also demonstrates the urgent need for improved tools for sensitive and 
specific BU diagnosis in the field (a point-of-care diagnostic test). Although the quality of 
clinical diagnosis in Bankim has improved since the survey (increasing from 23 % laboratory 
confirmation to 56 % two years after the survey), the number of false positive clinical 
diagnoses is still very high. Prevention of unnecessary antibiotic treatment in those wrongly 
diagnosed patients is fundamental for preventing the development of resistant mycobacteria, 
especially because tuberculosis is highly endemic in most BU-endemic regions and the risk 
for misdiagnosis of cutaneous tuberculosis as BU is substantial [10]. Additionally, rifampicin 
and streptomycin both have side effects, especially in children, and treating BU-unrelated 
skin conditions with eight weeks of these drugs is immoderate at best. According to the 
WHO, laboratory confirmation of clinical BU diagnosis is essential for the following reasons: 
(1) to confirm the precise prevalence and incidence of BU in a given area, (2) to confirm new 
foci, especially where health care workers lack experience with BU, (3) to help manage the 
disease by surgical and/or antimycobacterial treatment and (4) to confirm and differentiate 
relapse and reinfection after treatment [11]. Of the available four methods for laboratory 
confirmation, only smear examination for AFB after Ziehl-Neelsen staining is feasible in a 
remote area like the Bankim HD. With positivity rates between 40 - 78 %, this method has a 
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low sensitivity and additionally only limited specificity [11]. For example M. tuberculosis from 
a cutaneous tuberculosis case also appears positive in the smear examination. The current 
gold standard of diagnosis, which is the highly sensitive and specific IS2404 qPCR, requires 
sophisticated laboratory equipment and trained personnel. Nevertheless the WHO recently 
recommended that by the end of 2014, at least 70 % of reported cases should be laboratory 
reconfirmed by a positive PCR result. It remains to be seen whether this goal is achievable, 
considering the costs of the methods, the logistic challenges in sample transport and the 
limited capacities of the laboratories in the respective countries. Special attention should also 
be given to quality control because the high sensitivity of the method requires strict 
procedures for avoiding cross-contamination and thus false positive results.  
For the Bankim HD, swab samples were transported for laboratory confirmation to the Swiss 
TPH in Basel. Although a preliminary set up of qPCR in Bankim was feasible, frequent power 
failures and the lack of appropriate premises and trained personnel hinder the sustainable 
establishment of this diagnostic method at a peripheral level. Additionally the build-up of very 
good structures solely for BU diagnosis, without improvement of the standard of treatment at 
the local health facilities should be avoided. Besides laboratory confirmation of clinically 
diagnosed cases, cultivation of the circulating M. ulcerans strains was performed at the 
Swiss TPH (Results Chapter 2). Due to the slow growth rate, cultivation of M. ulcerans does 
not have significant diagnostic value. Furthermore culturing has a low sensitivity, especially 
when culture initiation is done long after sampling. With a turnover time of 4 - 6 months, we 
achieved a per patient positivity rate of 43.1 %, which is comparable to rates reported 
elsewhere [12,13]. But even though primary cultivation of M. ulcerans isolates is not crucial 
for immediate laboratory confirmation of the diagnosis, it remains a basis for studies on 
molecular typing, phylogenetic analyses and monitoring of drug resistance of the locally 
circulating strains (Results Chapter 3). The primary isolates obtained from the Mapé basin 
region build the core of a M. ulcerans strain collection stored at the Swiss TPH. The use of 
these strains, for example for identification of transmission patterns (Results Chapter 3) or 
the development of appropriate animal models for microbiological investigations (Results 
Chapter 4 - 7), should ideally lead to a long-term benefit for the BU-affected communities.  
Another very important outcome of the survey in Bankim was the detailed knowledge 
gained about the new field site and the proper identification of all the villages and the origin 
of the patients (by GPS). Contrary to local beliefs, the reported BU cases were not primarily 
associated with the lake but rather with the Mbam river composing the Southern border of 
the Bankim HD (Results Chapter 1). Subsequent studies investigating possible 
environmental reservoirs in this area confirmed this first finding and identified village water 
sources as being repeatedly positive for M. ulcerans DNA [14]. The combination of the 
findings from whole genome sequencing of the above-mentioned primary isolates from 
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patients in the Mapé area with the information on the residential origin of the corresponding 
patients was expected to give further insight into BU transmission patterns in the region 
(Results Chapter 3). Unfortunately no clear correlation was seen and transmission of BU 
remains enigmatic.  
Lastly, the survey revealed the importance of socioeconomic factors leading to late care 
seeking of BU-affected patients. Antimicrobial treatment of BU is in principle free of cost for 
the patients. Unfortunately streptomycin requires daily injections for which the patients have 
to come to the health post either every day or they have to stay for the entire treatment 
period when travelling distances are too long. As we have also seen in the initial survey, the 
proportion of affected children between the age of 5 and 15 is very high (Results Chapter 1). 
Very often when children have to stay for a prolonged time at a health facility, a caretaker 
has to accompany them, therefore abandoning the rest of the family and the daily work. 
During their stay, both the patient and the caretaker have to provide their own meals, which 
adds another financial burden besides the travelling costs. To further illustrate the problem, a 
study in central Cameroon has described that the cost burden of BU accounts for up to 25 % 
of a household’s yearly earnings [15]. One of the obvious solutions to minimize the stay at 
treatment facilities would be a completely oral antibiotic treatment. Currently studies are 
under way to test the efficacy of fully or partially replacing streptomycin with clarithromycin, 
which would abolish the need for injections, and initial results appear promising [16–19]. On 
the other hand, proper wound care, which has a huge impact on good healing progression of 
BU, and improved diagnosis are problems that will have to be solved independently of an all-
oral treatment strategy.  
Ultimately, prevention of BU by a vaccine would eliminate a major part of the above-
described problems; hence the development of such a vaccine remains one of the highly 
desirable achievements in BU research.  
Is a vaccine against Buruli ulcer a utopia? 
Together with sanitation, vaccination has been the most important contribution to public 
health during the last 100 years and probably the most effective measure in the prevention of 
infectious diseases. Since the development of the first vaccines by Jenner and Pasteur, 
progress in basic immunology and the development of novel technologies has resulted in 
many more vaccines being successfully used worldwide today [20]. Unfortunately tackling 
microbes that do not grow in vitro (M. leprae), that have an intracellular phase (M. 
tuberculosis) or are of high antigenic variability (Plasmodium species) has been unsuccessful 
thus far [21].  
The evidence that protective immunity against M. ulcerans can develop in humans is 
incomplete but nevertheless there are indications that development of a vaccine is feasible. 
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The first piece of evidence comes from serological studies investigating antibody responses 
in BU affected and non-affected persons [22–26]. A study by Dobos et al. investigated 
humoral immune responses in BU patients to M. ulcerans culture filtrate antigens in order to 
identify novel diagnostic antigens. Specific IgG responses were frequently found in BU 
patients but interestingly also in some non-exposed US tuberculosis patients as well as in 
healthy controls from BU endemic areas [22]. While a part of these responses might be 
attributed to antigenic cross-reactivity of M. tuberculosis and M. ulcerans, this factor did not 
play a role in a study using the 18 kDa small heat shock protein (shsp, MUL2232) as a 
serological marker [23]. MUL2232 does not have a homolog in M. bovis and M. tuberculosis. 
Antibodies against the protein were frequently found in sera of BU patients and healthy 
household contacts but only rarely in controls from regions where the disease is not 
endemic. The authors of the study therefore concluded, that only a small portion of M. 
ulcerans-infected individuals actually develop clinical disease [23]. A second piece of 
evidence originates from a study done in the 1970s on the treatment of M. ulcerans infection 
with clofazimine, in which the authors report healing without surgery in the placebo group in 6 
out of 21 patients [27]. Other scientific reports on self-healing of BU are very rare but 
anecdotal descriptions of early BU lesions just disappearing after a certain time are more 
frequent [28]. Both of the above-described phenomena may have several explanations, one 
of which would be the development of a protective immune response. Thus the immune 
system seems to be, under certain circumstances, able to cope with a M. ulcerans infection. 
When Yeboah-Manu and colleagues used the 18 kDa shsp as a serological marker for the 
identification of new BU endemic areas in Ghana, one of their conclusions was that unknown 
host factors as well as unknown pathogen factors might determine how frequently exposure 
to M. ulcerans leads to clinical disease [24]. Only one host-factor study for BU has been 
done so far [29] but more of such investigations might deliver important insights into the 
reasons for why only some people develop the disease. Moreover, such studies might 
explain the observed bimodality in age distribution (Results Chapter 1). 
The third indication for the existence of a protective immune response against BU derives 
from histopathological investigations on secondary lesions emerging after chemotherapy. 
Analysis of tissue specimens from secondary lesions of two patients revealed typical BU 
histopathology of a cured lesion with massive leukocyte infiltrates and large B-cell clusters, 
indicating that treatment may lead to a priming of the response that is later sufficient to 
resolve secondary lesions [30]. Lastly, Bacille Calmette-Guérin (BCG) vaccination was found 
to confer limited protection against BU [31–33], indicating that vaccine-mediated protection 
against BU is possible, but the antigenic cross-reactivity between M. ulcerans and M. bovis 
might not be sufficient to achieve complete protection by BCG vaccination. 
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One frequently asked question is, where would such a vaccine be implemented once it is 
developed? Implementation would have to consider the very focal distribution of BU on a 
country level (as seen in Results Chapter 1). The goal for BU vaccination would certainly not 
be a mass vaccination program on a countrywide scale, but would rather be confined to the 
affected communities. Because a majority of the affected patients are children between the 
age of five and 15 (Results Chapter 1), immunization would especially need to protect young 
children. The focal distribution of BU would facilitate the introduction of a vaccine as a 
preventive measure, because fewer doses would have to be produced and distributed, thus 
considerably decreasing the logistic effort. Another important application could be therapeutic 
vaccination. BU patients could receive the vaccine as soon as they report to the health 
centre, because stimulation of the right immune mechanisms by vaccination might help the 
immune system to eliminate the infection. 
What are possible vaccination approaches against M. ulcerans? 
Toxin neutralization by antibodies 
Mycolactone, the key virulence factor of M. ulcerans, is a primary target for vaccine 
development. Neutralizing antibodies could potentially prevent the pathology, although it is 
not entirely clear how good the chances are that bacterial proliferation without the presence 
of toxin activity could be inhibited by the immune system [34]. Unfortunately, mycolactone is 
a lipid molecule that is poorly immunogenic. Attempts to generate antisera against the 
molecule were not successful for a long time. Only recently, the generation of a set of 
monoclonal antibodies against mycolactone succeeded in our laboratory at the Swiss TPH 
(unpublished results) and the molecule used for immunization has just entered active 
immune protection experiments in mice. Another way of tackling mycolactone production was 
attempted by immunization of mice against polyketide synthase domains on the pMUM01 
plasmid [35]. Despite good immunogenicity of the DNA vaccine prime - recombinant protein 
boost regimen, no significant protection was seen in the immunized mice when delay to foot 
pad swelling was assessed. The induced antibodies would have to reach the inside of the 
mycobacteria to possibly interfere with toxin production, a rationale which is difficult to 
comprehend.  
Live attenuated mycobacteria 
One of the most used vaccines is BCG, a live attenuated M. bovis strain used for vaccination 
against M. tuberculosis. BCG is known to induce significant cross-reactive immune 
responses against other mycobacteria thus BCG-mediated protection against BU was 
suspected [36]. Indeed, two very large clinical studies in Uganda reported timely limited 
protection in a proportion of people as well as a shortening of the duration of ulcers in 
patients [31,32]. Furthermore, BCG vaccinated children and adults seemed to develop 
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osteomyelitis less frequently than non-vaccinated individuals [33]. In line with these 
observations, BCG vaccination appears to delay the onset of foot pad swelling in a mouse 
model of BU [35,37]. Both in humans as well as in the animal model, the BCG-induced 
immune response is apparently insufficiently cross-reactive or not of the right nature to 
confer sustained protection against M. ulcerans infection. In order to induce more specific 
immune responses, live attenuated strains of M. ulcerans were generated by random 
transposon mutagenesis [38]. Immunization of mice with those mycolactone deficient M. 
ulcerans strains and BCG vaccination resulted in comparable protection from BU in the 
mouse model [39]. Besides the lack of increased protective potential compared to BCG, 
mycolactone deficient M. ulcerans vaccine strains would require at least one additional 
targeted mutation to address safety concerns.  
Subunit vaccination 
Subunit vaccines tend to have a substantially better safety profile than live attenuated 
vaccines, although this often comes at the cost of strongly reduced immunogenicity that has 
to be compensated for with an immunogenic delivery system [40]. Protein subunit 
vaccination was investigated for BU with two different protein vaccine candidates. Firstly, 
heat shock protein (Hsp) 65 of M. leprae was tested in a DNA vaccination approach but was 
only marginally able to reduce the M. ulcerans burden in infected mouse tails after six weeks 
of infection [41]. Secondly, Ag85A was successful in delaying foot pad swelling in mice 
immunized with a DNA prime encoding either the M. tuberculosis version of the protein or the 
homolog of M. ulcerans (MUL4987) and a recombinant protein boost [42]. Protection 
conferred with MUL4987 by this approach was comparable to BCG immunization and 
significantly better than the DNA vaccine encoding the M. tuberculosis Ag85A [42].  
Encouraged by these data we further evaluated the potential to develop a protein subunit 
vaccine by formulating three protein vaccine candidate antigens with different delivery 
systems and by assessing their protective potential in a mouse foot pad model of BU 
(Results Chapter 4 - 6).  
What is the right antigen for protein subunit vaccination against M. ulcerans 
disease? 
The lack of correlates of protection made it difficult to choose vaccine candidates for the 
development of a protein subunit vaccine against BU. Because the whole genome sequence 
of M. ulcerans is available [43], the strategy of reverse vaccinology could have been applied 
[21]. This approach was successfully used for the first time to identify novel protein vaccine 
candidates against serogroup B Neisseria meningitidis (MenB) [44]. In a first step, the 
complete MenB genome was screened for open reading frames coding for putative surface-
exposed or secreted proteins. In a second step, 350 of the approximately 600 predicted 
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genes were expressed in E. coli and mice were immunized with the purified proteins to 
obtain antisera. Those were tested for bactericidal antibodies in an in vitro assay, with the 
background knowledge that such antibodies correlate with protection in humans. Of the 28 
identified antigens, five were finally combined to a multicomponent vaccine as the first 
vaccine against MenB [45]. An attempt to directly translate those single steps to the 
development of a vaccine against M. ulcerans would encounter several problems. A major 
obstacle is that it is not clear whether immune protection can be mediated by humoral and/or 
cellular immune responses. If binding of antibodies to the mycobacterial cells were 
suspected to be protective, screening of the M. ulcerans genome for surface-exposed and 
secreted proteins would be possible, but the expression of all hits in E. coli and the 
subsequent immunization of mice would be a challenging task for a research group working 
on BU with limited resources. The next major obstacle in the whole approach would be 
encountered when antisera would have to be tested in an in vitro format to reduce the 
number of candidates and to separate those that potentially confer protection in vivo. No 
correlates of protection for BU are known today (see next section), and the extremely slow 
growth rate of M. ulcerans would make opsonophagocytosis assays very complicated. The 
best approach may thus be the expression of all M. ulcerans proteins and their subsequent 
testing in the mouse foot pad model. Taking into account that the progression of the infection 
is slow and experiments would have to be performed under BSL-3 conditions, this approach 
would be extremely costly. Alternatively to a pure reverse vaccinology approach, antigens 
could be chosen based on experience from vaccine development against closely related 
pathogens. M. ulcerans homologs of lead vaccine candidates against tuberculosis could, for 
example, be considered. Unfortunately genome analysis has revealed that M. ulcerans has 
lost a substantial amount of genes during its evolution from M. marinum [46]. Among those 
are many of the known immunodominant antigens like the M. marinum homolog of the 6 kDa 
early secretory antigenic target protein (ESAT-6) as well as the 10 kDa culture filtrate protein 
(CFP-10) from M. tuberculosis [47].  
How did we face those problems and what delivery strategies did we try? 
Encountering all these difficulties, we identified two new M. ulcerans protein vaccine 
candidates based on the main criterion of surface exposure for antibody-mediated protection. 
The 18 kDa shsp (MUL2232) was identified among the immunodominant antigens by 
generating a panel of monoclonal antibodies after vaccination with whole cells. It has a 
homolog in M. leprae but not in M. bovis and M. tuberculosis [23]. The second candidate, 
MUL3720, has no homologs in other prevalent pathogenic mycobacteria. It is a highly 
interesting candidate because it is cell surface associated and highly expressed in M. 
ulcerans. Furthermore, its structure suggests an involvement in host-pathogen interaction. 
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Together with these two new candidates, we also included the previously tested Ag85A 
(MUL4987) into our panel of protein vaccine candidates. 
 
With the most straight-forward approach of expressing the protein vaccine candidates as 
recombinant proteins in E. coli and administering them with an adjuvant, we did not see any 
protection in the mouse model (Results Chapter 4). The adjuvant (TRL-4 agonist) was 
superior compared to Alum in induction of humoral responses, but as opposed to previous 
reports with other antigens, we did not see a clear polarization of the cellular response 
towards a TH1 type [48,49]. Already from the results of this study, we concluded that antibody 
responses against the protein vaccine candidates are not sufficient for protection against BU. 
Further confirmation of this conclusion came from the results of two studies employing 
systems to deliver the vaccine candidate antigens that are known to induce both humoral as 
well as strong cellular responses (Results Chapters 5 and 6). For the VSV replicon approach, 
we observed for MUL2232 a slight but significant reduction in bacterial load of mice 
immunized with a replicon prime - recombinant protein boost regimen (Results Chapter 5). 
Enhanced induction of cellular immunity could supposedly be the reason for this difference 
from the recombinant protein-adjuvant formulation. The most complicated immunization 
strategy in terms of applicability, infection-treatment-vaccination with genetically modified P. 
berghei parasites, did induce a slight transient delay in foot pad swelling with parasites 
expressing MUL4987 in the mouse model of BU (Results Chapter 6).  
Overall, the results from subunit vaccination were somewhat disappointing, when comparing 
the effect of protein subunit vaccination with the different delivery systems to the effect of 
vaccination with live attenuated M. ulcerans performed in other laboratories [39]. The 
comparison of our findings with the published data on vaccination with live attenuated M. 
ulcerans indicated that the presence of several immunogens is required to achieve 
substantial protection. On the other hand, protection mediated by live attenuated vaccination 
is also not complete [39]. This result may be explained by the concept of deceptive imprinting 
[50]. Already described for other pathogens, such as the human deficiency virus (HIV), it 
describes the dominance of minor, non-protective antigens over antigens that would be 
protective if properly seen and processed by the immune system. We would therefore 
deduce that live attenuated vaccination is not necessarily the best way forward, and that a 
combination of antigens in a multi-component subunit vaccination is more promising. From 
the delivery systems we have evaluated, the VSV replicon holds especially great potential for 
easily combining several antigens to a multivalent subunit vaccine (Results Chapter 5). 
Based on our first results, we would most likely combine MUL2232 and MUL4987 in one 
replicon or alternatively co-administer two replicons simultaneously. Further, more candidate 
antigens should be tested. 
248 Discussion 
 
What is the nature of a protective immune response against M. ulcerans? 
As a partner in the EU-funded collaborative project BuruliVac, we not only aimed at 
evaluating the potential for developing a protein subunit-vaccine against M. ulcerans, but 
also at gaining insight into the nature of protective immune responses against M. ulcerans 
and correlates of protection. The initial idea was to test a defined set of protein vaccine 
candidates with different delivery systems in a mouse model of BU. For successful 
formulations, an in-depth analysis of the vaccination-induced immune response was planned. 
Because we did not observe substantial protection for any of the formulations, this last 
objective remained unrealized. As already pointed out earlier, we concluded that a profound 
antibody response against the chosen protein vaccine candidates is not sufficient for 
protection. Inferred from early histopathological findings, M. ulcerans was considered for a 
long time to be a purely extracellular pathogen [51,52]. Therefore, it was rational to consider 
that antibodies could be the major effector molecules in fighting the disease. Opsonisation of 
the mycobacteria could enhance phagocytosis, increase intra-macrophage killing or improve 
antigen presentation and the induction of protective T-cell responses [53]. In contrast to M. 
ulcerans, the closely related M. tuberculosis and M. leprae are both mainly intracellular 
pathogens for which T-cell responses with a TH1 polarization are regarded as crucial for 
protection [54]. Yet, more recently, in vitro and experimental animal infection model studies 
indicated that an initial intracellular proliferation phase of M. ulcerans exists [55,56] and may 
have relevance for disease progression and the nature of protective immune responses [52]. 
Healing of BU in human patients is accompanied by granuloma formation [51,57], as well as 
the change of the Burulin skin test from negative to positive [22]. Analyses of the cytokine 
profiles have demonstrated the induction of a TH2 response in patients, which is switched to 
a predominantly TH1 profile during healing [58]. However some of the results in this field of 
research on BU are contradictory and conclusions should be drawn with caution [26,59–61]. 
Mycolactone has been reported to impair the responsiveness of T-cells to stimulation [62] 
and to inhibit tumor necrosis factors (TNF) and IL-10 secretion of human monocytes [63]. 
Furthermore the toxin apparently supresses dendritic cell functions [64]. Studies also imply 
that mycolactone diffuses into peripheral blood and to lymphoid organs and induces systemic 
immunosuppression [65,66]. Most of the results concerning effector functions of mycolactone 
are currently under debate. Strikingly, only a minority of mice developed antibodies against 
M. ulcerans proteins in all the different experiments we have performed so far (Results 
Chapter 4). 
While it is not clear to what extent the toxin plays a role in inhibition of the systemic immune 
system, its local effects are devastating. In the end, the induction of anti-mycolactone 
antibodies by vaccination might therefore be the key for the development of a protective 
immune response against BU.  
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How to improve the animal models for BU? 
Natural as well as experimental infection with M. ulcerans is possible in a range of animal 
species [67–75]. The most frequently used model for BU is the mouse foot pad infection in 
BALB/c or C57BL/6 mice [4]. There is some notion that the two different inbred mouse 
strains could have differential susceptibility to the disease, but formal investigations are 
missing. The M. ulcerans strain used for infection of the mice is incredibly important, because 
strains of different geographical origin induce different immune responses and pathology in 
mice [76]. Most likely this is in part due to the different type of mycolactone that is produced 
by these strains. Many studies on BU in mice employ a Malaysian M. ulcerans strain, which 
produces mycolactone A/B (strain 1615) and was isolated in 1964 [77]. To work with a strain 
that is as close as possible to the strains circulating in the countries with highest BU 
prevalence (for which a vaccine would be of greatest benefit) we used a low passage 
Cameroonian M. ulcerans strain that was isolated in 2010 (S1013) (Results Chapters 2, 4 - 
6). Dosing of the inoculum remains a major problem. Although several research groups claim 
that counting of the AFB according to Shepard and McRae [78] is feasible, this approach was 
never successful in our hands. M. ulcerans cells have a strong tendency to clump in aqueous 
solutions, thus making dilutions for infection inaccurate. By applying as few steps in handling 
as possible and adjusting the infection dose to the wet weight of the bacteria, we achieved a 
quite reliable dosing scheme for mouse infections (Results Chapter 4 - 6). Read-outs for the 
progression of the infection remain difficult. An immediate approach is the measurement of 
foot pad swelling, although oedema does not always correlate with bacterial load (Results 
Chapter 6). Classical colony forming unit (CFU) plating remains an important tool for 
enumeration of M. ulcerans from infected foot pads. Unfortunately the slow growth rate of M. 
ulcerans makes this approach very time consuming, prone to contamination and again, 
clump formation is a problem. As an alternative, we have adapted an already published 
qPCR method [79,80] for use on lysed mouse foot pads (Results Chapter 4 - 6). It is not 
possible to distinguish dead from live bacteria with this method, but a comparison to the 
infection dose as well as between differently treated mice is possible and considerably faster 
than CFU plating. Because every time point for determination of the AFB load requires the 
entire foot pad, it is necessary to euthanize parts of the experimental groups if assessment 
during the course of the experiment is desired. The use of luminescent M. ulcerans would be 
an alternative to avoid this problem [81,82]. To successfully apply this method, one would 
have to ensure that the genetically altered luminescent M. ulcerans are as virulent as wild-
type bacteria.  
One of the major drawbacks of the mouse model of BU is the lack of similarity between 
mouse foot pads and human skin. Mouse feet are a small entire limb with almost no fat 
tissue but contain bone, whereas human skin is thicker, with more subcutaneous tissue that 
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contains fat in substantial amounts. To compare pathology and especially histopathology 
with human BU, the mouse is not ideal. We therefore developed an alternative model for 
studying certain aspects of BU - the pig (Results Chapter 7). Pig skin and human skin are 
almost not distinguishable microscopically [83]. Furthermore, the pig immune system 
resembles the human one more than the mouse immune system does [84,85]. As shown in 
Results Chapter 7, the pig is an ideal alternative model to study early infection phases of BU. 
Drawbacks of the pig model are the costs as well as the size of the animal, which requires 
special facilities and trained personnel. On the other hand, the size of the animals allows for 
replicates on the same individual, therefore decreasing the number of pigs used per 
experiment. It is possible to use the pig as a model for testing advanced vaccine candidates 
as well as therapeutic interventions. Both animal models have the major drawback that in 
Switzerland, the experiments have to be performed under BLS3 conditions. This fact 
complicates housing and handling of the animals, sample processing and increases the 
costs tremendously.  
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Conclusions 
During and after a survey in 2010 in the BU-endemic Mapé basin of Cameroon, clinically 
diagnosed patients were laboratory confirmed at the Swiss TPH in Basel. By establishing an 
optimal procedure for culture initiation from patient swab samples, even after long time spans 
between sampling and processing, we facilitated the build-up of a M. ulcerans strain 
database at the Swiss TPH. The isolated strains can be used in the future for molecular 
typing, phylogenetic analyses and monitoring of drug resistance of the locally circulating 
strains. A first such study combined whole genome sequencing analysis with detailed 
information on the patient locations and thus revealed the presence of two phylogenetic 
clonal complexes of M. ulcerans in Cameroon. We did not gain deeper insight into 
transmission patterns of the disease, which is most probably due to the limited genomic 
diversity observed between the M. ulcerans strains.  
 
As long as it is not clearly known how BU is contracted, interruption of transmission is not an 
option. A vaccine against M. ulcerans would therefore be the most effective measure for 
prevention of BU and could also be used therapeutically.  
- Within the framework of this thesis, we profiled two new protein vaccine candidates of 
M. ulcerans, MUL2232 and MUL3720, selected based on their surface location. 
Additionally, one more antigen previously associated with partial protection 
(MUL4987) was included. 
- We successfully delivered the vaccine candidate antigens with three different delivery 
systems: i) as recombinant proteins together with an adjuvant, ii) as VSV replicons 
and iii) with genetically modified Plasmodium berghei parasites in an infection - 
treatment - vaccination approach. All three delivery systems induced potent antibody 
responses and were evaluated for their protective potential in a BU mouse model. 
- No full protection from BU was observed, but slight partial protection was achieved by 
immunization with a replicon - prime / recombinant protein boost regimen with a VSV 
replicon encoding MUL2232. Furthermore, a transient delay of foot pad swelling was 
observed in mice receiving infection – treatment – vaccination with P. berghei 
expressing MUL4987. This indicates that antibody responses against the chosen 
protein vaccine candidates are not sufficient to confer full protection. The combination 
of several antigens to a multivalent vaccine would be an option for potentially 
improving the protective effect. Due to its ability to accept large amounts of foreign 
stretches of RNA, the VSV replicon system offers great potential for developing such 
multivalent vaccines. Furthermore, a combination of different vaccination approaches 
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could also prove successful. In the end, the inclusion of a component inducing anti-
mycolactone antibodies might be crucial to design a protective vaccine.  
The model that is currently most used, the mouse foot pad model, has the advantage that 
large numbers of mice can easily be housed and handled. The pig model, which we have 
established within the framework of this thesis, has not only higher costs but also needs 
special housing, which is not easily available. On the other hand, the pathology of BU is 
reflected substantially better in the pig model. For studying host-pathogen interaction in early 
BU lesions as well as for evaluation of advanced vaccination and therapeutic approaches, 
the pig therefore represents an ideal BU animal model.  
 
Overall, our contributions as well as the results from other partners within the EU-funded 
collaborative BuruliVac project demonstrated that a vaccine against BU is not easily 
accomplished. Future investments into vaccine development against BU should concentrate 
on multivalent vaccine approaches as well as early combination of different vaccination 
strategies. Vaccines for therapeutic use against BU could also play a major role in fighting M. 
ulcerans caused suffering. 
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